Difference between revisions of "Editing test page 2"
Jump to navigation
Jump to search
m (Blanked the page) Tag: Blanking |
m |
||
Line 1: | Line 1: | ||
− | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | |
+ | !Surname | ||
+ | !Forename | ||
+ | !Gender | ||
+ | !Site | ||
+ | !City | ||
+ | !Region | ||
+ | !Country | ||
+ | !First active year | ||
+ | !Last active year | ||
+ | !Study group(s) | ||
+ | !Sponsor(s) | ||
+ | !Conditions | ||
+ | !Total publications | ||
+ | !Senior publications | ||
+ | !Phase 3 RCTs | ||
+ | !FDA pivotal studies | ||
+ | !Co-authorships | ||
+ | !Co-authors | ||
+ | !Vital status | ||
+ | |- | ||
+ | |A'Hern | ||
+ | |Roger P. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1987 | ||
+ | |2015 | ||
+ | |London Gynaecological Oncology Group; TOPIC Trial Group | ||
+ | | | ||
+ | |Breast cancer; Ovarian cancer; Prostate cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |100 | ||
+ | |83 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aamdal | ||
+ | |Steinar | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Norway | ||
+ | |1989 | ||
+ | |2015 | ||
+ | |EORTC; Nordic Melanoma Cooperative Group | ||
+ | | | ||
+ | |Melanoma; Small cell lung cancer | ||
+ | |7 | ||
+ | |2 | ||
+ | |6 | ||
+ | |0 | ||
+ | |87 | ||
+ | |84 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aanur | ||
+ | |Praveen | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Malignant pleural mesothelioma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aapro | ||
+ | |Matti S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium; Switzerland | ||
+ | |1984 | ||
+ | |2018 | ||
+ | |EORTC; International Collaborative Cancer Group | ||
+ | | | ||
+ | |Breast cancer; Endometrial cancer | ||
+ | |5 | ||
+ | |3 | ||
+ | |5 | ||
+ | |1 | ||
+ | |109 | ||
+ | |108 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aaron | ||
+ | |Lorne | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aaronson | ||
+ | |Neil K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2001 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Melanoma; Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aarts | ||
+ | |Maureen J. B. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |2006 | ||
+ | |2017 | ||
+ | |BOOG; Dutch WIN-O Consortium | ||
+ | | | ||
+ | |Breast cancer; Renal cell carcinoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |38 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aasebo | ||
+ | |Ulf | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Norway | ||
+ | |1989 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer; Small cell lung cancer | ||
+ | |7 | ||
+ | |1 | ||
+ | |7 | ||
+ | |0 | ||
+ | |65 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aass | ||
+ | |Nina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Norway | ||
+ | |1996 | ||
+ | |2012 | ||
+ | |EORTC; MRC | ||
+ | | | ||
+ | |Renal cell carcinoma; Testicular cancer | ||
+ | |5 | ||
+ | |1 | ||
+ | |4 | ||
+ | |0 | ||
+ | |48 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aastroem | ||
+ | |Lennart | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2014 | ||
+ | |2022 | ||
+ | |SPCG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aavall Lundqvist | ||
+ | |Elisabeth | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |1999 | ||
+ | |2017 | ||
+ | |AGO; Gynecologic Cancer Intergroup | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |64 | ||
+ | |52 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abacioglu | ||
+ | |Ufuk | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abad | ||
+ | |Alberto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1989 | ||
+ | |2012 | ||
+ | |TTD | ||
+ | | | ||
+ | |Colorectal cancer; Non-small cell lung cancer | ||
+ | |3 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |53 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abada | ||
+ | |Paolo B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |42 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abadie Lacourtoisie | ||
+ | |Sophie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2006 | ||
+ | |2019 | ||
+ | |GINECO | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |55 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abaskharoun | ||
+ | |Mena | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abaza | ||
+ | |Yasmin | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Acute promyelocytic leukemia | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbadessa | ||
+ | |A. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |CNS lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbadessa | ||
+ | |Giovanni | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbal | ||
+ | |Claire | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2006 | ||
+ | |2015 | ||
+ | |GRAALL | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbas | ||
+ | |Abbas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Esophageal adenocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbas | ||
+ | |Haider | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2009 | ||
+ | |2014 | ||
+ | |COG | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbas | ||
+ | |Mohammad | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbas | ||
+ | |Moncef | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2011 | ||
+ | |FFCD | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbas | ||
+ | |Richat | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbas | ||
+ | |Tahir | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2016 | ||
+ | |2020 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbattista | ||
+ | |Antonello | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2014 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |50 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbink | ||
+ | |Floor | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |2011 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbott | ||
+ | |Amanda | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Gastrointestinal stromal tumor | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbott | ||
+ | |R. L. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1982 | ||
+ | |1989 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbott | ||
+ | |Thomas M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1979 | ||
+ | |1989 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbou | ||
+ | |Clement Claude | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1986 | ||
+ | |1993 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abboud | ||
+ | |Camille N. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1993 | ||
+ | |2016 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |49 | ||
+ | |49 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abboud | ||
+ | |Miguel R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Lebanon | ||
+ | |2017 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Sickle cell anemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbrederis | ||
+ | |Klaus | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbruzzese | ||
+ | |Alberto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abbruzzese | ||
+ | |James L. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1988 | ||
+ | |2010 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Colorectal cancer; Esophageal adenocarcinoma; Hepatocellular carcinoma; Pancreatic cancer | ||
+ | |5 | ||
+ | |3 | ||
+ | |2 | ||
+ | |0 | ||
+ | |47 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdalla | ||
+ | |K. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Brazil | ||
+ | |2011 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdallah | ||
+ | |Al Ola | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |55 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdallah | ||
+ | |Rehab | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdeddaim | ||
+ | |Cyril | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2017 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Endometrial cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdel Hamid | ||
+ | |Abdel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2007 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Thyroid cancer differentiated | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdel Rahman | ||
+ | |Omar | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Egypt | ||
+ | |2010 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdel Rahman | ||
+ | |Sultan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1997 | ||
+ | |2018 | ||
+ | |EORTC; European Society for Hyperthermic Oncology | ||
+ | | | ||
+ | |Soft tissue sarcoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |40 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdel Wahab | ||
+ | |Manal | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2010 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdel Wahab | ||
+ | |Omar | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2019 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic myelomonocytic leukemia; Erdheim-Chester disease; Essential thrombocythemia; Hairy cell leukemia; Langerhans cell histiocytosis; Polycythemia vera; Rosai-Dorfman-Destombes disease | ||
+ | |6 | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |124 | ||
+ | |114 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdel Wahab | ||
+ | |Sherif | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2010 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdelfattah | ||
+ | |Murad | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdelghany | ||
+ | |Osama | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Endometrial cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |46 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdi | ||
+ | |Ehtesham A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Australia | ||
+ | |1994 | ||
+ | |2021 | ||
+ | |ALLG; IBCSG | ||
+ | | | ||
+ | |Breast cancer; Diffuse large B-cell lymphoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |95 | ||
+ | |72 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdiche | ||
+ | |Menouar Samir | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2008 | ||
+ | |2020 | ||
+ | |GETUG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdo | ||
+ | |Andre | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Brazil | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdul Razak | ||
+ | |Albiruni R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Soft tissue sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdulkadyrov | ||
+ | |Kudrat M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2004 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Chronic myeloid leukemia; Essential thrombocythemia; Multiple myeloma | ||
+ | |6 | ||
+ | |0 | ||
+ | |4 | ||
+ | |2 | ||
+ | |117 | ||
+ | |76 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdullaev | ||
+ | |S. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abdullah | ||
+ | |Shaad E. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Uveal melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abe | ||
+ | |Hajime | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abe | ||
+ | |Osahiko | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1981 | ||
+ | |1994 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |23 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abe | ||
+ | |Rikiya | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2009 | ||
+ | |Adjuvant CEF Research Group for Breast Cancer | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |27 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abe | ||
+ | |Tetsuya | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2008 | ||
+ | |2015 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abe | ||
+ | |Yasunobu | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Adult T-cell leukemia-lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abedi | ||
+ | |Mehrdad | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; Follicular lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |37 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abel | ||
+ | |Edvard | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2013 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abel | ||
+ | |Ulrich | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Pancreatic cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |40 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abella | ||
+ | |Eugenia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2013 | ||
+ | |GELCAB; GELTAMO; GESIDA; PETHEMA | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; HIV-associated lymphoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |68 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abellan | ||
+ | |Pascual Fernandez | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2008 | ||
+ | |GEM; PETHEMA | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abeloff | ||
+ | |Martin D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1979 | ||
+ | |2009 | ||
+ | |Breast Cancer Intergroup of North America; CALGB; ECOG; SWOG | ||
+ | | | ||
+ | |Breast cancer; Small cell lung cancer | ||
+ | |10 | ||
+ | |4 | ||
+ | |10 | ||
+ | |0 | ||
+ | |89 | ||
+ | |59 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abels | ||
+ | |J. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |1989 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |22 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abelson | ||
+ | |Herbert T. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1982 | ||
+ | |1986 | ||
+ | | | ||
+ | | | ||
+ | |Osteosarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abenhardt | ||
+ | |Wolfgang | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1997 | ||
+ | |2017 | ||
+ | |GCLLSG | ||
+ | | | ||
+ | |Breast cancer; Chronic lymphocytic leukemia | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |52 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abergel | ||
+ | |Armand | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1995 | ||
+ | |2019 | ||
+ | |FFCD | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |48 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abernethy | ||
+ | |Amy | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abeyakoon | ||
+ | |Sarath | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abgrall | ||
+ | |Jean Francois | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1991 | ||
+ | |1997 | ||
+ | |Intergroupe Francais des Leucemies Myeloides Chroniques | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abhyankar | ||
+ | |Sunil | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2018 | ||
+ | |BMT CTN | ||
+ | | | ||
+ | |Graft versus host disease | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abi Gerges | ||
+ | |Dany | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Lebanon | ||
+ | |2008 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abianui | ||
+ | |Abongnwen | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2018 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abidi | ||
+ | |Muneer H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2020 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Hodgkin lymphoma; Multiple myeloma | ||
+ | |6 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |82 | ||
+ | |48 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abidoye | ||
+ | |Oyewale O. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |2 | ||
+ | |64 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abildgaard | ||
+ | |Niels | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |48 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abir | ||
+ | |Esshagh | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1965 | ||
+ | |1965 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ablin | ||
+ | |Arthur R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1988 | ||
+ | |1988 | ||
+ | |CCG | ||
+ | | | ||
+ | |T-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aboelhassan | ||
+ | |Rasha | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Egypt | ||
+ | |2013 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Malignant pleural mesothelioma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abonour | ||
+ | |Rafat | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2018 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |53 | ||
+ | |50 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abou Alfa | ||
+ | |Ghassan K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2001 | ||
+ | |2021 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Cholangiocarcinoma; Hepatocellular carcinoma; Pancreatic cancer | ||
+ | |13 | ||
+ | |11 | ||
+ | |7 | ||
+ | |4 | ||
+ | |267 | ||
+ | |191 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abou Nassar | ||
+ | |Karim | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2013 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma; Venous thromboembolism | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |44 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abou Rached | ||
+ | |Antoine | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1990 | ||
+ | |1995 | ||
+ | |Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aboulafia | ||
+ | |David | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |2009 | ||
+ | |AIDS Malignancy Consortium | ||
+ | | | ||
+ | |HIV-associated lymphoma; Kaposi sarcoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |33 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |Aby | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Acute promyelocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |Christine | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2003 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |George | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |India | ||
+ | |2012 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |50 | ||
+ | |50 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |Jacinta | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2008 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |37 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |Jean E. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2001 | ||
+ | |2019 | ||
+ | |tAnGo trial collaborators | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |102 | ||
+ | |66 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |Julie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abraham | ||
+ | |Mirta | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2013 | ||
+ | |Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |37 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrahamse Testroote | ||
+ | |Martine C. J. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |2006 | ||
+ | |2014 | ||
+ | |HOVON | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrahamsson | ||
+ | |Jonas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2004 | ||
+ | |2019 | ||
+ | |Nordic Society of Paediatric Haematology and Oncology (NOPHO) | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |18 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrahamsson | ||
+ | |Per Anders | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2007 | ||
+ | |Atrasentan Phase III Study Group Institutions | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abram | ||
+ | |Paul | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abram | ||
+ | |Steven R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |68 | ||
+ | |68 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abramov | ||
+ | |M. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2011 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrams | ||
+ | |Jeffrey S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1982 | ||
+ | |2018 | ||
+ | |CALGB; NCIC-CTG | ||
+ | | | ||
+ | |Breast cancer; Melanoma | ||
+ | |9 | ||
+ | |1 | ||
+ | |6 | ||
+ | |2 | ||
+ | |145 | ||
+ | |85 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrams | ||
+ | |K. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1988 | ||
+ | |1994 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrams | ||
+ | |Paul G. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1984 | ||
+ | |1984 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrams | ||
+ | |Ross A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1987 | ||
+ | |2011 | ||
+ | |Radiation Therapy Oncology Group; RTOG | ||
+ | | | ||
+ | |Cholangiocarcinoma; Pancreatic cancer; Prostate cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |36 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrams | ||
+ | |Thomas A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |59 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abramson | ||
+ | |David H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Uveal melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abramson | ||
+ | |Jeremy S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2005 | ||
+ | |2022 | ||
+ | |Alliance; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society; CALGB | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma | ||
+ | |8 | ||
+ | |3 | ||
+ | |5 | ||
+ | |3 | ||
+ | |156 | ||
+ | |140 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abramson | ||
+ | |Neil | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1979 | ||
+ | |2001 | ||
+ | |ECOG; NSABP | ||
+ | | | ||
+ | |Breast cancer; Multiple myeloma | ||
+ | |5 | ||
+ | |0 | ||
+ | |6 | ||
+ | |0 | ||
+ | |63 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abramson | ||
+ | |Vandana G. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2022 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Breast cancer; CNS carcinoma; Thyroid cancer | ||
+ | |6 | ||
+ | |1 | ||
+ | |2 | ||
+ | |2 | ||
+ | |131 | ||
+ | |98 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrao Miziara | ||
+ | |Jose Elias | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Brazil | ||
+ | |2006 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |62 | ||
+ | |52 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abratt | ||
+ | |Raymond Pierre | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Africa | ||
+ | |1995 | ||
+ | |2011 | ||
+ | |GLOB 2 group | ||
+ | | | ||
+ | |Non-small cell lung cancer; Prostate cancer | ||
+ | |6 | ||
+ | |3 | ||
+ | |6 | ||
+ | |0 | ||
+ | |58 | ||
+ | |53 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrey | ||
+ | |Lauren E. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland; USA | ||
+ | |1992 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT; CNS lymphoma; Glioblastoma; High-grade glioma pediatric; Stem cell mobilization | ||
+ | |9 | ||
+ | |4 | ||
+ | |1 | ||
+ | |1 | ||
+ | |101 | ||
+ | |76 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abrisqueta | ||
+ | |Pau | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2005 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma | ||
+ | |5 | ||
+ | |1 | ||
+ | |2 | ||
+ | |1 | ||
+ | |111 | ||
+ | |87 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abromowitch | ||
+ | |Minnie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1979 | ||
+ | |2012 | ||
+ | |COG | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric | ||
+ | |3 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |30 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abruzzese | ||
+ | |Elisabetta | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2004 | ||
+ | |2018 | ||
+ | |EORTC; FIL; GIMEMA; LYSA | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hodgkin lymphoma | ||
+ | |7 | ||
+ | |0 | ||
+ | |5 | ||
+ | |1 | ||
+ | |174 | ||
+ | |122 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abruzzo | ||
+ | |Lynne V. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Hodgkin lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abshire | ||
+ | |T. C. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2000 | ||
+ | |2000 | ||
+ | |POG | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abt | ||
+ | |Markus | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |1998 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Colon cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abu Samra | ||
+ | |Maisun | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2010 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |32 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abu Zahra | ||
+ | |Hakam | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |1984 | ||
+ | |1998 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |38 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abuav | ||
+ | |Rachel | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Cutaneous T-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abubakr | ||
+ | |Yousif A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |30 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Abulizi | ||
+ | |G. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |China | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Accario Winslow | ||
+ | |Chrisann | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2009 | ||
+ | |Gynecologic Cancer Intergroup | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Accomando | ||
+ | |Emilio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1987 | ||
+ | |1992 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Accortanzo | ||
+ | |Valeria | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1996 | ||
+ | |2016 | ||
+ | |GONO | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acha | ||
+ | |Tomas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2001 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Wilms tumor | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acharya | ||
+ | |Sandip | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |India | ||
+ | |2009 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |36 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acharyya | ||
+ | |Suddhasatta | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Achebe | ||
+ | |Maureen M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Sickle cell anemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |32 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Achille | ||
+ | |Emmanuel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2007 | ||
+ | |GERCOR | ||
+ | | | ||
+ | |Colon cancer; Colorectal cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |41 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acholonu | ||
+ | |Sandra | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Achour | ||
+ | |Eddine | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2001 | ||
+ | | | ||
+ | | | ||
+ | |CNS lymphoma; Stem cell mobilization | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Achtelik | ||
+ | |W. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2001 | ||
+ | |DeCOG | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Achtnicht | ||
+ | |U. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1985 | ||
+ | |1992 | ||
+ | | | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acin | ||
+ | |Yolene | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2009 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Gastrointestinal stromal tumor; Pancreatic cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acker | ||
+ | |Thomas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2012 | ||
+ | |“Aktion Bronchialkarzinom” (ABC Study Group) | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ackerman | ||
+ | |Charlotte | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2007 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ackerman | ||
+ | |Ilana | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Australia | ||
+ | |2022 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |45 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ackerman | ||
+ | |Judie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ackerstaff | ||
+ | |Annemiek H. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ackerstein | ||
+ | |Aliza | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |1998 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ackland | ||
+ | |Stephen P. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Australia | ||
+ | |1990 | ||
+ | |2012 | ||
+ | |AGITG; ANZ BCTG; Australasian Gastro-Intestinal Trials Group; Trans-Tasman Radiation Oncology Group; TROG | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Esophageal cancer; Rectal cancer | ||
+ | |8 | ||
+ | |1 | ||
+ | |8 | ||
+ | |1 | ||
+ | |109 | ||
+ | |97 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acosta Rivera | ||
+ | |Mirelis | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acosta | ||
+ | |Mark | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Cutaneous T-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acosta | ||
+ | |Soraida C. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Cuba | ||
+ | |2006 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acquino Parsons | ||
+ | |C. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2001 | ||
+ | | | ||
+ | | | ||
+ | |Endometrial cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acs | ||
+ | |Peter I. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Acton | ||
+ | |Gary | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adab | ||
+ | |Fawzi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2002 | ||
+ | |2017 | ||
+ | |CRUK | ||
+ | | | ||
+ | |Pancreatic cancer; Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |65 | ||
+ | |65 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adachi | ||
+ | |Hisanobu | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Upper tract urothelial carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adachi | ||
+ | |Isamu | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |1993 | ||
+ | |1996 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adachi | ||
+ | |Susumu | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Malignant pleural mesothelioma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adak | ||
+ | |Sudeshna | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1991 | ||
+ | |2001 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Non-small cell lung cancer; Small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |12 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adam | ||
+ | |H. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1982 | ||
+ | |1994 | ||
+ | |SAKK | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adam | ||
+ | |Rene | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1994 | ||
+ | |2017 | ||
+ | |SARAH Trial Group | ||
+ | | | ||
+ | |Colorectal cancer; Hepatocellular carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |52 | ||
+ | |52 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adam | ||
+ | |Zdenek | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |4 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |45 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamchuk | ||
+ | |Hryhoriy | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Ukraine | ||
+ | |2008 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adami | ||
+ | |Bernd | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adami | ||
+ | |Fausto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1999 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Light-chain (AL) amyloidosis; POEMS syndrome | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adami | ||
+ | |Francesca | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1996 | ||
+ | |2016 | ||
+ | |GONO | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adami | ||
+ | |Hans Olov | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden; USA | ||
+ | |1989 | ||
+ | |2018 | ||
+ | |SPCG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |6 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |78 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamkewicz | ||
+ | |Joanne I. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Inherited coagulopathy | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamo | ||
+ | |Francesco | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2006 | ||
+ | |EORTC; FIL; GIMEMA | ||
+ | | | ||
+ | |Acute myeloid leukemia; Hodgkin lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |37 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamo | ||
+ | |Vincenzo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |2005 | ||
+ | |Italian Lung Cancer Project; Italian Multicentre Breast Study with Epirubicin | ||
+ | | | ||
+ | |Breast cancer; Colon cancer; Non-small cell lung cancer; Ovarian cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |138 | ||
+ | |121 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamou | ||
+ | |Adamos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2009 | ||
+ | |HeCOG; HORG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |35 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Bonne | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Vascular sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |George L. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1989 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer; Nasopharyngeal carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |17 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Grenfell | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1984 | ||
+ | |2004 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Hodgkin lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |28 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Hans Peter | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2003 | ||
+ | |AGO | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Julian | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2001 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma; Mantle cell lymphoma; Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |49 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |M. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2002 | ||
+ | |ICON | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Paul T. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2015 | ||
+ | |NSABP | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |39 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Richard A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2005 | ||
+ | |2021 | ||
+ | |MRC | ||
+ | | | ||
+ | |Anal cancer; Colorectal cancer | ||
+ | |5 | ||
+ | |2 | ||
+ | |5 | ||
+ | |0 | ||
+ | |99 | ||
+ | |79 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adams | ||
+ | |Sylvia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |47 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamska | ||
+ | |Krystyna | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Poland | ||
+ | |2008 | ||
+ | |2014 | ||
+ | |Canadian Brain Tumor Consortium; CENTRIC study team; EORTC | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |36 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamski | ||
+ | |Henri | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2011 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |Cutaneous squamous cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamson | ||
+ | |Peter C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2020 | ||
+ | |Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma | ||
+ | | | ||
+ | |Anaplastic large cell lymphoma pediatric; B-cell acute lymphoblastic leukemia pediatric; Non-Hodgkin lymphoma pediatric | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |3 | ||
+ | |50 | ||
+ | |50 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adamus | ||
+ | |Jerzy | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1974 | ||
+ | |1982 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Addamo | ||
+ | |B. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2004 | ||
+ | |AML Study Group Ulm | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adde | ||
+ | |Magdalena | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2001 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Burkitt lymphoma; Diffuse large B-cell lymphoma; HIV-associated lymphoma | ||
+ | |2 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Addeo | ||
+ | |Raffaele | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2003 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Addison | ||
+ | |Alicia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Mantle cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adebamowo | ||
+ | |Clement | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Nigeria | ||
+ | |2004 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adelman | ||
+ | |Carrie A. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2020 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |38 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adelson | ||
+ | |Mark D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1985 | ||
+ | |1999 | ||
+ | |GOG | ||
+ | | | ||
+ | |Endometrial cancer; Ovarian cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adelstein | ||
+ | |David J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1988 | ||
+ | |2018 | ||
+ | |RTOG; SWOG | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Head and neck cancer; Oropharyngeal cancer | ||
+ | |6 | ||
+ | |4 | ||
+ | |4 | ||
+ | |0 | ||
+ | |62 | ||
+ | |56 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ademokun | ||
+ | |Debo | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2008 | ||
+ | |2019 | ||
+ | |National Cancer Research Institute Haemato-oncology Clinical Studies Group | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ademuyiwa | ||
+ | |Foluso | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adeniran | ||
+ | |Adebowale | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2021 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Papillary renal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adenis | ||
+ | |Antoine | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1992 | ||
+ | |2022 | ||
+ | |EORTC; FFCD; FNCLCC; French Sarcoma Group; GI Group of the French Anti-Cancer Centers; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO); UNICANCER | ||
+ | | | ||
+ | |Anal cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastrointestinal stromal tumor; Pancreatic cancer | ||
+ | |18 | ||
+ | |2 | ||
+ | |12 | ||
+ | |5 | ||
+ | |322 | ||
+ | |225 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ades | ||
+ | |Lionel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1993 | ||
+ | |2022 | ||
+ | |EAPLG; European APL Group; French Belgian Swiss APL group; Groupe Francophone des Myelodysplasies; PETHEMA | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome | ||
+ | |8 | ||
+ | |7 | ||
+ | |6 | ||
+ | |1 | ||
+ | |182 | ||
+ | |121 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adeva | ||
+ | |Jorge | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |51 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adewoye | ||
+ | |Adeboye H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adhoute | ||
+ | |X. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2003 | ||
+ | |2015 | ||
+ | |FFCD | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adib | ||
+ | |Deyaa | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adibi | ||
+ | |Mehrad | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Upper tract urothelial carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adie | ||
+ | |Sam | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Australia | ||
+ | |2022 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |45 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adiguzel | ||
+ | |Ibrahim | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adinin | ||
+ | |Rosnie B. | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adjei | ||
+ | |Alex A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1999 | ||
+ | |2017 | ||
+ | |ECOG-ACRIN; NCCTG | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |38 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adkins | ||
+ | |Douglas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer; Soft tissue sarcoma; Thyroid cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |2 | ||
+ | |54 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adler Reichel | ||
+ | |S. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2001 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adler | ||
+ | |Brian | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Sickle cell anemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adler | ||
+ | |Mathias | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1991 | ||
+ | |2011 | ||
+ | |CONKO; GHSG | ||
+ | | | ||
+ | |Hodgkin lymphoma; Pancreatic cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |66 | ||
+ | |59 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adotevi | ||
+ | |Olivier | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2014 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Anal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adrian | ||
+ | |Nicole | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Adrover | ||
+ | |Encarna | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1999 | ||
+ | |2015 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |122 | ||
+ | |74 | ||
+ | |1 | ||
+ | |- | ||
+ | |Advani | ||
+ | |Anjali S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2019 | ||
+ | |CALGB; SWOG | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Diffuse large B-cell lymphoma; Follicular lymphoma; Myelodysplastic syndrome | ||
+ | |7 | ||
+ | |3 | ||
+ | |1 | ||
+ | |1 | ||
+ | |112 | ||
+ | |91 | ||
+ | |1 | ||
+ | |- | ||
+ | |Advani | ||
+ | |Ranjana H. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1995 | ||
+ | |2022 | ||
+ | |ECOG; WMCTG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant; Mantle cell lymphoma; Mediastinal gray-zone lymphoma; Peripheral T-cell lymphoma; Primary mediastinal B-cell lymphoma; Waldenstroem macroglobulinemia | ||
+ | |38 | ||
+ | |6 | ||
+ | |5 | ||
+ | |5 | ||
+ | |607 | ||
+ | |314 | ||
+ | |1 | ||
+ | |- | ||
+ | |Advani | ||
+ | |Suresh H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aeberhard | ||
+ | |Peter | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1981 | ||
+ | |2008 | ||
+ | |SAKK | ||
+ | | | ||
+ | |Colon cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |12 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aebersold | ||
+ | |Daniel M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2011 | ||
+ | |SAKK | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aebi | ||
+ | |Stefan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |1993 | ||
+ | |2021 | ||
+ | |BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; SAKK | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |9 | ||
+ | |2 | ||
+ | |5 | ||
+ | |0 | ||
+ | |179 | ||
+ | |83 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aerts | ||
+ | |Joachim G. J. V. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |2007 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer | ||
+ | |9 | ||
+ | |1 | ||
+ | |6 | ||
+ | |1 | ||
+ | |152 | ||
+ | |125 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afable | ||
+ | |Manuel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2012 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Myelodysplastic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afanasyev | ||
+ | |Boris V. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2003 | ||
+ | |2020 | ||
+ | |SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic lymphocytic leukemia; Mantle cell lymphoma; Myelodysplastic syndrome | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |2 | ||
+ | |95 | ||
+ | |95 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afchain | ||
+ | |Pauline | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afenjar | ||
+ | |Karen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2008 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; Gastric cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |62 | ||
+ | |47 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afflitto | ||
+ | |Anthony J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Affronti | ||
+ | |M. L. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afra | ||
+ | |Denes | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1988 | ||
+ | |2008 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Anaplastic glioma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Afrin | ||
+ | |Lawrence B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Systemic mastocytosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aft | ||
+ | |Rebecca | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aftab | ||
+ | |Dana T. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aftimos | ||
+ | |Philippe | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |57 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agajanian | ||
+ | |Richy | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agaram | ||
+ | |Narasimhan P. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2018 | ||
+ | |Alliance | ||
+ | | | ||
+ | |Desmoid tumor | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Archi | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |India | ||
+ | |2012 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |50 | ||
+ | |50 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Jaiprakash | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |India | ||
+ | |2000 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |3 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |87 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Mohan B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |India | ||
+ | |2007 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Neeraj | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2022 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Bladder cancer; Prostate cancer; Renal cell carcinoma | ||
+ | |15 | ||
+ | |2 | ||
+ | |8 | ||
+ | |3 | ||
+ | |299 | ||
+ | |211 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Prasheen | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |32 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Rishu | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Australia | ||
+ | |2015 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Mantle cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Shefali | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Epithelioid sarcoma; Follicular lymphoma; Ovarian cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |3 | ||
+ | |71 | ||
+ | |71 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwal | ||
+ | |Suresh K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic lymphocytic leukemia; Multiple myeloma | ||
+ | |4 | ||
+ | |0 | ||
+ | |0 | ||
+ | |3 | ||
+ | |71 | ||
+ | |60 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwala | ||
+ | |A. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agarwala | ||
+ | |Sanjiv S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1974 | ||
+ | |2017 | ||
+ | |ECOG; EORTC | ||
+ | | | ||
+ | |Head and neck cancer; Melanoma | ||
+ | |16 | ||
+ | |5 | ||
+ | |13 | ||
+ | |3 | ||
+ | |268 | ||
+ | |198 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agate | ||
+ | |Laura | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2014 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Thyroid cancer differentiated; Thyroid cancer medullary | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agathocleous | ||
+ | |Agathoclis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2010 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agbalika | ||
+ | |Felix | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Castleman disease | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agelaki | ||
+ | |Sophia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |2001 | ||
+ | |2017 | ||
+ | |HORG | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Non-small cell lung cancer; Small cell lung cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |65 | ||
+ | |39 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agelidou | ||
+ | |Athina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |1999 | ||
+ | |2011 | ||
+ | |HORG | ||
+ | | | ||
+ | |Non-small cell lung cancer; Small cell lung cancer | ||
+ | |8 | ||
+ | |0 | ||
+ | |7 | ||
+ | |0 | ||
+ | |99 | ||
+ | |47 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agelidou | ||
+ | |Maria | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |2000 | ||
+ | |2013 | ||
+ | |HORG | ||
+ | | | ||
+ | |Non-small cell lung cancer; Small cell lung cancer | ||
+ | |6 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |79 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ageno | ||
+ | |Walter | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2008 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ager | ||
+ | |Phyllis Joyce | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1984 | ||
+ | |1990 | ||
+ | |NSABP | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agerbaek | ||
+ | |Mads | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |2002 | ||
+ | |2021 | ||
+ | |EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |56 | ||
+ | |55 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aggarwal | ||
+ | |Charu | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aggarwal | ||
+ | |Sanjay | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |37 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aggerholm | ||
+ | |Anni | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agha | ||
+ | |Mounzer E. | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |104 | ||
+ | |100 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aghajanian | ||
+ | |Carol A. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2005 | ||
+ | |2021 | ||
+ | |GOG | ||
+ | | | ||
+ | |Endometrial cancer; Leiomyosarcoma; Low-grade serous ovarian cancer; Ovarian cancer | ||
+ | |19 | ||
+ | |3 | ||
+ | |11 | ||
+ | |6 | ||
+ | |375 | ||
+ | |215 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aghemo | ||
+ | |E. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agis | ||
+ | |Hermine | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Austria | ||
+ | |2000 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |31 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aglietta | ||
+ | |Massimo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1998 | ||
+ | |2022 | ||
+ | |Italian Group for the Study of Gastrointestinal Cancer | ||
+ | | | ||
+ | |Colorectal cancer; Multiple myeloma; Osteosarcoma; Soft tissue sarcoma | ||
+ | |8 | ||
+ | |1 | ||
+ | |4 | ||
+ | |2 | ||
+ | |138 | ||
+ | |119 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agnelli | ||
+ | |Giancarlo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2010 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |6 | ||
+ | |3 | ||
+ | |6 | ||
+ | |0 | ||
+ | |81 | ||
+ | |51 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agnelli | ||
+ | |L. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2013 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Plasma cell leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agodoa | ||
+ | |Irene | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Sickle cell anemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agopian | ||
+ | |Julie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2009 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Systemic mastocytosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agostara | ||
+ | |Biagio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |2010 | ||
+ | |GOIM; Gruppo Oncologico Italia Meridionale | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Non-small cell lung cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |53 | ||
+ | |46 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agostinelli | ||
+ | |Claudio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2006 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agostini | ||
+ | |Cecile | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agrawal | ||
+ | |Manish | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agrawal | ||
+ | |Rajiv K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1996 | ||
+ | |2019 | ||
+ | |NEAT Investigators and the SCTBG; tAnGo trial collaborators | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |120 | ||
+ | |71 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agrawal | ||
+ | |Samir | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2012 | ||
+ | |NCRI | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Multiple myeloma; Stem cell mobilization | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agrawal | ||
+ | |Shruti | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia pediatric; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |2 | ||
+ | |42 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agresta | ||
+ | |Samuel V. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |4 | ||
+ | |0 | ||
+ | |0 | ||
+ | |2 | ||
+ | |109 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agricola | ||
+ | |Karen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Subependymal giant cell astrocytoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |23 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguado Fraile | ||
+ | |Elia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguado | ||
+ | |M. Jose | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |1999 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguggini | ||
+ | |S. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguiar | ||
+ | |Melanie | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2012 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguiar | ||
+ | |Ricardo C. T. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Hypereosinophilic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguilera | ||
+ | |Nadia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Cuba | ||
+ | |2006 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguilo | ||
+ | |Rafael | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2010 | ||
+ | |Spanish Lung Cancer Group | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agulnik | ||
+ | |Jason | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2008 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer nonsquamous | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agulnik | ||
+ | |Mark B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Epithelioid sarcoma; Head and neck cancer; Osteosarcoma; Soft tissue sarcoma; Vascular sarcoma | ||
+ | |7 | ||
+ | |1 | ||
+ | |3 | ||
+ | |2 | ||
+ | |132 | ||
+ | |100 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agunwamba | ||
+ | |Blessing U. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agura | ||
+ | |Edward | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1997 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT; Chronic lymphocytic leukemia; Hodgkin lymphoma | ||
+ | |8 | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |131 | ||
+ | |83 | ||
+ | |1 | ||
+ | |- | ||
+ | |Agus | ||
+ | |David B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1993 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |38 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aguzzi | ||
+ | |Rasha | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Paroxysmal nocturnal hemoglobinuria | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ah See | ||
+ | |Antoinne K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ah See | ||
+ | |Mei Lin | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2007 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |31 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahern | ||
+ | |Charlotte | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2013 | ||
+ | |COG | ||
+ | | | ||
+ | |Anaplastic large cell lymphoma pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlberg | ||
+ | |Lucia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |48 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlborn | ||
+ | |Miriam | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2012 | ||
+ | |2021 | ||
+ | |GHSG | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlgren | ||
+ | |Goeran M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2005 | ||
+ | |2018 | ||
+ | |SPCG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |30 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlgren | ||
+ | |James D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1984 | ||
+ | |1989 | ||
+ | |MAOP | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlgren | ||
+ | |Johan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2004 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |57 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlgren | ||
+ | |Tomas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2002 | ||
+ | |2015 | ||
+ | |Nordic Lymphoma Group | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlman | ||
+ | |Hakan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1979 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Adrenocortical carcinoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahlmann | ||
+ | |Martina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2020 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Hemophagocytic lymphohistiocytosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahluwalia | ||
+ | |Manmeet S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |47 | ||
+ | |46 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmad | ||
+ | |Chaudhary E. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2016 | ||
+ | |2020 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmad | ||
+ | |Rizvana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2009 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmad | ||
+ | |Shaharyar | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2013 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmadi | ||
+ | |Jamshid | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1992 | ||
+ | |2015 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Meningioma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmadi | ||
+ | |Tahamtan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma; Light-chain (AL) amyloidosis; Mantle cell lymphoma; Multiple myeloma | ||
+ | |16 | ||
+ | |1 | ||
+ | |6 | ||
+ | |9 | ||
+ | |409 | ||
+ | |214 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmann | ||
+ | |David L. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1977 | ||
+ | |1995 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; Melanoma | ||
+ | |7 | ||
+ | |2 | ||
+ | |7 | ||
+ | |1 | ||
+ | |54 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmann | ||
+ | |Frederick R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmann | ||
+ | |Gregory J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2018 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |42 | ||
+ | |39 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmed | ||
+ | |Asra | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |28 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmed | ||
+ | |Atif A. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2021 | ||
+ | |COG | ||
+ | | | ||
+ | |Ewing sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmed | ||
+ | |Ikhlaaq | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1998 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmed | ||
+ | |Nazma | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2006 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahmed | ||
+ | |Sairah | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Mantle cell lymphoma; Transformed lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Chul | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Blastic plasmacytoid dendritic cell neoplasm | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Daniel H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |31 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Hanjong | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2014 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Inhye E. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Jae Sook | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2009 | ||
+ | |2015 | ||
+ | |Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; CNS leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |36 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Jin Hee | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2007 | ||
+ | |2022 | ||
+ | |KCSG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |1 | ||
+ | |79 | ||
+ | |66 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Jin Seok | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2002 | ||
+ | |2020 | ||
+ | |KCSG | ||
+ | | | ||
+ | |Breast cancer; CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Small cell lung cancer | ||
+ | |15 | ||
+ | |1 | ||
+ | |10 | ||
+ | |4 | ||
+ | |230 | ||
+ | |152 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Joong Bae | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2008 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer; Rectal cancer | ||
+ | |6 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |103 | ||
+ | |65 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Myung Ju | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2002 | ||
+ | |2021 | ||
+ | |KCSG | ||
+ | | | ||
+ | |CNS carcinoma; Esophageal squamous cell carcinoma; Head and neck cancer; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; NTRK; Small cell lung cancer | ||
+ | |41 | ||
+ | |4 | ||
+ | |20 | ||
+ | |11 | ||
+ | |735 | ||
+ | |423 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Sei Hyun | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2012 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Sung Ja | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Yeon S. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |1983 | ||
+ | | | ||
+ | | | ||
+ | |Immune thrombocytopenia | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahn | ||
+ | |Yong Chan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2003 | ||
+ | |2015 | ||
+ | |Consortium for Improving Survival of Lymphoma; KCSG | ||
+ | | | ||
+ | |Extranodal NK- and T-cell lymphoma nasal type; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer | ||
+ | |4 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |69 | ||
+ | |60 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahren | ||
+ | |Bo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1991 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Neuroendocrine tumor | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahrens | ||
+ | |S. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2001 | ||
+ | | | ||
+ | | | ||
+ | |Ewing sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahsan | ||
+ | |S. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahsan | ||
+ | |Sama | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom; USA | ||
+ | |2015 | ||
+ | |2022 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Melanoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |57 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ahuja | ||
+ | |Harish | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ai | ||
+ | |Ping | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |China | ||
+ | |2011 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Nasopharyngeal carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |67 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ai | ||
+ | |Weiyun | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Transformed lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ai | ||
+ | |Xinghao | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |China | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer nonsquamous; Small cell lung cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |57 | ||
+ | |51 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aiba | ||
+ | |Keisuke | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2010 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Colon cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |41 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aiello | ||
+ | |Maria | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aieta | ||
+ | |Michele | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2007 | ||
+ | |2018 | ||
+ | |Reader study level-I and level-II Groups | ||
+ | | | ||
+ | |Breast cancer; Testicular cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |40 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aihara | ||
+ | |Satomi | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |41 | ||
+ | |41 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aihara | ||
+ | |Tomohiko | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2002 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aikata | ||
+ | |Hiroshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2008 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |35 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aikawa | ||
+ | |Keiko | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |1995 | ||
+ | |2010 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Adult T-cell leukemia-lymphoma; Diffuse large B-cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |32 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aiken | ||
+ | |Robert | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |68 | ||
+ | |68 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ailawadhi | ||
+ | |Sikander | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |70 | ||
+ | |51 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aimone | ||
+ | |Paola | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2007 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Chronic myeloid leukemia pediatric; Head and neck cancer; Renal cell carcinoma | ||
+ | |7 | ||
+ | |0 | ||
+ | |3 | ||
+ | |4 | ||
+ | |146 | ||
+ | |116 | ||
+ | |1 | ||
+ | |- | ||
+ | |Airatovich Gafanov | ||
+ | |Rustem | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2016 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |107 | ||
+ | |78 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aird | ||
+ | |William | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2000 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Airewele | ||
+ | |Gladstone | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia pediatric; Sickle cell anemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |56 | ||
+ | |56 | ||
+ | |1 | ||
+ | |- | ||
+ | |Airoma | ||
+ | |G. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |1996 | ||
+ | |GOSCI | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aisa | ||
+ | |Yoshinobu | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2015 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aisner | ||
+ | |D. L. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aisner | ||
+ | |Joseph A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1976 | ||
+ | |2003 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Breast cancer; Head and neck cancer; Soft tissue sarcoma; Thymoma | ||
+ | |9 | ||
+ | |3 | ||
+ | |6 | ||
+ | |0 | ||
+ | |93 | ||
+ | |65 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aisner | ||
+ | |Seena C. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1982 | ||
+ | |2017 | ||
+ | |ECOG; ECOG-ACRIN; SECSG; SWOG | ||
+ | | | ||
+ | |Non-small cell lung cancer; Small cell lung cancer; Thymoma | ||
+ | |8 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |72 | ||
+ | |56 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aitchison | ||
+ | |Michael A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1998 | ||
+ | |2018 | ||
+ | |EORTC; MRC | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |3 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |48 | ||
+ | |47 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aitini | ||
+ | |Enrico | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1987 | ||
+ | |2014 | ||
+ | |GERCOR; GISCAD; Italian Group for the Study of Digestive Tract Cancer; Mammella InterGruppo | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Diffuse large B-cell lymphoma; Gastric cancer; Malignant pleural mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer | ||
+ | |13 | ||
+ | |0 | ||
+ | |10 | ||
+ | |0 | ||
+ | |216 | ||
+ | |176 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aitken | ||
+ | |Casey N. | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Transformed lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aivado | ||
+ | |Manuel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2010 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Immune thrombocytopenia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aix | ||
+ | |Santiago Ponce | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2014 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aizawa | ||
+ | |Masataka | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Upper tract urothelial carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ajani | ||
+ | |Jaffer A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1990 | ||
+ | |2022 | ||
+ | |RTOG; USA Intergroup | ||
+ | | | ||
+ | |Anal cancer; Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer | ||
+ | |21 | ||
+ | |11 | ||
+ | |13 | ||
+ | |5 | ||
+ | |316 | ||
+ | |237 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ajaz | ||
+ | |Mazhar | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2016 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akabane | ||
+ | |Hiromitsu | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2006 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |21 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akaike | ||
+ | |Makoto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2003 | ||
+ | |2014 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akaike | ||
+ | |Tomoko | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Merkel cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |28 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akamaru | ||
+ | |Yusuke | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2007 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akamatsu | ||
+ | |Hiroaki | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |53 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akamatsu | ||
+ | |Hiroki | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2011 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Rectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akapame | ||
+ | |Sydney | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akard | ||
+ | |Luke | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Testicular cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |2 | ||
+ | |40 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akaza | ||
+ | |Hideyuki | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2000 | ||
+ | |2020 | ||
+ | |Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |6 | ||
+ | |3 | ||
+ | |5 | ||
+ | |1 | ||
+ | |66 | ||
+ | |57 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akazawa | ||
+ | |Kohei | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2010 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akazawa | ||
+ | |Rio | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2013 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akbulut | ||
+ | |Hakan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2005 | ||
+ | |Turkish Oncology Group | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |25 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akdas | ||
+ | |Atif | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Turkey | ||
+ | |1997 | ||
+ | |2009 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aker | ||
+ | |Memet | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |1998 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akerley | ||
+ | |Wallace | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2016 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Melanoma; Non-small cell lung cancer; Small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |1 | ||
+ | |74 | ||
+ | |72 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akerman | ||
+ | |Maans | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1989 | ||
+ | |2008 | ||
+ | |Nordic Lymphoma Group | ||
+ | | | ||
+ | |Autologous HSCT; Diffuse large B-cell lymphoma; Mantle cell lymphoma | ||
+ | |2 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |30 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akewanlop | ||
+ | |Charuwan | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Thailand | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akhter | ||
+ | |Chameli | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Bangladesh | ||
+ | |2004 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akilov | ||
+ | |Oleg E. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Cutaneous T-cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |57 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akimasa | ||
+ | |Nakao | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2007 | ||
+ | |Chubu Clinical Cancer Group | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akimov | ||
+ | |Mikhail | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2020 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |31 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akin | ||
+ | |Cem | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2003 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Hypereosinophilic syndrome; Systemic mastocytosis | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akinaga | ||
+ | |Shiro | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2010 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Adult T-cell leukemia-lymphoma; CNS leukemia; Cutaneous T-cell lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |54 | ||
+ | |47 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akita | ||
+ | |Hirotoshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |1992 | ||
+ | | | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akiya | ||
+ | |Toshikazu | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akiyama | ||
+ | |Hideki | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |2013 | ||
+ | |JALSG | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akiyoshi | ||
+ | |Kohei | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2019 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Carcinoma of unknown primary | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akkermans Vogelaar | ||
+ | |Janine M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |2013 | ||
+ | |2022 | ||
+ | |Dutch Pancreatic Cancer Group | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |60 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akopov | ||
+ | |Audrey | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akpek | ||
+ | |Gorgun | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2016 | ||
+ | |BMT CTN | ||
+ | | | ||
+ | |Autologous HSCT; HIV-associated lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akram Hussain | ||
+ | |Syed Md | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Bangladesh | ||
+ | |2004 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akram | ||
+ | |Muhammed | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aksnes | ||
+ | |Anne Kirsti | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Norway | ||
+ | |2008 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aktan | ||
+ | |Gursel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2005 | ||
+ | |2022 | ||
+ | |NeoALTTO Study Team | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |6 | ||
+ | |0 | ||
+ | |5 | ||
+ | |2 | ||
+ | |123 | ||
+ | |95 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aktan | ||
+ | |Melih | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Turkey | ||
+ | |2010 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aktas | ||
+ | |Bahriye | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2000 | ||
+ | |2019 | ||
+ | |GBG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |7 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |144 | ||
+ | |87 | ||
+ | |1 | ||
+ | |- | ||
+ | |Akusawa | ||
+ | |Hiroshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1987 | ||
+ | |1996 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Akash | ||
+ | |Samhar I. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Atypical hemolytic uremic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Ali | ||
+ | |Haifa Kathrin | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1997 | ||
+ | |2017 | ||
+ | |OSHO | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT; Autologous HSCT; Chronic lymphocytic leukemia; CNS lymphoma; Follicular lymphoma; Myelofibrosis | ||
+ | |10 | ||
+ | |1 | ||
+ | |5 | ||
+ | |1 | ||
+ | |165 | ||
+ | |117 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Batran | ||
+ | |Salah Eddin | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2000 | ||
+ | |2020 | ||
+ | |AIO | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Follicular lymphoma; Gastric cancer; Gastrointestinal stromal tumor; Mantle cell lymphoma; Marginal zone lymphoma; MSI-H or dMMR; Waldenstroem macroglobulinemia | ||
+ | |19 | ||
+ | |6 | ||
+ | |10 | ||
+ | |2 | ||
+ | |415 | ||
+ | |280 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Booz | ||
+ | |Hoda | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2012 | ||
+ | |2018 | ||
+ | |De-ESCALaTE HPV Trial Group | ||
+ | | | ||
+ | |Oropharyngeal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Dewik | ||
+ | |Nader | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Qatar | ||
+ | |2015 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Essential thrombocythemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Fayoumi | ||
+ | |Suliman | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Myelofibrosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Ghuzlan | ||
+ | |Abir | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2013 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Thyroid cancer differentiated | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Kali | ||
+ | |Aref | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Myelodysplastic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Kateb | ||
+ | |Hussam | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Rajabi | ||
+ | |Raed | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |2 | ||
+ | |44 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Sakaff | ||
+ | |Nedal | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2001 | ||
+ | |2019 | ||
+ | |Herceptin Adjuvant (HERA) Trial Study Team | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |26 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |al Sarraf | ||
+ | |Muhyi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1977 | ||
+ | |1999 | ||
+ | |Radiation Therapy Oncology Group; RTOG; SWOG | ||
+ | | | ||
+ | |Esophageal cancer; Glioblastoma; Melanoma; Nasopharyngeal carcinoma; Prostate cancer | ||
+ | |7 | ||
+ | |2 | ||
+ | |6 | ||
+ | |1 | ||
+ | |70 | ||
+ | |53 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Sawaf | ||
+ | |Othman | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2005 | ||
+ | |2022 | ||
+ | |GCLLSG | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |6 | ||
+ | |2 | ||
+ | |4 | ||
+ | |1 | ||
+ | |148 | ||
+ | |80 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Shukri | ||
+ | |Salman | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Toubah | ||
+ | |Taymeyah E. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Tweigeri | ||
+ | |Taher | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |1997 | ||
+ | |2005 | ||
+ | |BCIRG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |31 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Al Zoubi | ||
+ | |Ammar | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |28 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alabiso | ||
+ | |O. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Malignant pleural mesothelioma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alakel | ||
+ | |N. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2012 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alakl | ||
+ | |May | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1994 | ||
+ | |2010 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Light-chain (AL) amyloidosis | ||
+ | |5 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |82 | ||
+ | |81 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alam | ||
+ | |A. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alam | ||
+ | |Rafeul | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2001 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Hypereosinophilic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alam | ||
+ | |Yasmin | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2006 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |70 | ||
+ | |47 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alama | ||
+ | |A. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |1987 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alamoudi | ||
+ | |Sameer | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2003 | ||
+ | |2015 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Transformed lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alamouti | ||
+ | |Sepideh | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alanko | ||
+ | |Tuomo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Finland | ||
+ | |2000 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |56 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alao | ||
+ | |Hawwa | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Hypereosinophilic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alapi | ||
+ | |Krisztina Zuborne | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2012 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alarcon | ||
+ | |Jesus | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alashkar | ||
+ | |Ferras | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2021 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Paroxysmal nocturnal hemoglobinuria | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alatorre Alexander | ||
+ | |Jorge | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Mexico | ||
+ | |2016 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alattar | ||
+ | |Mona Lisa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2011 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alavi | ||
+ | |Jane | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |CNS lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alba | ||
+ | |Emilio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1995 | ||
+ | |2021 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |13 | ||
+ | |3 | ||
+ | |12 | ||
+ | |1 | ||
+ | |280 | ||
+ | |186 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albain | ||
+ | |Kathy S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1989 | ||
+ | |2021 | ||
+ | |Breast Cancer Intergroup of North America; NCIC-CTG; NSABP; RTOG; SWOG | ||
+ | | | ||
+ | |Breast cancer; Non-small cell lung cancer | ||
+ | |19 | ||
+ | |4 | ||
+ | |12 | ||
+ | |3 | ||
+ | |361 | ||
+ | |250 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albala | ||
+ | |Maurice M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1968 | ||
+ | |1968 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albanell | ||
+ | |Juan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1987 | ||
+ | |2014 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |38 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albano | ||
+ | |Edythe | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albano | ||
+ | |Francesco | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2004 | ||
+ | |2019 | ||
+ | |GIMEMA | ||
+ | | | ||
+ | |Acute promyelocytic leukemia; Chronic myeloid leukemia | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |113 | ||
+ | |69 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alberici | ||
+ | |Federico | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1994 | ||
+ | |2015 | ||
+ | |GOIRC; POLAR-01 Trial Investigators | ||
+ | | | ||
+ | |Erdheim-Chester disease; Renal cell carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |34 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alberola | ||
+ | |Vincente | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1989 | ||
+ | |2012 | ||
+ | |Spanish Lung Cancer Group | ||
+ | | | ||
+ | |Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | ||
+ | |6 | ||
+ | |1 | ||
+ | |6 | ||
+ | |2 | ||
+ | |109 | ||
+ | |85 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albers | ||
+ | |Gregory W. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albers | ||
+ | |Mary E. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1990 | ||
+ | |1998 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albers | ||
+ | |Peter | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1994 | ||
+ | |2021 | ||
+ | |AUO; EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group | ||
+ | | | ||
+ | |Bladder cancer; Prostate cancer; Testicular cancer | ||
+ | |9 | ||
+ | |3 | ||
+ | |8 | ||
+ | |0 | ||
+ | |156 | ||
+ | |127 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albert | ||
+ | |Catherine M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |NTRK | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |3 | ||
+ | |28 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albert | ||
+ | |Donald | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albert | ||
+ | |Istvan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Hungary | ||
+ | |2006 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |1 | ||
+ | |74 | ||
+ | |64 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albert | ||
+ | |Michael H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2003 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albert | ||
+ | |Paul S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albert | ||
+ | |Ute Susann | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alberti | ||
+ | |Daniele | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albertini | ||
+ | |Mark R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2019 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Melanoma; Uveal melanoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |67 | ||
+ | |58 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alberto | ||
+ | |Pierre | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1979 | ||
+ | |1994 | ||
+ | |SAKK | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |22 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alberts | ||
+ | |David S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1974 | ||
+ | |2019 | ||
+ | |GOG; GRACES Clinical Trial Consortium; Gynecologic Cancer Intergroup; SWOG | ||
+ | | | ||
+ | |Cervical cancer; Multiple myeloma; Ovarian cancer | ||
+ | |16 | ||
+ | |13 | ||
+ | |11 | ||
+ | |1 | ||
+ | |144 | ||
+ | |105 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alberts | ||
+ | |Steven R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1997 | ||
+ | |2017 | ||
+ | |CALGB; ECOG; NCCTG; SWOG | ||
+ | | | ||
+ | |Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Pancreatic cancer | ||
+ | |10 | ||
+ | |2 | ||
+ | |8 | ||
+ | |2 | ||
+ | |121 | ||
+ | |97 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albertsen | ||
+ | |Birgitte Klug | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |2008 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albertson | ||
+ | |Tina M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albertsson | ||
+ | |Maria | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |1991 | ||
+ | |2015 | ||
+ | |Nordic Gastrointestinal Tumour Adjuvant Therapy Group | ||
+ | | | ||
+ | |Colon cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma | ||
+ | |4 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |34 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albiges | ||
+ | |Laurence | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France; USA | ||
+ | |2004 | ||
+ | |2022 | ||
+ | |GETUG | ||
+ | | | ||
+ | |Non-clear cell renal cell carcinoma; Papillary renal cell carcinoma; Prostate cancer; Renal cell carcinoma | ||
+ | |9 | ||
+ | |3 | ||
+ | |7 | ||
+ | |2 | ||
+ | |187 | ||
+ | |143 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albitar | ||
+ | |Maher | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; CNS leukemia; Hypereosinophilic syndrome; Myelodysplastic syndrome; Systemic mastocytosis | ||
+ | |7 | ||
+ | |0 | ||
+ | |2 | ||
+ | |3 | ||
+ | |98 | ||
+ | |74 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albo | ||
+ | |Vincent C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1988 | ||
+ | |1988 | ||
+ | |CCG | ||
+ | | | ||
+ | |T-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albright | ||
+ | |A. L. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |1999 | ||
+ | |CCG | ||
+ | | | ||
+ | |Medulloblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albright | ||
+ | |Robert E. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1999 | ||
+ | |2000 | ||
+ | |Temodal Brain Tumor Group | ||
+ | | | ||
+ | |Anaplastic glioma; Glioblastoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |36 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albritton | ||
+ | |Karen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Ewing sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Albuquerque | ||
+ | |Marco | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alcaide | ||
+ | |Julia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2010 | ||
+ | |2018 | ||
+ | |TTD | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alcaide | ||
+ | |Miguel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alcaraz | ||
+ | |Antonio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2011 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |50 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alcedo | ||
+ | |Juan Carlos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Panama | ||
+ | |2002 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; Cervical cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alcindor | ||
+ | |Thierry | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2003 | ||
+ | |2019 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Gastric cancer; Liposarcoma; Soft tissue sarcoma; Tenosynovial giant cell tumor | ||
+ | |7 | ||
+ | |0 | ||
+ | |6 | ||
+ | |2 | ||
+ | |138 | ||
+ | |107 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aldaoud | ||
+ | |Ali | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1996 | ||
+ | |2017 | ||
+ | |European Mantle Cell Lymphoma Network; GCLLSG; GLSG | ||
+ | | | ||
+ | |Autologous HSCT; Chronic lymphocytic leukemia; Follicular lymphoma; Mantle cell lymphoma; Stem cell mobilization | ||
+ | |6 | ||
+ | |0 | ||
+ | |6 | ||
+ | |1 | ||
+ | |111 | ||
+ | |75 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aldape | ||
+ | |Kenneth D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada; USA | ||
+ | |2002 | ||
+ | |2017 | ||
+ | |Canadian Brain Tumor Consortium; CENTRIC study team; EORTC; RTOG | ||
+ | | | ||
+ | |Anaplastic glioma; Glioblastoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |6 | ||
+ | |0 | ||
+ | |137 | ||
+ | |102 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alderdice | ||
+ | |M. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alderete | ||
+ | |Daniel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1987 | ||
+ | |1997 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alderson | ||
+ | |Derek | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1989 | ||
+ | |2017 | ||
+ | |MRC | ||
+ | | | ||
+ | |Colorectal cancer; Esophageal adenocarcinoma | ||
+ | |3 | ||
+ | |1 | ||
+ | |4 | ||
+ | |0 | ||
+ | |42 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alderuccio | ||
+ | |Juan Pablo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Transformed lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aldrighetti | ||
+ | |Daniela | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2004 | ||
+ | |GONO | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aldrighetti | ||
+ | |Luca | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aledo | ||
+ | |Alexander | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2014 | ||
+ | |COG | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |37 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aledort | ||
+ | |Louis M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1991 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Immune thrombocytopenia | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |35 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alegakis | ||
+ | |Athanasios | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alegre | ||
+ | |Adrian | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2004 | ||
+ | |2021 | ||
+ | |GEM; PETHEMA | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |8 | ||
+ | |0 | ||
+ | |3 | ||
+ | |2 | ||
+ | |199 | ||
+ | |112 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aleinikova | ||
+ | |Olga | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belarus | ||
+ | |2001 | ||
+ | |2020 | ||
+ | |EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute myeloid leukemia pediatric; Allogeneic HSCT | ||
+ | |2 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |49 | ||
+ | |49 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alekar | ||
+ | |Shilpa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aleksandrovic | ||
+ | |Jasna | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1991 | ||
+ | |2000 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alekseev | ||
+ | |Boris Yakovlevich | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2010 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma | ||
+ | |22 | ||
+ | |0 | ||
+ | |15 | ||
+ | |8 | ||
+ | |482 | ||
+ | |310 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alekseev | ||
+ | |Sergey | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2012 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |79 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alekseeva | ||
+ | |Yulia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aleman | ||
+ | |Berthe M. P. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |1988 | ||
+ | |2017 | ||
+ | |EORTC; GELA | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |3 | ||
+ | |1 | ||
+ | |5 | ||
+ | |0 | ||
+ | |75 | ||
+ | |56 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aleman | ||
+ | |Karen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Kaposi sarcoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |27 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alencar | ||
+ | |Alvaro | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2019 | ||
+ | |Blood Cancer Research Partnership of the Leukemia and Lymphoma Society | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alese | ||
+ | |Olatunji B. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alessandri | ||
+ | |S. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1982 | ||
+ | |1986 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alessandrino | ||
+ | |Emilio Paolo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1996 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma; Stem cell mobilization | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |77 | ||
+ | |60 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alessandroni | ||
+ | |Paolo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexander | ||
+ | |Eben | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1969 | ||
+ | |1980 | ||
+ | |BTSG | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |27 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexander | ||
+ | |Sarah | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2011 | ||
+ | |2021 | ||
+ | |Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma | ||
+ | | | ||
+ | |Anaplastic large cell lymphoma pediatric; Non-Hodgkin lymphoma pediatric | ||
+ | |3 | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |38 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexandre | ||
+ | |Jerome | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2006 | ||
+ | |2016 | ||
+ | |JGOG | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexandris | ||
+ | |Ekaterine | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexandru | ||
+ | |Aurelia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Romania | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |77 | ||
+ | |52 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexanian | ||
+ | |Raymond | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1965 | ||
+ | |2008 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |14 | ||
+ | |10 | ||
+ | |3 | ||
+ | |2 | ||
+ | |90 | ||
+ | |48 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexeeva | ||
+ | |Julia A. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2004 | ||
+ | |2016 | ||
+ | |SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network | ||
+ | | | ||
+ | |Acute myeloid leukemia; Mantle cell lymphoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |65 | ||
+ | |63 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexis Vigier | ||
+ | |Magda | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1990 | ||
+ | |2021 | ||
+ | |France Intergroupe des Leucemies Myeloides Chroniques; GOELAMS | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Mantle cell lymphoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |106 | ||
+ | |96 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexopoulos | ||
+ | |Athanasios | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |2003 | ||
+ | |Greek Oncology Cooperative Group (GOCG) for Lung Cancer; HORG | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |19 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alexopoulos | ||
+ | |Constantinos G. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2007 | ||
+ | |ELCWP | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |51 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alfaro | ||
+ | |Elizabeth | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1987 | ||
+ | |1997 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alfaro | ||
+ | |Vicente | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2008 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |84 | ||
+ | |76 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alfieri | ||
+ | |Sergio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2005 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Rectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alfonsi | ||
+ | |Marc | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1994 | ||
+ | |2020 | ||
+ | |GORTEC | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |9 | ||
+ | |0 | ||
+ | |8 | ||
+ | |0 | ||
+ | |162 | ||
+ | |84 | ||
+ | |1 | ||
+ | |- | ||
+ | |Algarra | ||
+ | |Lorenzo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2014 | ||
+ | |2021 | ||
+ | |PETHEMA Group | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |32 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Algazi | ||
+ | |Alain P. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |CNS melanoma; Melanoma | ||
+ | |7 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |166 | ||
+ | |91 | ||
+ | |1 | ||
+ | |- | ||
+ | |Algeri | ||
+ | |Renato | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1991 | ||
+ | |2000 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Algul | ||
+ | |Hana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2015 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Adnan | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2005 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |49 | ||
+ | |49 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Arif N. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1990 | ||
+ | |2018 | ||
+ | |RTOG | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Haris | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Graft versus host disease | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Haythem | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Thyroid cancer medullary | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |36 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Kulsam | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Marco | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2017 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Thymoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Nasim | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2010 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Gastrointestinal stromal tumor; Leiomyosarcoma; Soft tissue sarcoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |38 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Ridvan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Saad | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2015 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Endometrial cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Sahra | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2006 | ||
+ | |2017 | ||
+ | |MRC; UK NCRI | ||
+ | | | ||
+ | |Acute myeloid leukemia; Essential thrombocythemia; Myelofibrosis | ||
+ | |4 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |53 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Shamshad | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1992 | ||
+ | |2014 | ||
+ | |GOG | ||
+ | | | ||
+ | |Cervical cancer; Vulvar cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Shyanne | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ali | ||
+ | |Siraj M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Non-small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |121 | ||
+ | |106 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aliberti | ||
+ | |Camillo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aliberti | ||
+ | |Sandra | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2009 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Osteosarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alietti | ||
+ | |Alessandra | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |39 | ||
+ | |39 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alimam | ||
+ | |Samah | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2012 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Essential thrombocythemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alimena | ||
+ | |Giuliana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2001 | ||
+ | |2016 | ||
+ | |EORTC; GIMEMA; GIMEMA CML Working Party | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic myeloid leukemia | ||
+ | |8 | ||
+ | |0 | ||
+ | |3 | ||
+ | |2 | ||
+ | |171 | ||
+ | |108 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alinari | ||
+ | |Lapo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |51 | ||
+ | |39 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aljijakli | ||
+ | |Ahmad | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2008 | ||
+ | |2012 | ||
+ | |ALFA | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aljitawi | ||
+ | |Omar S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2011 | ||
+ | |2011 | ||
+ | |BMT CTN | ||
+ | | | ||
+ | |Allogeneic HSCT | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aljumaily | ||
+ | |Raid | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alkan | ||
+ | |Serhan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alkhouri | ||
+ | |Naim | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Thrombocytopenia in liver disease | ||
+ | |1 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alkindi | ||
+ | |Salam | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Oman | ||
+ | |2017 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Sickle cell anemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alkuzweny | ||
+ | |Baha | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allaham | ||
+ | |Wassim | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2011 | ||
+ | |2017 | ||
+ | |SARAH Trial Group | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |36 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allal | ||
+ | |Abdelkarim S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2011 | ||
+ | |SAKK | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |28 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allan | ||
+ | |John N. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2021 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Waldenstroem macroglobulinemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allan | ||
+ | |Karen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2008 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allan | ||
+ | |Norman C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1986 | ||
+ | |1995 | ||
+ | |MRC | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alland | ||
+ | |Leila | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; Breast cancer; Chronic myeloid leukemia; Hypereosinophilic syndrome; Systemic mastocytosis | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |43 | ||
+ | |41 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allangba | ||
+ | |Olivier | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2013 | ||
+ | |2018 | ||
+ | |IFM | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |77 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allard | ||
+ | |Christian | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2003 | ||
+ | |2010 | ||
+ | |Intergroupe Francais des Leucemies Myeloides Chroniques; SPIRIT Investigators | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allegra | ||
+ | |Carmen J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1991 | ||
+ | |2020 | ||
+ | |NSABP; SWOG | ||
+ | | | ||
+ | |Colon cancer; Colorectal cancer; Rectal cancer | ||
+ | |11 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |153 | ||
+ | |82 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allegrini | ||
+ | |Giacomo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2001 | ||
+ | |2015 | ||
+ | |GONO | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |75 | ||
+ | |48 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen Mersh | ||
+ | |T. G. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1988 | ||
+ | |1994 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Aaron M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Israel | ||
+ | |2008 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Andrew R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Carl | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2020 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Hemophagocytic lymphohistiocytosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Jeffrey C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1985 | ||
+ | |1999 | ||
+ | |CCG | ||
+ | | | ||
+ | |High-grade glioma pediatric; Low-grade glioma; Medulloblastoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |47 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Jennifer L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2015 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Endometrial cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Jill N. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma; Pancreatic cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |56 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |John | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1995 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |L. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1984 | ||
+ | |1985 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Lee F. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Cutaneous T-cell lymphoma; Immune thrombocytopenia; Peripheral T-cell lymphoma; Thrombocytopenia in liver disease | ||
+ | |4 | ||
+ | |1 | ||
+ | |3 | ||
+ | |1 | ||
+ | |47 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Mary S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Peter J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Roberta S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allen | ||
+ | |Steven L. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1977 | ||
+ | |2015 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; Adult T-cell leukemia-lymphoma; Breast cancer; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma | ||
+ | |9 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |128 | ||
+ | |100 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allepuz | ||
+ | |Alex | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2013 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Chronic myeloid leukemia pediatric | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |2 | ||
+ | |63 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allerton | ||
+ | |Rozenn | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2009 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; CNS carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allevi | ||
+ | |G. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allewelt | ||
+ | |Heather | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Marginal zone lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allgeier | ||
+ | |Anouk | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |1988 | ||
+ | |2012 | ||
+ | |EORTC; NCIC-CTG | ||
+ | | | ||
+ | |Anaplastic glioma; Glioblastoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |84 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allietta | ||
+ | |Nathalie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2006 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |20 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allione | ||
+ | |Bernardino | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1993 | ||
+ | |2020 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic myelomonocytic leukemia; HIV-associated lymphoma; Multiple myeloma | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |81 | ||
+ | |80 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allis | ||
+ | |Simona | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allison | ||
+ | |James | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Anal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |28 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allison | ||
+ | |Mary Ann K. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allman | ||
+ | |David | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1996 | ||
+ | |2001 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allmark | ||
+ | |Christine | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allmer | ||
+ | |Christine | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2008 | ||
+ | |NCCTG | ||
+ | | | ||
+ | |Mantle cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alloisio | ||
+ | |M. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allolio | ||
+ | |Bruno | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2004 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Adrenocortical carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |36 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allotey | ||
+ | |David | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2011 | ||
+ | |2021 | ||
+ | |UK NCRI | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allouache | ||
+ | |Djelila | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1999 | ||
+ | |2022 | ||
+ | |GINECO; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) | ||
+ | | | ||
+ | |Breast cancer; Carcinoma of unknown primary | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |58 | ||
+ | |55 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allouache | ||
+ | |Nedla | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2006 | ||
+ | |2019 | ||
+ | |GETUG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allred | ||
+ | |Alicia J. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma; Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |60 | ||
+ | |59 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allred | ||
+ | |D. Craig | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1989 | ||
+ | |2011 | ||
+ | |ACOSOG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |38 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allred | ||
+ | |Jacob B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Light-chain (AL) amyloidosis; Multiple myeloma; Myelofibrosis | ||
+ | |7 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |126 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allsup | ||
+ | |David J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2006 | ||
+ | |2017 | ||
+ | |NCRI | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |38 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Allum | ||
+ | |William H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1976 | ||
+ | |2017 | ||
+ | |British Stomach Cancer Group; MAGIC Trial Participants; MRC | ||
+ | | | ||
+ | |Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer | ||
+ | |5 | ||
+ | |3 | ||
+ | |5 | ||
+ | |0 | ||
+ | |40 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ally | ||
+ | |Mina S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Cutaneous basal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alm | ||
+ | |Gunnar | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |1983 | ||
+ | |1983 | ||
+ | | | ||
+ | | | ||
+ | |Neuroendocrine tumor | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |- | ||
+ | |Almeida | ||
+ | |Antonio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Portugal | ||
+ | |2010 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Myelodysplastic syndrome | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |48 | ||
+ | |39 | ||
+ | |1 | ||
+ | |- | ||
+ | |Almeida | ||
+ | |M. S. S. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Brazil | ||
+ | |2006 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Almenar | ||
+ | |Daniel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2005 | ||
+ | |Spanish Germ Cell Cancer Cooperative Group; Spanish Lung Cancer Group | ||
+ | | | ||
+ | |Non-small cell lung cancer; Testicular cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |38 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Almenar | ||
+ | |Sergio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1999 | ||
+ | |2010 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |64 | ||
+ | |49 | ||
+ | |1 | ||
+ | |- | ||
+ | |Almond | ||
+ | |Jennifer P. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2001 | ||
+ | |European Study Group for Pancreatic Cancer | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aloe | ||
+ | |Alessandra | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aloj | ||
+ | |Luigi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2014 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso Carrion | ||
+ | |Lorenzo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2021 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Uveal melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso Garcia | ||
+ | |Miriam | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1995 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | ||
+ | |2 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |44 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso Gordoa | ||
+ | |Teresa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2016 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Clear cell renal cell carcinoma; Renal cell carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |56 | ||
+ | |55 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso Orduna | ||
+ | |Vicente | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2006 | ||
+ | |2012 | ||
+ | |TTD | ||
+ | | | ||
+ | |Colorectal cancer; Esophageal adenocarcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Carmen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1994 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Guillermo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2010 | ||
+ | |Spanish Lung Cancer Group | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Liuba | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Cuba | ||
+ | |2006 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Maria Carmen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1978 | ||
+ | |1995 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |13 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Mirta Garcia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2009 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Natalia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2013 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Burkitt lymphoma; HIV-associated lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonso | ||
+ | |Silvia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alonzo | ||
+ | |Todd A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1979 | ||
+ | |2014 | ||
+ | |CCG; COG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute myeloid leukemia pediatric; Chronic myeloid leukemia pediatric | ||
+ | |4 | ||
+ | |1 | ||
+ | |4 | ||
+ | |1 | ||
+ | |46 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alousi | ||
+ | |Amin M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2020 | ||
+ | |BMT CTN | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT; Follicular lymphoma; Graft versus host disease; Mantle cell lymphoma; Transformed lymphoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |84 | ||
+ | |60 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alpen | ||
+ | |B. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |1997 | ||
+ | | | ||
+ | | | ||
+ | |MALT lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alquati | ||
+ | |Palmiro | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1991 | ||
+ | |2005 | ||
+ | |Epirubicin-Lonidamine Group | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |46 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alsayed | ||
+ | |Yazan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |4 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |59 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alsina Maqueda | ||
+ | |Maria | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2011 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer | ||
+ | |8 | ||
+ | |0 | ||
+ | |8 | ||
+ | |2 | ||
+ | |161 | ||
+ | |129 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alsina | ||
+ | |Melissa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2001 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |14 | ||
+ | |0 | ||
+ | |2 | ||
+ | |4 | ||
+ | |279 | ||
+ | |159 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altavilla | ||
+ | |Giuseppe | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1983 | ||
+ | |2012 | ||
+ | |Associazione Italiana Oncologia Toracica; Groupe Francais de Pneumo-Cancerologie; Italian Lung Cancer Project; Italian Lung Cancer Task Force; Italian Multicentre Breast Study with Epirubicin; Spanish Lung Cancer Group | ||
+ | | | ||
+ | |Breast cancer; Non-small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |1 | ||
+ | |157 | ||
+ | |151 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altenhofer | ||
+ | |Petra | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Austria | ||
+ | |2010 | ||
+ | |2016 | ||
+ | |AGMT | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alter | ||
+ | |Robert S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alterio | ||
+ | |D. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2008 | ||
+ | |2017 | ||
+ | |GSTTC | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |36 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altermatt | ||
+ | |Hans J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2007 | ||
+ | |BIG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altes | ||
+ | |Albert | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Althaus | ||
+ | |Betsy L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; Gastric cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |42 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Althausen | ||
+ | |Alex F. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1993 | ||
+ | |1993 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altieri | ||
+ | |Vincenzo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2011 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |Penile cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altinbas | ||
+ | |M. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |2005 | ||
+ | |Turkish Oncology Group | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altinmakas | ||
+ | |Emre | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Non-clear cell renal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altintas | ||
+ | |Sevilay | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |2011 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altman | ||
+ | |Arnold | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altman | ||
+ | |Jessica K. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2022 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; Hairy cell leukemia; Myelodysplastic syndrome | ||
+ | |10 | ||
+ | |0 | ||
+ | |4 | ||
+ | |2 | ||
+ | |248 | ||
+ | |176 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altman | ||
+ | |Stanley J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1979 | ||
+ | |1993 | ||
+ | |COG; SWOG | ||
+ | | | ||
+ | |Breast cancer; Soft tissue sarcoma; Testicular cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altmann | ||
+ | |Bettina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2003 | ||
+ | |2021 | ||
+ | |DSHNHL; FLYER Trial Investigators; German Lymphoma Alliance | ||
+ | | | ||
+ | |Autologous HSCT; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma | ||
+ | |4 | ||
+ | |1 | ||
+ | |4 | ||
+ | |0 | ||
+ | |130 | ||
+ | |90 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altorjai | ||
+ | |Gabriela | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altorki | ||
+ | |Nasser K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altug | ||
+ | |Sedat | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Turkey | ||
+ | |2009 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer nonsquamous | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Altwein | ||
+ | |Jens Erik | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1986 | ||
+ | |1991 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alu | ||
+ | |Massimiliano | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alumkal | ||
+ | |Joshi J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2017 | ||
+ | |Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |40 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alva | ||
+ | |Ajjai S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2021 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Bladder cancer; Clear cell renal cell carcinoma; Papillary renal cell carcinoma; Renal cell carcinoma | ||
+ | |4 | ||
+ | |1 | ||
+ | |3 | ||
+ | |2 | ||
+ | |100 | ||
+ | |92 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarado | ||
+ | |Gladys | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarado | ||
+ | |Yesid | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Myelodysplastic syndrome | ||
+ | |4 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |115 | ||
+ | |66 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez Cabellos | ||
+ | |Ruth | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2013 | ||
+ | |2013 | ||
+ | |GOTEL | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez de Celis | ||
+ | |Isabel | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2004 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez Larran | ||
+ | |Alberto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Myelofibrosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez Secord | ||
+ | |Angeles | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1999 | ||
+ | |2022 | ||
+ | |GOG | ||
+ | | | ||
+ | |Endometrial cancer; Gestational trophoblastic neoplasia; Low-grade serous ovarian cancer; Ovarian cancer | ||
+ | |8 | ||
+ | |1 | ||
+ | |7 | ||
+ | |2 | ||
+ | |149 | ||
+ | |122 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez Twose | ||
+ | |Ivan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2018 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Systemic mastocytosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez Vicent | ||
+ | |J. J. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Ana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2005 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Axxx | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Argentina | ||
+ | |1991 | ||
+ | |1999 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Elena | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1987 | ||
+ | |1999 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Isabel | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1995 | ||
+ | |2020 | ||
+ | |ANZ BCTG; GEICAM; Intergroup Exemestane Study | ||
+ | | | ||
+ | |Breast cancer; Diffuse large B-cell lymphoma | ||
+ | |9 | ||
+ | |0 | ||
+ | |9 | ||
+ | |1 | ||
+ | |230 | ||
+ | |159 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Ivan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2006 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Hodgkin lymphoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Jose Valero | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2008 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Ofelia A. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Sickle cell anemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Pablo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2007 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Thyroid cancer differentiated | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarez | ||
+ | |Ronald D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1985 | ||
+ | |2008 | ||
+ | |GOG; GRACES Clinical Trial Consortium; SWOG | ||
+ | | | ||
+ | |Cervical cancer; Endometrial cancer; Ovarian cancer | ||
+ | |5 | ||
+ | |1 | ||
+ | |4 | ||
+ | |0 | ||
+ | |39 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvarnas | ||
+ | |Joseph C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2016 | ||
+ | |BMT CTN | ||
+ | | | ||
+ | |Autologous HSCT; HIV-associated lymphoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alvegaard | ||
+ | |Thor | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2004 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Gastrointestinal stromal tumor | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |58 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aly | ||
+ | |Abdalla | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alyasova | ||
+ | |Anna | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Russian Federation | ||
+ | |2010 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer; Renal cell carcinoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |95 | ||
+ | |89 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alyea | ||
+ | |Edwin P. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2003 | ||
+ | |2017 | ||
+ | |BMT CTN; CALGB | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma | ||
+ | |3 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |60 | ||
+ | |51 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alzate | ||
+ | |Stefanie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alzieu | ||
+ | |Claude | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1984 | ||
+ | |2006 | ||
+ | |FNCLCC | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Alzouebi | ||
+ | |Mymoona | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2005 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |46 | ||
+ | |46 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amabile | ||
+ | |Marilina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2009 | ||
+ | |GIMEMA; GIMEMA CML Working Party; Italian Cooperative Study Group on Myeloid Leukemia | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |51 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amado | ||
+ | |Rafael G. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |2 | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amador Barciela | ||
+ | |Maria L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2014 | ||
+ | |2021 | ||
+ | |PETHEMA Group | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |32 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amador | ||
+ | |Rosa M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Cuba | ||
+ | |2006 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amadori | ||
+ | |Dino | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1981 | ||
+ | |2017 | ||
+ | |GONO; International Collaborative Cancer Group | ||
+ | | | ||
+ | |Bladder cancer; Breast cancer; Colorectal cancer; Gastric cancer; Hepatocellular carcinoma | ||
+ | |14 | ||
+ | |4 | ||
+ | |11 | ||
+ | |0 | ||
+ | |196 | ||
+ | |155 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amadori | ||
+ | |Sergio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1984 | ||
+ | |2020 | ||
+ | |AIEOP; EORTC; German-Austrian Acute Myeloid Leukemia Study Group; GIMEMA; Study Alliance Leukemia | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; CNS leukemia; Diffuse large B-cell lymphoma; Multiple myeloma; Myelodysplastic syndrome | ||
+ | |30 | ||
+ | |7 | ||
+ | |21 | ||
+ | |3 | ||
+ | |594 | ||
+ | |249 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amaducci | ||
+ | |Laura | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1997 | ||
+ | |2021 | ||
+ | |GIM; Reader study level-I and level-II Groups | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |77 | ||
+ | |71 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amagai | ||
+ | |Kenji | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2008 | ||
+ | |2018 | ||
+ | |Tokyo Cooperative Oncology Group | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |70 | ||
+ | |61 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amam | ||
+ | |Josif | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2005 | ||
+ | |2019 | ||
+ | |FLYER Trial Investigators; German Lymphoma Alliance | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |43 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amann | ||
+ | |G. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2001 | ||
+ | | | ||
+ | | | ||
+ | |Ewing sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amano | ||
+ | |Hodaka | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1986 | ||
+ | |2002 | ||
+ | |Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract | ||
+ | | | ||
+ | |Periampullary adenocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amant | ||
+ | |Frederic | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |1998 | ||
+ | |2010 | ||
+ | |EORTC; NCIC-CTG | ||
+ | | | ||
+ | |Breast cancer; Ovarian cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |32 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amar | ||
+ | |Avraham | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |1998 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amaravadi | ||
+ | |Ravi K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amare | ||
+ | |Mammo | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1977 | ||
+ | |1983 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amato | ||
+ | |Giovanni | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2013 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |CNS melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amato | ||
+ | |Robert J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1985 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Penile cancer; Prostate cancer; Renal cell carcinoma; Testicular cancer | ||
+ | |5 | ||
+ | |2 | ||
+ | |3 | ||
+ | |0 | ||
+ | |39 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amato | ||
+ | |S. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Argentina | ||
+ | |1995 | ||
+ | |1999 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amatruda | ||
+ | |Thomas T. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2015 | ||
+ | |NCCTG | ||
+ | | | ||
+ | |Melanoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |48 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amatu | ||
+ | |Alessio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2012 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer; Non-small cell lung cancer; NTRK | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |2 | ||
+ | |63 | ||
+ | |57 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambarkhane | ||
+ | |Sumeet | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2016 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Transformed lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |36 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambinder | ||
+ | |Richard F. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2018 | ||
+ | |A5264/AMC-067 REACT-KS Team; AIDS Malignancy Consortium; BMT CTN | ||
+ | | | ||
+ | |Autologous HSCT; Burkitt lymphoma; Diffuse large B-cell lymphoma; Graft versus host disease; HIV-associated lymphoma; Hodgkin lymphoma; Kaposi sarcoma | ||
+ | |9 | ||
+ | |2 | ||
+ | |4 | ||
+ | |0 | ||
+ | |136 | ||
+ | |109 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambo | ||
+ | |Y. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2007 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambros | ||
+ | |Peter F. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Austria | ||
+ | |2002 | ||
+ | |2018 | ||
+ | |SIOP Europe Neuroblastoma Group (SIOPEN) | ||
+ | | | ||
+ | |Neuroblastoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |50 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrose | ||
+ | |David | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrosetti | ||
+ | |Achille | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1995 | ||
+ | |2017 | ||
+ | |FIL; IELSG | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; CNS lymphoma; Hairy cell leukemia; Hodgkin lymphoma; MALT lymphoma; Mantle cell lymphoma | ||
+ | |7 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |211 | ||
+ | |166 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrosini | ||
+ | |Giovanni | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1983 | ||
+ | |2011 | ||
+ | |Italian Multicentre Breast Study with Epirubicin | ||
+ | | | ||
+ | |Breast cancer; Rectal cancer | ||
+ | |3 | ||
+ | |2 | ||
+ | |2 | ||
+ | |0 | ||
+ | |97 | ||
+ | |96 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrosini | ||
+ | |Grazia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Uveal melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrosini | ||
+ | |Maria Teresa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2007 | ||
+ | |GIMEMA--Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto; Italian Multiple Myeloma Network | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |52 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrosio | ||
+ | |Francesca | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2009 | ||
+ | |2017 | ||
+ | |GOIRC | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ambrun | ||
+ | |Alexis | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2016 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Hereditary hemorrhagic telangiectasia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amellal | ||
+ | |Nadia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany; USA | ||
+ | |1999 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |3 | ||
+ | |53 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amendola | ||
+ | |Angela | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2006 | ||
+ | |GIMEMA | ||
+ | | | ||
+ | |Immune thrombocytopenia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amenedo Gancedo | ||
+ | |Margarita | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1999 | ||
+ | |2020 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer; Ovarian cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |93 | ||
+ | |48 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ames | ||
+ | |Frederick C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1977 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |65 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ames | ||
+ | |Patricia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ameye | ||
+ | |Lieveke | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |1998 | ||
+ | |2015 | ||
+ | |BIG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amiel | ||
+ | |Jean Louis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1969 | ||
+ | |1969 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amillano | ||
+ | |Kepa | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |39 | ||
+ | |39 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amin | ||
+ | |Amanda L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amin | ||
+ | |Asim | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Renal cell carcinoma; Small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |1 | ||
+ | |2 | ||
+ | |107 | ||
+ | |74 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amin | ||
+ | |Bipinkumar | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2011 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amin | ||
+ | |Himal | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |92 | ||
+ | |61 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amin | ||
+ | |Mahul B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada; USA | ||
+ | |1994 | ||
+ | |2020 | ||
+ | |RTOG | ||
+ | | | ||
+ | |Prostate cancer; Upper tract urothelial carcinoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |61 | ||
+ | |57 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aminossadati | ||
+ | |Behnaz | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Neuroendocrine tumor; Pancreatic NET | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amiot | ||
+ | |Martine | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2012 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amista | ||
+ | |P. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amler | ||
+ | |Susanne | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2000 | ||
+ | |2018 | ||
+ | |AML-CG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Autologous HSCT; Ewing sarcoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |84 | ||
+ | |84 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ammassari | ||
+ | |Adriana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |HIV-associated lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amonkar | ||
+ | |Mayur | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer; Head and neck cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |43 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amorim | ||
+ | |Gilberto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2019 | ||
+ | |CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group) | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |37 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amoroso | ||
+ | |Domenico | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2007 | ||
+ | |2018 | ||
+ | |GOIRC | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Non-small cell lung cancer | ||
+ | |5 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |105 | ||
+ | |85 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amoroso | ||
+ | |Mariangela | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Cervical cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amoroso | ||
+ | |Vito | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amos | ||
+ | |Claire L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2005 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |141 | ||
+ | |83 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amott | ||
+ | |S. J. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1984 | ||
+ | |1996 | ||
+ | |MRC | ||
+ | | | ||
+ | |Rectal cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amoura | ||
+ | |Zahir | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2014 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Erdheim-Chester disease | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amrein | ||
+ | |Philip C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2004 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amthauer | ||
+ | |Holger | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2012 | ||
+ | |Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amundsen | ||
+ | |Tore | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |21 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amunni | ||
+ | |Gianni | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Cervical cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amutio | ||
+ | |Elena | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2003 | ||
+ | |Programa de Estudio y Traitmiento de las Hemopatias Malignas | ||
+ | | | ||
+ | |Acute promyelocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amylon | ||
+ | |Michael D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1987 | ||
+ | |1999 | ||
+ | |POG | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Graft versus host disease; T-cell acute lymphoblastic leukemia pediatric | ||
+ | |3 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |36 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Amzal | ||
+ | |Billy | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2011 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |An | ||
+ | |Gang | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |China | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |An | ||
+ | |J. Y. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Korea | ||
+ | |2013 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |An | ||
+ | |Ruifang | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |China | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |70 | ||
+ | |60 | ||
+ | |1 | ||
+ | |- | ||
+ | |An | ||
+ | |Xin | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |China | ||
+ | |2010 | ||
+ | |2022 | ||
+ | |South China Breast Cancer Group (SCBCG) | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |58 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |An | ||
+ | |Xuebei | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; CNS carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |28 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anagnostopoulos | ||
+ | |Achilles | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |2007 | ||
+ | |2022 | ||
+ | |HORG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic myelomonocytic leukemia; Colon cancer; Myelodysplastic syndrome | ||
+ | |5 | ||
+ | |0 | ||
+ | |4 | ||
+ | |1 | ||
+ | |104 | ||
+ | |80 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anagnostopoulos | ||
+ | |Athanasios | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma; Waldenstroem macroglobulinemia | ||
+ | |5 | ||
+ | |2 | ||
+ | |1 | ||
+ | |0 | ||
+ | |58 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anagnostopoulos | ||
+ | |Ioannis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1999 | ||
+ | |2016 | ||
+ | |European PTLD Network; German PTLD Study Group. | ||
+ | | | ||
+ | |Post-transplant lymphoproliferative disorder | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |51 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anagnostopoulos | ||
+ | |Nikolaos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma; Waldenstroem macroglobulinemia | ||
+ | |5 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |59 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anagnostopoulou | ||
+ | |Ourania | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anaissie | ||
+ | |Elias | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1990 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |9 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |122 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anak | ||
+ | |Oezlem | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland; USA | ||
+ | |1999 | ||
+ | |2021 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Autologous HSCT; Colorectal cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Hepatocellular carcinoma; Renal cell carcinoma; Subependymal giant cell astrocytoma; Transformed lymphoma | ||
+ | |7 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |147 | ||
+ | |139 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anand | ||
+ | |Aseem | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2010 | ||
+ | |Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anand | ||
+ | |Palka | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ananthakrishnan | ||
+ | |Revathi | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anasetti | ||
+ | |Claudio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1985 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Chronic myeloid leukemia | ||
+ | |2 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |28 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anastasi | ||
+ | |John | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2008 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anastasia | ||
+ | |Antonella | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2008 | ||
+ | |2021 | ||
+ | |FIL; Rete Ematologica Lombarda–CLL Workgroup | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Follicular lymphoma; Hairy cell leukemia; Hodgkin lymphoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |136 | ||
+ | |121 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anastasopoulou | ||
+ | |Anastasia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2001 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Cervical cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ancell | ||
+ | |Kristin | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Uveal melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anchisi | ||
+ | |Sandro | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2007 | ||
+ | |2016 | ||
+ | |SAKK | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |39 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anciaux | ||
+ | |Nicole | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2006 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ancliff | ||
+ | |Philip | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ancona | ||
+ | |Ermanno | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1992 | ||
+ | |2001 | ||
+ | | | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ancukiewicz | ||
+ | |Marek | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andel | ||
+ | |Johannes | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Austria | ||
+ | |2007 | ||
+ | |2016 | ||
+ | |AGMT | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |45 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andergassen | ||
+ | |Ulrich | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2005 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderl | ||
+ | |Janet | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderlini | ||
+ | |Paolo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma | ||
+ | |6 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |101 | ||
+ | |55 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anders | ||
+ | |Carey K. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2022 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Breast cancer; CNS carcinoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |1 | ||
+ | |90 | ||
+ | |68 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anders | ||
+ | |Robert A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; MSI-H or dMMR | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |79 | ||
+ | |57 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Barbara L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |E. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |1990 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |J. C. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1994 | ||
+ | |1994 | ||
+ | | | ||
+ | | | ||
+ | |Immune thrombocytopenia | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |James S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1992 | ||
+ | |1996 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Janet W. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1977 | ||
+ | |2002 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Acute promyelocytic leukemia; Breast cancer; Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma | ||
+ | |6 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |56 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Jay C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Joern Erik | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |1994 | ||
+ | |2000 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |John | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1992 | ||
+ | |1997 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Jorn | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |1977 | ||
+ | |2013 | ||
+ | |DBCG; Intergroup Exemestane Study; Scandinavian Breast Group | ||
+ | | | ||
+ | |Breast cancer; Diffuse large B-cell lymphoma | ||
+ | |10 | ||
+ | |2 | ||
+ | |8 | ||
+ | |1 | ||
+ | |126 | ||
+ | |76 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Knud West | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1977 | ||
+ | |1983 | ||
+ | |DBCG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |12 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Niels Frost | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |2005 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |101 | ||
+ | |92 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Niels S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |2000 | ||
+ | |2016 | ||
+ | |Nordic Lymphoma Group | ||
+ | | | ||
+ | |Autologous HSCT; Mantle cell lymphoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |67 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersen | ||
+ | |Willie A. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |2004 | ||
+ | |GOG | ||
+ | | | ||
+ | |Cervical cancer; Endometrial cancer | ||
+ | |4 | ||
+ | |4 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Abraham | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Esophageal adenocarcinoma; Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |40 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Barrie | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |1997 | ||
+ | |GOG | ||
+ | | | ||
+ | |Cervical cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Barry | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2001 | ||
+ | |2010 | ||
+ | |CCG; COG | ||
+ | | | ||
+ | |Ewing sarcoma; Neuroblastoma; Osteosarcoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Cathy | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1980 | ||
+ | |1987 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT; Diffuse large B-cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Charles K. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |47 | ||
+ | |47 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Clay M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1995 | ||
+ | |2022 | ||
+ | |RTOG | ||
+ | | | ||
+ | |Esophageal cancer; Melanoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |41 | ||
+ | |41 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Daniel M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2021 | ||
+ | |ECOG | ||
+ | | | ||
+ | |Breast cancer; Follicular lymphoma; Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |74 | ||
+ | |74 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |David R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2003 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Antiphospholipid antibody syndrome; Venous thromboembolism | ||
+ | |3 | ||
+ | |2 | ||
+ | |3 | ||
+ | |0 | ||
+ | |65 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Harald | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |1978 | ||
+ | |2016 | ||
+ | |Nordic Lymphoma Group; Scandinavian Breast Group | ||
+ | | | ||
+ | |Autologous HSCT; Breast cancer; CNS lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma | ||
+ | |7 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |92 | ||
+ | |76 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Heather A. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2006 | ||
+ | |BTOG | ||
+ | | | ||
+ | |Esophageal cancer; Gastric cancer; Non-small cell lung cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |4 | ||
+ | |0 | ||
+ | |47 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |J. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Anaplastic glioma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |James R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1972 | ||
+ | |2019 | ||
+ | |CALGB; CCG; COG; ECOG | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Melanoma; Rhabdomyosarcoma; Soft tissue sarcoma | ||
+ | |14 | ||
+ | |2 | ||
+ | |11 | ||
+ | |1 | ||
+ | |164 | ||
+ | |124 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Jeanne E. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1995 | ||
+ | |2002 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Jeffrey | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |40 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Jennifer J. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1976 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT; Light-chain (AL) amyloidosis | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |John B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1995 | ||
+ | |2012 | ||
+ | |MRC; NCIC | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |52 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Karen S. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |33 | ||
+ | |33 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Kenneth C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1982 | ||
+ | |2022 | ||
+ | |CALGB; FIRST Trial Team; IFM; SWOG; Waldenstroem's Macroglobulinemia Clinical Trials Group | ||
+ | | | ||
+ | |Autologous HSCT; Diffuse large B-cell lymphoma; Multiple myeloma; Waldenstroem macroglobulinemia | ||
+ | |38 | ||
+ | |18 | ||
+ | |13 | ||
+ | |9 | ||
+ | |818 | ||
+ | |389 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Larry D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |4 | ||
+ | |1 | ||
+ | |2 | ||
+ | |2 | ||
+ | |167 | ||
+ | |151 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Lisa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Lxxx | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |1994 | ||
+ | |BNLI | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |12 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Mary Ann | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Australia | ||
+ | |2011 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia; Mantle cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |34 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Michael J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark; USA | ||
+ | |1979 | ||
+ | |2015 | ||
+ | |BIG | ||
+ | | | ||
+ | |Breast cancer; Cutaneous T-cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |29 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Nancy | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2020 | ||
+ | |GOG | ||
+ | | | ||
+ | |Gestational trophoblastic neoplasia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Nicole D. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT; CNS lymphoma; Stem cell mobilization | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Patricia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1985 | ||
+ | |1992 | ||
+ | |SWOG | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Peter M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Osteosarcoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Richard T. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1979 | ||
+ | |1991 | ||
+ | |NCCTG | ||
+ | | | ||
+ | |Non-small cell lung cancer; Small cell lung cancer | ||
+ | |2 | ||
+ | |2 | ||
+ | |2 | ||
+ | |0 | ||
+ | |24 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Russell D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2009 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Sibyl | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2003 | ||
+ | |2010 | ||
+ | |Sorafenib TARGET Clinical Trial Group | ||
+ | | | ||
+ | |Clear cell renal cell carcinoma; Renal cell carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |27 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Stewart J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1982 | ||
+ | |2018 | ||
+ | |BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; NSABP | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |11 | ||
+ | |0 | ||
+ | |11 | ||
+ | |2 | ||
+ | |153 | ||
+ | |81 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Sxxx | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1996 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Tara | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2009 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anderson | ||
+ | |Thomas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1972 | ||
+ | |2008 | ||
+ | |ECOG; Hoosier Oncology Group; US Oncology | ||
+ | | | ||
+ | |Colorectal cancer; Non-small cell lung cancer; Ovarian cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersson | ||
+ | |Borje S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1990 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT; Breast cancer; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Multiple myeloma | ||
+ | |8 | ||
+ | |3 | ||
+ | |2 | ||
+ | |0 | ||
+ | |125 | ||
+ | |99 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersson | ||
+ | |Haakan | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2010 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Endometrial cancer; Ovarian cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |29 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersson | ||
+ | |Michael | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Denmark | ||
+ | |1977 | ||
+ | |2021 | ||
+ | |BIG; DBCG; EORTC; GBG; Herceptin Adjuvant (HERA) Trial Study Team; monarchE Committee Members | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |17 | ||
+ | |2 | ||
+ | |13 | ||
+ | |3 | ||
+ | |299 | ||
+ | |203 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersson | ||
+ | |Per-Ola | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |2011 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersson | ||
+ | |Ronny | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |1998 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andersson | ||
+ | |Swen Olof | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |1989 | ||
+ | |2018 | ||
+ | |SPCG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |6 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |78 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Jiro | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2014 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Kiyoshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2002 | ||
+ | |2021 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple myeloma; Peripheral T-cell lymphoma | ||
+ | |12 | ||
+ | |1 | ||
+ | |5 | ||
+ | |1 | ||
+ | |229 | ||
+ | |166 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Masahiko | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2000 | ||
+ | |2021 | ||
+ | |JCOG; WJOG; WJTOG | ||
+ | | | ||
+ | |Cholangiocarcinoma; Colorectal cancer; Non-small cell lung cancer; Non-small cell lung cancer squamous; Small cell lung cancer | ||
+ | |14 | ||
+ | |0 | ||
+ | |13 | ||
+ | |0 | ||
+ | |260 | ||
+ | |168 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Masahiro | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2006 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Masashi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2009 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Nobutoshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |1988 | ||
+ | |2011 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |3 | ||
+ | |3 | ||
+ | |3 | ||
+ | |0 | ||
+ | |43 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ando | ||
+ | |Yuichi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2012 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andoh | ||
+ | |J. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2009 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andorsky | ||
+ | |David | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Diffuse large B-cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrade | ||
+ | |Luciana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Brazil | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andre | ||
+ | |Fabrice | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2006 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |16 | ||
+ | |4 | ||
+ | |9 | ||
+ | |4 | ||
+ | |336 | ||
+ | |223 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andre | ||
+ | |Marc P. E. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |1996 | ||
+ | |2021 | ||
+ | |EORTC; European Mantle Cell Lymphoma Network; FIL; GELA; Lymphoma Study Association; LYSA; SFGM | ||
+ | | | ||
+ | |Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Peripheral T-cell lymphoma; Transformed lymphoma | ||
+ | |14 | ||
+ | |1 | ||
+ | |14 | ||
+ | |1 | ||
+ | |340 | ||
+ | |212 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andre | ||
+ | |Niko | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2007 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andre | ||
+ | |Thierry | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1996 | ||
+ | |2022 | ||
+ | |AERO; FFCD; FNCLCC; GERCOR; GISCAD; Group Cooperateur Multidisciplinaire en Oncologie; HORG; PRODIGE investigators, GERCOR, Federation Francaise de Cancerologie Digestive, UNICANCER | ||
+ | | | ||
+ | |Anal cancer; Colon cancer; Colorectal cancer; Desmoid tumor; Esophageal adenocarcinoma; Gastric cancer; MSI-H or dMMR; Pancreatic cancer; Rectal cancer | ||
+ | |35 | ||
+ | |16 | ||
+ | |20 | ||
+ | |5 | ||
+ | |612 | ||
+ | |348 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andre | ||
+ | |Valerie A. M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2021 | ||
+ | |monarchE Committee Members | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |34 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreadis | ||
+ | |Charalambos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1998 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Transformed lymphoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |2 | ||
+ | |3 | ||
+ | |124 | ||
+ | |101 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreas | ||
+ | |Stefan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2005 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreasson | ||
+ | |Bjoern | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2007 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreeff | ||
+ | |Michael | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1984 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; CNS leukemia; Hypereosinophilic syndrome | ||
+ | |15 | ||
+ | |1 | ||
+ | |2 | ||
+ | |1 | ||
+ | |273 | ||
+ | |130 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreescu | ||
+ | |Astrid C. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |55 | ||
+ | |55 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreesen | ||
+ | |Reinhard | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2012 | ||
+ | |Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK | ||
+ | | | ||
+ | |Breast cancer; Hodgkin lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |44 | ||
+ | |44 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreetta | ||
+ | |Claudia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andren | ||
+ | |Ove | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Sweden | ||
+ | |1989 | ||
+ | |2018 | ||
+ | |SPCG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreola | ||
+ | |Giovanna | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2019 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Waldenstroem macroglobulinemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |53 | ||
+ | |53 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreoli | ||
+ | |Laura | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2018 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Antiphospholipid antibody syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreopoulos | ||
+ | |Demetrios | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Cyprus | ||
+ | |2001 | ||
+ | |2021 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreou | ||
+ | |Cal | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2006 | ||
+ | |2008 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreou | ||
+ | |Pantelis | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2013 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |47 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andresen Daniil | ||
+ | |Corina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2018 | ||
+ | |PLATO collaborators | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |7 | ||
+ | |7 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andreuccetti | ||
+ | |Michele | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2001 | ||
+ | |2010 | ||
+ | |GONO | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |34 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrews | ||
+ | |Chris | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2012 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Myelofibrosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrews | ||
+ | |Glen I. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2010 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrews | ||
+ | |Michael B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrews | ||
+ | |Stephen | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2007 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrews | ||
+ | |Vivienne E. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2008 | ||
+ | |2019 | ||
+ | |National Cancer Research Institute Haemato-oncology Clinical Studies Group | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andric | ||
+ | |Zoran | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Serbia | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |39 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrien | ||
+ | |J. M. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1985 | ||
+ | |1993 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrieu | ||
+ | |Jean Marie | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andriole | ||
+ | |Gerald L. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1994 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andritsos | ||
+ | |Leslie A. | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Androulakis | ||
+ | |Ioannis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |2002 | ||
+ | |HeCOG | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Androulakis | ||
+ | |Nikolaos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |1999 | ||
+ | |2019 | ||
+ | |HORG | ||
+ | | | ||
+ | |Colon cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer | ||
+ | |7 | ||
+ | |0 | ||
+ | |6 | ||
+ | |0 | ||
+ | |108 | ||
+ | |59 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andrulis | ||
+ | |Irene L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |1989 | ||
+ | |2006 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Andtbacka | ||
+ | |Robert H. I. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Melanoma | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |1 | ||
+ | |34 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ang | ||
+ | |Agnes | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer; Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |45 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ang | ||
+ | |Kie Kian | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1994 | ||
+ | |2015 | ||
+ | |EORTC; RTOG | ||
+ | | | ||
+ | |Head and neck cancer | ||
+ | |9 | ||
+ | |5 | ||
+ | |5 | ||
+ | |1 | ||
+ | |120 | ||
+ | |73 | ||
+ | |0 | ||
+ | |- | ||
+ | |Ang | ||
+ | |Mei Kim | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Singapore | ||
+ | |2004 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Nasopharyngeal carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ang | ||
+ | |Peng Tiam | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1990 | ||
+ | |1994 | ||
+ | | | ||
+ | | | ||
+ | |Nasopharyngeal carcinoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angchaisuksiri | ||
+ | |Pantep | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Thailand | ||
+ | |2016 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Venous thromboembolism | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angele | ||
+ | |Martin | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |1997 | ||
+ | |2018 | ||
+ | |EORTC; European Society for Hyperthermic Oncology | ||
+ | | | ||
+ | |Soft tissue sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angeli | ||
+ | |Alberto | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |2005 | ||
+ | |Italian Group for the Study of Adrenal Cancer | ||
+ | | | ||
+ | |Adrenocortical carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angelopoulou | ||
+ | |Maria K. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2010 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Mantle cell lymphoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angelot Delettre | ||
+ | |Fanny | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2013 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Blastic plasmacytoid dendritic cell neoplasm | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angelsen | ||
+ | |Anders | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Norway | ||
+ | |1995 | ||
+ | |2018 | ||
+ | |Scandinavian Prostate Cancer Group; SPCG; Swedish Association for Urological Oncology | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |25 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angelucci | ||
+ | |Emanuele | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1995 | ||
+ | |2022 | ||
+ | |CYTO-PV Collaborative Group; FIL; GIMEMA; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation | ||
+ | | | ||
+ | |Aplastic anemia; Chronic lymphocytic leukemia; Chronic myelomonocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Polycythemia vera | ||
+ | |9 | ||
+ | |0 | ||
+ | |6 | ||
+ | |0 | ||
+ | |221 | ||
+ | |188 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angermund | ||
+ | |Ralf | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2006 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |20 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anghel | ||
+ | |Rodica | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Romania | ||
+ | |2008 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angiolillo | ||
+ | |Anne L. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2000 | ||
+ | |2021 | ||
+ | |CCG; COG | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia pediatric; Ewing sarcoma; Osteosarcoma | ||
+ | |4 | ||
+ | |2 | ||
+ | |3 | ||
+ | |1 | ||
+ | |63 | ||
+ | |43 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anglaret | ||
+ | |Bruno | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2012 | ||
+ | |GELA; IFM | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |78 | ||
+ | |61 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anglin | ||
+ | |Peter | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2003 | ||
+ | |2015 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Multiple myeloma; Transformed lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angra | ||
+ | |Natasha | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |28 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angrilli | ||
+ | |Francesco | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2000 | ||
+ | |2017 | ||
+ | |FIL; IELSG | ||
+ | | | ||
+ | |CNS lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma | ||
+ | |6 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |132 | ||
+ | |92 | ||
+ | |1 | ||
+ | |- | ||
+ | |Angyalfi | ||
+ | |Steve J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |1999 | ||
+ | |2022 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |41 | ||
+ | |41 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anichini | ||
+ | |Andrea | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2017 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anker | ||
+ | |Christopher J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2017 | ||
+ | |RTOG | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anker | ||
+ | |Gun | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2000 | ||
+ | |Scandinavian Breast Group | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annamalai | ||
+ | |Lakshmanan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Merkel cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anne | ||
+ | |P. Rani | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1999 | ||
+ | |2006 | ||
+ | |RTOG | ||
+ | | | ||
+ | |Esophageal adenocarcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annechini | ||
+ | |Giorgia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2016 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annecke | ||
+ | |K. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Germany | ||
+ | |2001 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annett | ||
+ | |Robert D. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2022 | ||
+ | |COG | ||
+ | | | ||
+ | |T-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annibali | ||
+ | |Ombretta | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2007 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Acute promyelocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |45 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annino | ||
+ | |Luciana | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1988 | ||
+ | |2016 | ||
+ | |EORTC; GIMEMA | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Multiple myeloma | ||
+ | |3 | ||
+ | |1 | ||
+ | |3 | ||
+ | |1 | ||
+ | |67 | ||
+ | |66 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annunziata | ||
+ | |Annalisa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2006 | ||
+ | |MITO | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Annunziata | ||
+ | |Mario | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia; Thrombotic thrombocytopenic purpura | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |32 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anota | ||
+ | |Amelie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2014 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Anal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansari | ||
+ | |Hassan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1983 | ||
+ | |1994 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |43 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansari | ||
+ | |Marc | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2007 | ||
+ | |2020 | ||
+ | |EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group; SIOPEL | ||
+ | | | ||
+ | |Allogeneic HSCT; Hepatoblastoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |53 | ||
+ | |53 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansari | ||
+ | |Rafat H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1984 | ||
+ | |2013 | ||
+ | |Alpha Oncology Research Network; CALGB; Fox Chase Network; Hoosier Oncology Group; NCIC-CTG; US Oncology | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer | ||
+ | |16 | ||
+ | |0 | ||
+ | |15 | ||
+ | |1 | ||
+ | |186 | ||
+ | |151 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansell | ||
+ | |Peter J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer; Non-small cell lung cancer squamous; Ovarian cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |70 | ||
+ | |67 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansell | ||
+ | |Stephen M. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2022 | ||
+ | |NCCTG | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma; Waldenstroem macroglobulinemia | ||
+ | |26 | ||
+ | |7 | ||
+ | |1 | ||
+ | |4 | ||
+ | |410 | ||
+ | |217 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anselmo | ||
+ | |Anna Paola | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1988 | ||
+ | |2004 | ||
+ | |FIL; GHSG | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Hodgkin lymphoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |57 | ||
+ | |50 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansfield | ||
+ | |Fred J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1961 | ||
+ | |1985 | ||
+ | |Cooperative Breast Cancer Group | ||
+ | | | ||
+ | |Breast cancer; Head and neck cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |23 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Ansstas | ||
+ | |George | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2016 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antal | ||
+ | |Joyce | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anter | ||
+ | |A. H. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anthes | ||
+ | |M. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2004 | ||
+ | | | ||
+ | | | ||
+ | |Glioblastoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anthoney | ||
+ | |Alan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2000 | ||
+ | |2021 | ||
+ | |Advanced Biliary Cancer Working Group; European Study Group for Pancreatic Cancer | ||
+ | | | ||
+ | |Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer; Periampullary adenocarcinoma | ||
+ | |5 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |119 | ||
+ | |84 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anthony | ||
+ | |Alan | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2006 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Cholangiocarcinoma; Gallbladder cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |52 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anthony | ||
+ | |Stephen P. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1997 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antimi | ||
+ | |Mauro | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1991 | ||
+ | |2003 | ||
+ | |Italian Co-operative Group on Bladder Cancer | ||
+ | | | ||
+ | |Bladder cancer; Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |27 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antin | ||
+ | |Joseph H. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2003 | ||
+ | |2016 | ||
+ | |BMT CTN | ||
+ | | | ||
+ | |Allogeneic HSCT; Chronic myeloid leukemia; Graft versus host disease; Multiple myeloma | ||
+ | |4 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |79 | ||
+ | |76 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antinori | ||
+ | |Andrea | ||
+ | |UNMATCHED | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |HIV-associated lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antman | ||
+ | |Karen | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1987 | ||
+ | |1993 | ||
+ | | | ||
+ | | | ||
+ | |Autologous HSCT; Breast cancer; Soft tissue sarcoma | ||
+ | |2 | ||
+ | |2 | ||
+ | |1 | ||
+ | |0 | ||
+ | |26 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antolin Novoa | ||
+ | |Silvia | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2008 | ||
+ | |2021 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |63 | ||
+ | |61 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anton Torres | ||
+ | |A. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |1998 | ||
+ | |TTD | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anton | ||
+ | |Antonio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1990 | ||
+ | |2020 | ||
+ | |CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group); Spanish Lung Cancer Group; TTD | ||
+ | | | ||
+ | |Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer | ||
+ | |17 | ||
+ | |0 | ||
+ | |17 | ||
+ | |2 | ||
+ | |380 | ||
+ | |273 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonarakis | ||
+ | |Emmanuel S. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |39 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonelli | ||
+ | |G. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1998 | ||
+ | |2002 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |9 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonescu | ||
+ | |Cristina R. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2002 | ||
+ | |2011 | ||
+ | |ACOSOG | ||
+ | | | ||
+ | |Gastrointestinal stromal tumor; Melanoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |31 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonia | ||
+ | |Scott J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer | ||
+ | |17 | ||
+ | |6 | ||
+ | |7 | ||
+ | |5 | ||
+ | |408 | ||
+ | |222 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonini | ||
+ | |Ninja F. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Netherlands | ||
+ | |2003 | ||
+ | |2009 | ||
+ | |Dutch Colorectal Cancer Group | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |36 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonioli | ||
+ | |Elisabetta | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2014 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma; Paroxysmal nocturnal hemoglobinuria | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |37 | ||
+ | |37 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antoniotti | ||
+ | |Carlotta | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2008 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |70 | ||
+ | |54 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antoniou | ||
+ | |Dimosthenis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |2000 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |33 | ||
+ | |27 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antoniou | ||
+ | |Nicos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |2000 | ||
+ | |2013 | ||
+ | |SEUG | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |9 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonuzzo | ||
+ | |Lorenzo | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2008 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |45 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antonyan | ||
+ | |Igor | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Ukraine | ||
+ | |2017 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anttila | ||
+ | |Pekka | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Finland | ||
+ | |2012 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antunes | ||
+ | |Luis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Brazil | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Antunovic | ||
+ | |Petar | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Anz | ||
+ | |Bertrand | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Chronic lymphocytic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aogi | ||
+ | |Kenjiro | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |1994 | ||
+ | |2021 | ||
+ | |JCOG; NSAS | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |9 | ||
+ | |0 | ||
+ | |8 | ||
+ | |1 | ||
+ | |140 | ||
+ | |103 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aokage | ||
+ | |Keiju | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2013 | ||
+ | |2020 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoki | ||
+ | |Daisuke | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2003 | ||
+ | |2021 | ||
+ | |JGOG | ||
+ | | | ||
+ | |Cervical cancer; Endometrial cancer; Ovarian cancer | ||
+ | |6 | ||
+ | |1 | ||
+ | |5 | ||
+ | |0 | ||
+ | |121 | ||
+ | |89 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoki | ||
+ | |Hiroshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Upper tract urothelial carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoki | ||
+ | |Takuya | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2001 | ||
+ | |2021 | ||
+ | |WJTOG | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoki | ||
+ | |Yoichi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2008 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Cervical cancer; Ovarian cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |60 | ||
+ | |57 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aondio | ||
+ | |Gian Marco | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2004 | ||
+ | |2009 | ||
+ | |IELSG | ||
+ | | | ||
+ | |CNS lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |31 | ||
+ | |31 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aotani | ||
+ | |Eriko | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2006 | ||
+ | |2016 | ||
+ | |JGOG | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |23 | ||
+ | |23 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoudjhane | ||
+ | |A. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2003 | ||
+ | |2014 | ||
+ | |Lymphoma Study Association | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoudjhane | ||
+ | |Malek | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |1989 | ||
+ | |2003 | ||
+ | |EORTC | ||
+ | | | ||
+ | |Hodgkin lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |28 | ||
+ | |28 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoyama | ||
+ | |H. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |1996 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |6 | ||
+ | |6 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoyama | ||
+ | |Norio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2011 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Esophageal cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |32 | ||
+ | |29 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aoyama | ||
+ | |Toru | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan; USA | ||
+ | |2011 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Gastric cancer; Rectal cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aozasa | ||
+ | |Katsuyuki | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2005 | ||
+ | |2005 | ||
+ | | | ||
+ | | | ||
+ | |Castleman disease | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apanovitch | ||
+ | |Anne Marie | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2005 | ||
+ | |2007 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |1 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aparicio | ||
+ | |Jorge | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1994 | ||
+ | |2011 | ||
+ | |Spanish Germ Cell Cancer Cooperative Group; TTD | ||
+ | | | ||
+ | |Colorectal cancer; Hodgkin lymphoma; Testicular cancer | ||
+ | |6 | ||
+ | |3 | ||
+ | |2 | ||
+ | |0 | ||
+ | |81 | ||
+ | |68 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aparicio | ||
+ | |Samuel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2008 | ||
+ | |2015 | ||
+ | |NCIC-CTG | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |26 | ||
+ | |26 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aparicio | ||
+ | |Thomas | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2000 | ||
+ | |2018 | ||
+ | |FFCD; SFRO; UNICANCER | ||
+ | | | ||
+ | |Colorectal cancer; Esophageal adenocarcinoma; Gastric cancer; Hepatocellular carcinoma; Pancreatic cancer | ||
+ | |5 | ||
+ | |2 | ||
+ | |5 | ||
+ | |0 | ||
+ | |89 | ||
+ | |71 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apfelbeck | ||
+ | |Ute | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Austria | ||
+ | |1994 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Chronic myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apffelstaedt | ||
+ | |Justus | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |South Africa | ||
+ | |1996 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |51 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aplenc | ||
+ | |Richard | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2014 | ||
+ | |COG | ||
+ | | | ||
+ | |Acute myeloid leukemia pediatric; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric | ||
+ | |3 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |44 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apolo | ||
+ | |Andrea B. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer; Renal cell carcinoma | ||
+ | |4 | ||
+ | |2 | ||
+ | |1 | ||
+ | |2 | ||
+ | |81 | ||
+ | |59 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apolone | ||
+ | |Giovanni | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1987 | ||
+ | |1998 | ||
+ | |EORTC; Gruppo Interdisciplinare Valutazione Interventi in Oncologia; Japanese Foundation for Cancer Research | ||
+ | | | ||
+ | |Colon cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aponte | ||
+ | |John | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1996 | ||
+ | |2002 | ||
+ | |Barcelona Liver Cancer Group | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |11 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apostolou | ||
+ | |Theofanis | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2008 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Light-chain (AL) amyloidosis | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |12 | ||
+ | |12 | ||
+ | |1 | ||
+ | |- | ||
+ | |Appel | ||
+ | |Tabea | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2006 | ||
+ | |2006 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Appel | ||
+ | |Wiebke | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2008 | ||
+ | |2017 | ||
+ | |CONVERT Study Team | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Appelbaum | ||
+ | |Frederick R. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1971 | ||
+ | |2021 | ||
+ | |CALGB; ECOG; SWOG | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; Allogeneic HSCT; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Follicular lymphoma; Graft versus host disease; Hairy cell leukemia; Myelodysplastic syndrome; T-cell acute lymphoblastic leukemia | ||
+ | |36 | ||
+ | |11 | ||
+ | |16 | ||
+ | |4 | ||
+ | |477 | ||
+ | |273 | ||
+ | |1 | ||
+ | |- | ||
+ | |Appenzeller | ||
+ | |Christina | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Switzerland | ||
+ | |2017 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apperley | ||
+ | |Jane F. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |1981 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hypereosinophilic syndrome | ||
+ | |12 | ||
+ | |1 | ||
+ | |1 | ||
+ | |4 | ||
+ | |227 | ||
+ | |140 | ||
+ | |1 | ||
+ | |- | ||
+ | |Appiani | ||
+ | |Carlos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Mantle cell lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Appleman | ||
+ | |Leonard J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aprea | ||
+ | |Pasquale | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2002 | ||
+ | |2013 | ||
+ | |SICOG | ||
+ | | | ||
+ | |Melanoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aprile | ||
+ | |Giuseppe | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2005 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer; Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |2 | ||
+ | |89 | ||
+ | |81 | ||
+ | |1 | ||
+ | |- | ||
+ | |Apte | ||
+ | |Ron N. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Israel | ||
+ | |2014 | ||
+ | |2017 | ||
+ | | | ||
+ | | | ||
+ | |Colorectal cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aqui | ||
+ | |Nicole A. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma; Mantle cell lymphoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aquino | ||
+ | |Sara | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2011 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |123 | ||
+ | |78 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arachchillage | ||
+ | |Deepa R. J. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2016 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Antiphospholipid antibody syndrome | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |13 | ||
+ | |13 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aracil | ||
+ | |Miguel | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2015 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aragon Ching | ||
+ | |Jeanny B. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Bladder cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |91 | ||
+ | |82 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arahmani | ||
+ | |Amal | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Belgium | ||
+ | |2011 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |2 | ||
+ | |55 | ||
+ | |51 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Gaku | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2001 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |48 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Kuniyoshi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |1993 | ||
+ | |2011 | ||
+ | |ACTS-GC Group; JCOG | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |2 | ||
+ | |2 | ||
+ | |2 | ||
+ | |0 | ||
+ | |21 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Makoto | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2019 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Carcinoma of unknown primary | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |20 | ||
+ | |20 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Masahide | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2006 | ||
+ | |2019 | ||
+ | |JGOG | ||
+ | | | ||
+ | |Endometrial cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |16 | ||
+ | |16 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Sally | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2006 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Allogeneic HSCT | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |45 | ||
+ | |45 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Yasuaki | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2010 | ||
+ | |2018 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |2 | ||
+ | |2 | ||
+ | |2 | ||
+ | |0 | ||
+ | |34 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arai | ||
+ | |Yoichi | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2013 | ||
+ | |Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer | ||
+ | | | ||
+ | |Bladder cancer; Prostate cancer; Upper tract urothelial carcinoma | ||
+ | |3 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |38 | ||
+ | |34 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arakelyan | ||
+ | |Nina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2013 | ||
+ | |GOELAMS | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |57 | ||
+ | |46 | ||
+ | |1 | ||
+ | |- | ||
+ | |Araki | ||
+ | |K. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1994 | ||
+ | |2001 | ||
+ | |JCOG | ||
+ | | | ||
+ | |Adult T-cell leukemia-lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Araki | ||
+ | |Nobuhito | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Japan | ||
+ | |2008 | ||
+ | |2016 | ||
+ | | | ||
+ | | | ||
+ | |Soft tissue sarcoma | ||
+ | |3 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |45 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arana Yi | ||
+ | |C. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2007 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |17 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arance | ||
+ | |Ana M. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |2009 | ||
+ | |2022 | ||
+ | |CheckMate 238 Collaborators | ||
+ | | | ||
+ | |CNS melanoma; Melanoma | ||
+ | |24 | ||
+ | |1 | ||
+ | |11 | ||
+ | |8 | ||
+ | |562 | ||
+ | |205 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aranda | ||
+ | |Enrique | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1994 | ||
+ | |2020 | ||
+ | |GEICAM; TTD | ||
+ | | | ||
+ | |Breast cancer; Colon cancer; Colorectal cancer; Esophageal adenocarcinoma | ||
+ | |9 | ||
+ | |7 | ||
+ | |7 | ||
+ | |0 | ||
+ | |179 | ||
+ | |127 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aranda | ||
+ | |Ignacio | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1999 | ||
+ | |2010 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |30 | ||
+ | |30 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aranda | ||
+ | |J. | ||
+ | |CBD | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1987 | ||
+ | |2003 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arango Hisijara | ||
+ | |Israel | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2013 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Marginal zone lymphoma; Waldenstroem macroglobulinemia | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |2 | ||
+ | |37 | ||
+ | |36 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arango Ossa | ||
+ | |Juan E. | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2011 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Polycythemia vera | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |42 | ||
+ | |42 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arasteh | ||
+ | |Keikawus | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1993 | ||
+ | |1998 | ||
+ | | | ||
+ | | | ||
+ | |Kaposi sarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |8 | ||
+ | |8 | ||
+ | |1 | ||
+ | |- | ||
+ | |Araujo | ||
+ | |Carla | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2008 | ||
+ | |2022 | ||
+ | |IFM | ||
+ | | | ||
+ | |Autologous HSCT; Multiple myeloma | ||
+ | |6 | ||
+ | |0 | ||
+ | |4 | ||
+ | |1 | ||
+ | |217 | ||
+ | |121 | ||
+ | |1 | ||
+ | |- | ||
+ | |Araujo | ||
+ | |John C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2008 | ||
+ | |2013 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |1 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |24 | ||
+ | |24 | ||
+ | |1 | ||
+ | |- | ||
+ | |Aravantinos | ||
+ | |Gerasimos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Greece | ||
+ | |1989 | ||
+ | |2012 | ||
+ | |HCOG; HeCOG | ||
+ | | | ||
+ | |Bladder cancer; Breast cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Testicular cancer | ||
+ | |13 | ||
+ | |2 | ||
+ | |11 | ||
+ | |0 | ||
+ | |212 | ||
+ | |101 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arazy | ||
+ | |Melina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2017 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |57 | ||
+ | |57 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arbogast | ||
+ | |Daria | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2010 | ||
+ | |2010 | ||
+ | | | ||
+ | | | ||
+ | |Thyroid cancer medullary | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arbuck | ||
+ | |Susan G. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1992 | ||
+ | |2003 | ||
+ | | | ||
+ | | | ||
+ | |Cervical cancer; Ovarian cancer | ||
+ | |2 | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |22 | ||
+ | |21 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arbushites | ||
+ | |Michael C. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2004 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer; Graft versus host disease | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |1 | ||
+ | |25 | ||
+ | |25 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcaini | ||
+ | |Luca | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2006 | ||
+ | |2021 | ||
+ | |FIL; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network | ||
+ | | | ||
+ | |Follicular lymphoma; Mantle cell lymphoma | ||
+ | |7 | ||
+ | |1 | ||
+ | |3 | ||
+ | |0 | ||
+ | |164 | ||
+ | |132 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcamone | ||
+ | |Manuela | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2012 | ||
+ | |2012 | ||
+ | | | ||
+ | | | ||
+ | |Follicular lymphoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |14 | ||
+ | |14 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcangeli | ||
+ | |Annarosa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |2008 | ||
+ | |Italian Oncology Group for Cancer Research | ||
+ | | | ||
+ | |Gastric cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |15 | ||
+ | |15 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcangeli | ||
+ | |Giuseppina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1995 | ||
+ | |1995 | ||
+ | | | ||
+ | | | ||
+ | |Hepatocellular carcinoma | ||
+ | |1 | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |3 | ||
+ | |3 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcangeli | ||
+ | |Valentina | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2010 | ||
+ | |2015 | ||
+ | |MITO | ||
+ | | | ||
+ | |Ovarian cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |22 | ||
+ | |22 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcari | ||
+ | |Annalisa | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |2003 | ||
+ | |2021 | ||
+ | |ANZ BCTG; FIL | ||
+ | | | ||
+ | |Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma | ||
+ | |4 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |93 | ||
+ | |78 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcasoy | ||
+ | |Murat O. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2009 | ||
+ | |2022 | ||
+ | | | ||
+ | | | ||
+ | |Myelofibrosis; Polycythemia vera | ||
+ | |6 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |161 | ||
+ | |74 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arce Lara | ||
+ | |Carlos | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2015 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Multiple myeloma | ||
+ | |1 | ||
+ | |0 | ||
+ | |0 | ||
+ | |0 | ||
+ | |10 | ||
+ | |10 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arce Salinas | ||
+ | |Claudia H. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Mexico | ||
+ | |2011 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |Breast cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |1 | ||
+ | |61 | ||
+ | |60 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arceci | ||
+ | |Robert J. | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |1979 | ||
+ | |2011 | ||
+ | |CCG; COG | ||
+ | | | ||
+ | |Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric; Chronic myeloid leukemia pediatric; Langerhans cell histiocytosis | ||
+ | |5 | ||
+ | |2 | ||
+ | |4 | ||
+ | |2 | ||
+ | |60 | ||
+ | |53 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcenas | ||
+ | |Anthony | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2000 | ||
+ | |2000 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |18 | ||
+ | |18 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcese | ||
+ | |William | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Italy | ||
+ | |1988 | ||
+ | |2015 | ||
+ | | | ||
+ | | | ||
+ | |Acute myeloid leukemia; Allogeneic HSCT | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |40 | ||
+ | |40 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archambaud | ||
+ | |Baptiste | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |France | ||
+ | |2017 | ||
+ | |2022 | ||
+ | |French Sarcoma Group | ||
+ | | | ||
+ | |Leiomyosarcoma | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |19 | ||
+ | |19 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archambault | ||
+ | |Robert | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Canada | ||
+ | |2000 | ||
+ | |2020 | ||
+ | | | ||
+ | | | ||
+ | |Prostate cancer | ||
+ | |2 | ||
+ | |0 | ||
+ | |2 | ||
+ | |0 | ||
+ | |23 | ||
+ | |17 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archer | ||
+ | |Caroline | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2007 | ||
+ | |2014 | ||
+ | | | ||
+ | | | ||
+ | |Pancreatic cancer | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |32 | ||
+ | |32 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archer | ||
+ | |J. Hunter | ||
+ | |Not yet determined | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2014 | ||
+ | |2022 | ||
+ | |COG | ||
+ | | | ||
+ | |T-cell acute lymphoblastic leukemia pediatric | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |35 | ||
+ | |35 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archer | ||
+ | |Laura | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |2003 | ||
+ | |2010 | ||
+ | |CALGB | ||
+ | | | ||
+ | |Renal cell carcinoma | ||
+ | |2 | ||
+ | |0 | ||
+ | |1 | ||
+ | |0 | ||
+ | |21 | ||
+ | |11 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archer | ||
+ | |Venice | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |United Kingdom | ||
+ | |2005 | ||
+ | |2019 | ||
+ | | | ||
+ | | | ||
+ | |Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | ||
+ | |4 | ||
+ | |0 | ||
+ | |3 | ||
+ | |2 | ||
+ | |49 | ||
+ | |38 | ||
+ | |1 | ||
+ | |- | ||
+ | |Archimbaud | ||
+ | |Eric | ||
+ | |M | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |1980 | ||
+ | |2004 | ||
+ | |ALFA; EAPLG; EORTC; European APL Group; GELA; HOVON | ||
+ | | | ||
+ | |Acute myeloid leukemia; Acute promyelocytic leukemia; Diffuse large B-cell lymphoma | ||
+ | |6 | ||
+ | |0 | ||
+ | |5 | ||
+ | |0 | ||
+ | |110 | ||
+ | |83 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcila | ||
+ | |Maria E. | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |USA | ||
+ | |2012 | ||
+ | |2021 | ||
+ | | | ||
+ | | | ||
+ | |ERBB2 (HER2); Erdheim-Chester disease; Multiple myeloma | ||
+ | |3 | ||
+ | |1 | ||
+ | |0 | ||
+ | |1 | ||
+ | |88 | ||
+ | |85 | ||
+ | |1 | ||
+ | |- | ||
+ | |Arcusa | ||
+ | |Angels | ||
+ | |F | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |Spain | ||
+ | |1988 | ||
+ | |2010 | ||
+ | |GEICAM | ||
+ | | | ||
+ | |Breast cancer; Gastric cancer | ||
+ | |3 | ||
+ | |0 | ||
+ | |3 | ||
+ | |0 | ||
+ | |59 | ||
+ | |52 | ||
+ | |1 | ||
+ | |- | ||
+ | } |
Revision as of 14:55, 14 January 2023
}
Surname | Forename | Gender | Site | City | Region | Country | First active year | Last active year | Study group(s) | Sponsor(s) | Conditions | Total publications | Senior publications | Phase 3 RCTs | FDA pivotal studies | Co-authorships | Co-authors | Vital status |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
A'Hern | Roger P. | M | United Kingdom | 1987 | 2015 | London Gynaecological Oncology Group; TOPIC Trial Group | Breast cancer; Ovarian cancer; Prostate cancer | 5 | 0 | 4 | 0 | 100 | 83 | 1 | ||||
Aamdal | Steinar | M | Norway | 1989 | 2015 | EORTC; Nordic Melanoma Cooperative Group | Melanoma; Small cell lung cancer | 7 | 2 | 6 | 0 | 87 | 84 | 1 | ||||
Aanur | Praveen | M | USA | 2016 | 2021 | Malignant pleural mesothelioma | 1 | 0 | 1 | 1 | 20 | 20 | 1 | |||||
Aapro | Matti S. | F | Belgium; Switzerland | 1984 | 2018 | EORTC; International Collaborative Cancer Group | Breast cancer; Endometrial cancer | 5 | 3 | 5 | 1 | 109 | 108 | 1 | ||||
Aaron | Lorne | M | 2006 | 2012 | Prostate cancer | 1 | 0 | 1 | 0 | 7 | 7 | 1 | ||||||
Aaronson | Neil K. | M | 1992 | 2001 | EORTC | Melanoma; Prostate cancer | 2 | 0 | 2 | 0 | 26 | 26 | 1 | |||||
Aarts | Maureen J. B. | F | Netherlands | 2006 | 2017 | BOOG; Dutch WIN-O Consortium | Breast cancer; Renal cell carcinoma | 3 | 0 | 2 | 0 | 38 | 30 | 1 | ||||
Aasebo | Ulf | M | Norway | 1989 | 2013 | Non-small cell lung cancer; Small cell lung cancer | 7 | 1 | 7 | 0 | 65 | 44 | 1 | |||||
Aass | Nina | F | Norway | 1996 | 2012 | EORTC; MRC | Renal cell carcinoma; Testicular cancer | 5 | 1 | 4 | 0 | 48 | 34 | 1 | ||||
Aastroem | Lennart | M | Sweden | 2014 | 2022 | SPCG | Prostate cancer | 2 | 0 | 2 | 0 | 21 | 21 | 1 | ||||
Aavall Lundqvist | Elisabeth | F | Sweden | 1999 | 2017 | AGO; Gynecologic Cancer Intergroup | Ovarian cancer | 4 | 0 | 4 | 0 | 64 | 52 | 1 | ||||
Abacioglu | Ufuk | M | 2000 | 2012 | Glioblastoma | 1 | 0 | 1 | 0 | 11 | 11 | 1 | ||||||
Abad | Alberto | M | Spain | 1989 | 2012 | TTD | Colorectal cancer; Non-small cell lung cancer | 3 | 1 | 3 | 0 | 53 | 44 | 1 | ||||
Abada | Paolo B. | M | USA | 2010 | 2019 | Hepatocellular carcinoma | 2 | 0 | 2 | 1 | 42 | 38 | 1 | |||||
Abadie Lacourtoisie | Sophie | F | France | 2006 | 2019 | GINECO | Breast cancer | 3 | 0 | 1 | 0 | 55 | 36 | 1 | ||||
Abaskharoun | Mena | F | USA | 2018 | 2022 | Melanoma | 1 | 0 | 0 | 1 | 21 | 21 | 1 | |||||
Abaza | Yasmin | F | USA | 2002 | 2017 | Acute promyelocytic leukemia | 1 | 1 | 0 | 0 | 26 | 26 | 1 | |||||
Abbadessa | A. | CBD | 2007 | 2007 | CNS lymphoma | 1 | 0 | 0 | 0 | 17 | 17 | 1 | ||||||
Abbadessa | Giovanni | M | USA | 2012 | 2018 | Hepatocellular carcinoma | 1 | 0 | 1 | 0 | 29 | 29 | 1 | |||||
Abbal | Claire | F | Switzerland | 2006 | 2015 | GRAALL | B-cell acute lymphoblastic leukemia | 1 | 0 | 1 | 0 | 19 | 19 | 1 | ||||
Abbas | Abbas | M | 2002 | 2010 | Esophageal adenocarcinoma | 1 | 0 | 0 | 0 | 8 | 8 | 1 | ||||||
Abbas | Haider | M | United Kingdom | 2009 | 2014 | COG | Esophageal cancer | 1 | 0 | 1 | 0 | 20 | 20 | 1 | ||||
Abbas | Mohammad | M | 2008 | 2012 | Multiple myeloma | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Abbas | Moncef | M | 2002 | 2011 | FFCD | Colorectal cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Abbas | Richat | M | USA | 2006 | 2011 | B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia | 1 | 0 | 0 | 1 | 14 | 14 | 1 | |||||
Abbas | Tahir | Not yet determined | Canada | 2016 | 2020 | NCIC-CTG | Colorectal cancer | 1 | 0 | 0 | 0 | 20 | 20 | 1 | ||||
Abbattista | Antonello | M | Italy | 2014 | 2019 | Non-small cell lung cancer | 3 | 0 | 0 | 1 | 50 | 28 | 1 | |||||
Abbink | Floor | F | Netherlands | 2011 | 2019 | Chronic myeloid leukemia pediatric | 1 | 0 | 0 | 1 | 15 | 15 | 1 | |||||
Abbott | Amanda | F | USA | 2012 | 2019 | Gastrointestinal stromal tumor | 1 | 0 | 0 | 0 | 15 | 15 | 1 | |||||
Abbott | R. L. | CBD | 1982 | 1989 | Bladder cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||||
Abbott | Thomas M. | M | 1979 | 1989 | SWOG | Ovarian cancer | 1 | 0 | 1 | 0 | 8 | 8 | 1 | |||||
Abbou | Clement Claude | M | France | 1986 | 1993 | Prostate cancer | 1 | 0 | 1 | 1 | 14 | 14 | 1 | |||||
Abboud | Camille N. | F | USA | 1993 | 2016 | ECOG | Acute myeloid leukemia | 2 | 0 | 1 | 0 | 49 | 49 | 1 | ||||
Abboud | Miguel R. | M | Lebanon | 2017 | 2019 | Sickle cell anemia | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
Abbrederis | Klaus | M | 1994 | 2003 | Chronic myeloid leukemia | 1 | 0 | 1 | 0 | 25 | 25 | 1 | ||||||
Abbruzzese | Alberto | M | 2003 | 2009 | Bladder cancer | 1 | 0 | 1 | 0 | 11 | 11 | 1 | ||||||
Abbruzzese | James L. | M | 1988 | 2010 | SWOG | Colorectal cancer; Esophageal adenocarcinoma; Hepatocellular carcinoma; Pancreatic cancer | 5 | 3 | 2 | 0 | 47 | 44 | 1 | |||||
Abdalla | K. | CBD | Brazil | 2011 | 2017 | Gastric cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Abdallah | Al Ola | M | USA | 2018 | 2021 | Multiple myeloma | 2 | 0 | 0 | 1 | 55 | 38 | 1 | |||||
Abdallah | Rehab | Not yet determined | USA | 2015 | 2021 | Prostate cancer | 1 | 0 | 0 | 0 | 27 | 27 | 1 | |||||
Abdeddaim | Cyril | M | France | 2017 | 2020 | Endometrial cancer | 1 | 0 | 0 | 1 | 14 | 14 | 1 | |||||
Abdel Hamid | Abdel | M | United Kingdom | 2007 | 2012 | Thyroid cancer differentiated | 1 | 0 | 1 | 0 | 27 | 27 | 1 | |||||
Abdel Rahman | Omar | M | Egypt | 2010 | 2013 | Hepatocellular carcinoma | 1 | 1 | 0 | 0 | 5 | 5 | 1 | |||||
Abdel Rahman | Sultan | M | Germany | 1997 | 2018 | EORTC; European Society for Hyperthermic Oncology | Soft tissue sarcoma | 2 | 0 | 1 | 0 | 40 | 26 | 1 | ||||
Abdel Wahab | Manal | F | 2010 | 2013 | Hepatocellular carcinoma | 1 | 0 | 0 | 0 | 5 | 5 | 1 | ||||||
Abdel Wahab | Omar | M | USA | 2002 | 2019 | ECOG | Acute myeloid leukemia; Chronic myelomonocytic leukemia; Erdheim-Chester disease; Essential thrombocythemia; Hairy cell leukemia; Langerhans cell histiocytosis; Polycythemia vera; Rosai-Dorfman-Destombes disease | 6 | 1 | 1 | 1 | 124 | 114 | 1 | ||||
Abdel Wahab | Sherif | M | 2010 | 2013 | Hepatocellular carcinoma | 1 | 0 | 0 | 0 | 5 | 5 | 1 | ||||||
Abdelfattah | Murad | M | 2001 | 2009 | Colorectal cancer | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Abdelghany | Osama | M | USA | 2011 | 2020 | Endometrial cancer | 2 | 0 | 0 | 0 | 46 | 24 | 1 | |||||
Abdi | Ehtesham A. | M | Australia | 1994 | 2021 | ALLG; IBCSG | Breast cancer; Diffuse large B-cell lymphoma | 4 | 0 | 3 | 0 | 95 | 72 | 1 | ||||
Abdiche | Menouar Samir | Not yet determined | France | 2008 | 2020 | GETUG | Prostate cancer | 1 | 0 | 1 | 0 | 17 | 17 | 1 | ||||
Abdo | Andre | M | Brazil | 2017 | 2021 | Chronic myeloid leukemia | 1 | 0 | 1 | 1 | 25 | 25 | 1 | |||||
Abdul Razak | Albiruni R. | M | Canada | 2015 | 2020 | Soft tissue sarcoma | 1 | 0 | 1 | 0 | 20 | 20 | 1 | |||||
Abdulkadyrov | Kudrat M. | F | Russian Federation | 2004 | 2019 | Chronic lymphocytic leukemia; Chronic myeloid leukemia; Essential thrombocythemia; Multiple myeloma | 6 | 0 | 4 | 2 | 117 | 76 | 1 | |||||
Abdullaev | S. | Not yet determined | USA | 2014 | 2022 | Colorectal cancer | 1 | 0 | 0 | 1 | 18 | 18 | 1 | |||||
Abdullah | Shaad E. | M | United Kingdom | 2017 | 2021 | Uveal melanoma | 1 | 0 | 1 | 1 | 27 | 27 | 1 | |||||
Abe | Hajime | M | 2002 | 2010 | Breast cancer | 1 | 0 | 1 | 0 | 20 | 20 | 1 | ||||||
Abe | Osahiko | UNMATCHED | 1981 | 1994 | Breast cancer | 2 | 0 | 2 | 0 | 23 | 17 | 1 | ||||||
Abe | Rikiya | F | 1996 | 2009 | Adjuvant CEF Research Group for Breast Cancer | Breast cancer | 2 | 0 | 2 | 0 | 27 | 24 | 1 | |||||
Abe | Tetsuya | M | Japan | 2008 | 2015 | JCOG | Non-small cell lung cancer | 1 | 1 | 1 | 0 | 19 | 19 | 1 | ||||
Abe | Yasunobu | M | Japan | 2012 | 2016 | Adult T-cell leukemia-lymphoma | 1 | 0 | 0 | 0 | 17 | 17 | 1 | |||||
Abedi | Mehrdad | M | USA | 2010 | 2021 | B-cell acute lymphoblastic leukemia; Follicular lymphoma | 2 | 0 | 0 | 1 | 37 | 37 | 1 | |||||
Abel | Edvard | M | Sweden | 2013 | 2020 | Head and neck cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Abel | Ulrich | M | 1990 | 2012 | Diffuse large B-cell lymphoma; Pancreatic cancer | 2 | 0 | 2 | 0 | 40 | 40 | 1 | ||||||
Abella | Eugenia | F | 2001 | 2013 | GELCAB; GELTAMO; GESIDA; PETHEMA | Chronic lymphocytic leukemia; HIV-associated lymphoma | 4 | 0 | 0 | 0 | 68 | 42 | 1 | |||||
Abellan | Pascual Fernandez | M | 1999 | 2008 | GEM; PETHEMA | Multiple myeloma | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Abeloff | Martin D. | M | USA | 1979 | 2009 | Breast Cancer Intergroup of North America; CALGB; ECOG; SWOG | Breast cancer; Small cell lung cancer | 10 | 4 | 10 | 0 | 89 | 59 | 1 | ||||
Abels | J. | CBD | 1983 | 1989 | EORTC | Acute myeloid leukemia | 2 | 0 | 2 | 0 | 22 | 15 | 1 | |||||
Abelson | Herbert T. | M | 1982 | 1986 | Osteosarcoma | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||||
Abenhardt | Wolfgang | M | Germany | 1997 | 2017 | GCLLSG | Breast cancer; Chronic lymphocytic leukemia | 4 | 0 | 4 | 0 | 52 | 37 | 1 | ||||
Abergel | Armand | M | France | 1995 | 2019 | FFCD | Hepatocellular carcinoma | 3 | 0 | 3 | 0 | 48 | 42 | 1 | ||||
Abernethy | Amy | F | USA | 2013 | 2017 | Melanoma | 1 | 0 | 1 | 1 | 22 | 22 | 1 | |||||
Abeyakoon | Sarath | UNMATCHED | 1996 | 2003 | Head and neck cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Abgrall | Jean Francois | M | France | 1991 | 1997 | Intergroupe Francais des Leucemies Myeloides Chroniques | Chronic myeloid leukemia | 1 | 0 | 1 | 0 | 11 | 11 | 1 | ||||
Abhyankar | Sunil | M | USA | 2018 | 2018 | BMT CTN | Graft versus host disease | 1 | 0 | 0 | 0 | 21 | 21 | 1 | ||||
Abi Gerges | Dany | M | Lebanon | 2008 | 2014 | Breast cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Abianui | Abongnwen | Not yet determined | Canada | 2018 | 2018 | Venous thromboembolism | 1 | 0 | 1 | 0 | 26 | 26 | 1 | |||||
Abidi | Muneer H. | M | USA | 2004 | 2020 | SWOG | Hodgkin lymphoma; Multiple myeloma | 6 | 0 | 3 | 1 | 82 | 48 | 1 | ||||
Abidoye | Oyewale O. | M | USA | 2014 | 2016 | Bladder cancer | 2 | 0 | 0 | 2 | 64 | 43 | 1 | |||||
Abildgaard | Niels | M | 2002 | 2013 | Multiple myeloma | 2 | 0 | 2 | 0 | 48 | 37 | 1 | ||||||
Abir | Esshagh | Not yet determined | 1965 | 1965 | B-cell acute lymphoblastic leukemia | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Ablin | Arthur R. | M | 1988 | 1988 | CCG | T-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 0 | 0 | 11 | 11 | 1 | |||||
Aboelhassan | Rasha | Not yet determined | Egypt | 2013 | 2019 | Malignant pleural mesothelioma | 1 | 0 | 0 | 0 | 25 | 25 | 1 | |||||
Abonour | Rafat | M | USA | 2004 | 2018 | ECOG | Multiple myeloma | 3 | 0 | 1 | 1 | 53 | 50 | 1 | ||||
Abou Alfa | Ghassan K. | M | USA | 2001 | 2021 | CALGB | Cholangiocarcinoma; Hepatocellular carcinoma; Pancreatic cancer | 13 | 11 | 7 | 4 | 267 | 191 | 1 | ||||
Abou Nassar | Karim | M | Canada | 2013 | 2019 | Follicular lymphoma; Venous thromboembolism | 2 | 0 | 1 | 1 | 44 | 44 | 1 | |||||
Abou Rached | Antoine | M | France | 1990 | 1995 | Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire | Hepatocellular carcinoma | 1 | 0 | 1 | 0 | 5 | 5 | 1 | ||||
Aboulafia | David | M | 1993 | 2009 | AIDS Malignancy Consortium | HIV-associated lymphoma; Kaposi sarcoma | 3 | 0 | 2 | 0 | 33 | 29 | 1 | |||||
Abraham | Aby | F | 1998 | 2010 | Acute promyelocytic leukemia | 1 | 0 | 0 | 0 | 11 | 11 | 1 | ||||||
Abraham | Christine | F | France | 2003 | 2019 | Prostate cancer | 1 | 0 | 1 | 0 | 27 | 27 | 1 | |||||
Abraham | George | M | India | 2012 | 2019 | Head and neck cancer | 1 | 0 | 1 | 0 | 50 | 50 | 1 | |||||
Abraham | Jacinta | F | United Kingdom | 2008 | 2018 | Breast cancer | 1 | 0 | 1 | 0 | 37 | 37 | 1 | |||||
Abraham | Jean E. | F | United Kingdom | 2001 | 2019 | tAnGo trial collaborators | Breast cancer | 4 | 0 | 4 | 0 | 102 | 66 | 1 | ||||
Abraham | Julie | F | France | 2014 | 2021 | Diffuse large B-cell lymphoma | 1 | 0 | 1 | 0 | 24 | 24 | 1 | |||||
Abraham | Mirta | F | 1996 | 2013 | Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group | Breast cancer | 1 | 0 | 1 | 0 | 37 | 37 | 1 | |||||
Abrahamse Testroote | Martine C. J. | F | Netherlands | 2006 | 2014 | HOVON | Chronic lymphocytic leukemia | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||
Abrahamsson | Jonas | M | Sweden | 2004 | 2019 | Nordic Society of Paediatric Haematology and Oncology (NOPHO) | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric | 2 | 0 | 2 | 0 | 18 | 17 | 1 | ||||
Abrahamsson | Per Anders | M | 2001 | 2007 | Atrasentan Phase III Study Group Institutions | Prostate cancer | 1 | 0 | 1 | 0 | 8 | 8 | 1 | |||||
Abram | Paul | M | 1998 | 2004 | Breast cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Abram | Steven R. | M | USA | 2007 | 2018 | Glioblastoma | 1 | 0 | 1 | 0 | 68 | 68 | 1 | |||||
Abramov | M. | CBD | Russian Federation | 2011 | 2017 | Gastric cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Abrams | Jeffrey S. | M | USA | 1982 | 2018 | CALGB; NCIC-CTG | Breast cancer; Melanoma | 9 | 1 | 6 | 2 | 145 | 85 | 1 | ||||
Abrams | K. | Not yet determined | 1988 | 1994 | Colorectal cancer | 1 | 0 | 1 | 0 | 4 | 4 | 1 | ||||||
Abrams | Paul G. | M | 1984 | 1984 | Follicular lymphoma | 1 | 0 | 0 | 0 | 11 | 11 | 1 | ||||||
Abrams | Ross A. | M | USA | 1987 | 2011 | Radiation Therapy Oncology Group; RTOG | Cholangiocarcinoma; Pancreatic cancer; Prostate cancer | 3 | 0 | 2 | 1 | 36 | 27 | 1 | ||||
Abrams | Thomas A. | M | USA | 2006 | 2018 | Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma | 3 | 0 | 0 | 0 | 59 | 40 | 1 | |||||
Abramson | David H. | M | USA | 2010 | 2014 | Uveal melanoma | 1 | 0 | 0 | 0 | 27 | 27 | 1 | |||||
Abramson | Jeremy S. | M | USA | 2005 | 2022 | Alliance; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society; CALGB | Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma | 8 | 3 | 5 | 3 | 156 | 140 | 1 | ||||
Abramson | Neil | M | USA | 1979 | 2001 | ECOG; NSABP | Breast cancer; Multiple myeloma | 5 | 0 | 6 | 0 | 63 | 40 | 1 | ||||
Abramson | Vandana G. | F | USA | 2010 | 2022 | NCIC-CTG | Breast cancer; CNS carcinoma; Thyroid cancer | 6 | 1 | 2 | 2 | 131 | 98 | 1 | ||||
Abrao Miziara | Jose Elias | M | Brazil | 2006 | 2015 | Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | 3 | 0 | 3 | 0 | 62 | 52 | 1 | |||||
Abratt | Raymond Pierre | M | South Africa | 1995 | 2011 | GLOB 2 group | Non-small cell lung cancer; Prostate cancer | 6 | 3 | 6 | 0 | 58 | 53 | 1 | ||||
Abrey | Lauren E. | F | Switzerland; USA | 1992 | 2018 | Autologous HSCT; CNS lymphoma; Glioblastoma; High-grade glioma pediatric; Stem cell mobilization | 9 | 4 | 1 | 1 | 101 | 76 | 1 | |||||
Abrisqueta | Pau | M | Spain | 2005 | 2021 | Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma | 5 | 1 | 2 | 1 | 111 | 87 | 1 | |||||
Abromowitch | Minnie | F | 1979 | 2012 | COG | B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric | 3 | 1 | 3 | 0 | 30 | 27 | 1 | |||||
Abruzzese | Elisabetta | F | Italy | 2004 | 2018 | EORTC; FIL; GIMEMA; LYSA | B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hodgkin lymphoma | 7 | 0 | 5 | 1 | 174 | 122 | 1 | ||||
Abruzzo | Lynne V. | F | USA | 2015 | 2020 | Chronic lymphocytic leukemia; Hodgkin lymphoma | 2 | 0 | 0 | 0 | 29 | 29 | 1 | |||||
Abshire | T. C. | Not yet determined | USA | 2000 | 2000 | POG | B-cell acute lymphoblastic leukemia pediatric | 1 | 1 | 0 | 0 | 4 | 4 | 1 | ||||
Abt | Markus | M | Switzerland | 1998 | 2005 | Colon cancer | 1 | 0 | 1 | 1 | 25 | 25 | 1 | |||||
Abu Samra | Maisun | Not yet determined | Germany | 2010 | 2019 | Acute myeloid leukemia | 1 | 0 | 1 | 0 | 32 | 32 | 1 | |||||
Abu Zahra | Hakam | M | Canada | 1984 | 1998 | NCIC-CTG | Breast cancer | 2 | 0 | 2 | 2 | 38 | 31 | 1 | ||||
Abuav | Rachel | F | USA | 2009 | 2009 | Cutaneous T-cell lymphoma | 1 | 0 | 0 | 1 | 13 | 13 | 1 | |||||
Abubakr | Yousif A. | M | 2002 | 2008 | Colorectal cancer | 2 | 0 | 3 | 0 | 30 | 29 | 1 | ||||||
Abulizi | G. | Not yet determined | China | 2017 | 2021 | Ovarian cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | |||||
Accario Winslow | Chrisann | F | 2001 | 2009 | Gynecologic Cancer Intergroup | Ovarian cancer | 1 | 0 | 1 | 0 | 15 | 15 | 1 | |||||
Accomando | Emilio | M | Italy | 1987 | 1992 | Head and neck cancer | 1 | 0 | 1 | 0 | 24 | 24 | 1 | |||||
Accortanzo | Valeria | F | Italy | 1996 | 2016 | GONO | Breast cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||
Acha | Tomas | M | Spain | 2001 | 2015 | Wilms tumor | 1 | 0 | 1 | 0 | 13 | 13 | 1 | |||||
Acharya | Sandip | M | India | 2009 | 2018 | Chronic myeloid leukemia | 2 | 0 | 1 | 1 | 36 | 32 | 1 | |||||
Acharyya | Suddhasatta | Not yet determined | USA | 2018 | 2021 | Non-small cell lung cancer | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Achebe | Maureen M. | F | USA | 2017 | 2021 | Sickle cell anemia | 2 | 0 | 1 | 0 | 32 | 23 | 1 | |||||
Achille | Emmanuel | M | 1996 | 2007 | GERCOR | Colon cancer; Colorectal cancer | 3 | 0 | 2 | 0 | 41 | 22 | 1 | |||||
Acholonu | Sandra | F | 2008 | 2008 | Allogeneic HSCT; Hodgkin lymphoma | 1 | 0 | 0 | 0 | 17 | 17 | 1 | ||||||
Achour | Eddine | UNMATCHED | 2001 | 2001 | CNS lymphoma; Stem cell mobilization | 1 | 0 | 0 | 0 | 11 | 11 | 1 | ||||||
Achtelik | W. | CBD | 1994 | 2001 | DeCOG | Melanoma | 1 | 0 | 1 | 0 | 15 | 15 | 1 | |||||
Achtnicht | U. | CBD | 1985 | 1992 | Renal cell carcinoma | 1 | 0 | 1 | 0 | 8 | 8 | 1 | ||||||
Acin | Yolene | F | France | 2009 | 2015 | Gastrointestinal stromal tumor; Pancreatic cancer | 2 | 0 | 1 | 0 | 33 | 29 | 1 | |||||
Acker | Thomas | M | 2002 | 2012 | “Aktion Bronchialkarzinom” (ABC Study Group) | Small cell lung cancer | 1 | 0 | 1 | 0 | 15 | 15 | 1 | |||||
Ackerman | Charlotte | F | United Kingdom | 2007 | 2016 | Bladder cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Ackerman | Ilana | Not yet determined | Australia | 2022 | 2022 | Venous thromboembolism | 1 | 0 | 1 | 0 | 45 | 45 | 1 | |||||
Ackerman | Judie | F | 2001 | 2006 | Pancreatic cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Ackerstaff | Annemiek H. | F | 2000 | 2010 | Head and neck cancer | 1 | 0 | 1 | 0 | 12 | 12 | 1 | ||||||
Ackerstein | Aliza | F | 1998 | 1998 | Allogeneic HSCT; Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Ackland | Stephen P. | M | Australia | 1990 | 2012 | AGITG; ANZ BCTG; Australasian Gastro-Intestinal Trials Group; Trans-Tasman Radiation Oncology Group; TROG | Breast cancer; Colorectal cancer; Esophageal cancer; Rectal cancer | 8 | 1 | 8 | 1 | 109 | 97 | 1 | ||||
Acosta Rivera | Mirelis | F | USA | 2012 | 2020 | Hepatocellular carcinoma | 1 | 0 | 0 | 1 | 20 | 20 | 1 | |||||
Acosta | Mark | M | USA | 2010 | 2010 | Cutaneous T-cell lymphoma | 1 | 0 | 1 | 1 | 8 | 8 | 1 | |||||
Acosta | Soraida C. | Not yet determined | Cuba | 2006 | 2016 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | |||||
Acquino Parsons | C. | CBD | 1995 | 2001 | Endometrial cancer | 1 | 0 | 0 | 0 | 6 | 6 | 1 | ||||||
Acs | Peter I. | M | 2008 | 2013 | Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 5 | 5 | 1 | ||||||
Acton | Gary | M | USA | 2010 | 2015 | Acute myeloid leukemia | 1 | 0 | 1 | 0 | 35 | 35 | 1 | |||||
Adab | Fawzi | M | United Kingdom | 2002 | 2017 | CRUK | Pancreatic cancer; Prostate cancer | 2 | 0 | 2 | 0 | 65 | 65 | 1 | ||||
Adachi | Hisanobu | Not yet determined | 2005 | 2013 | Bladder cancer; Upper tract urothelial carcinoma | 1 | 0 | 0 | 0 | 22 | 22 | 1 | ||||||
Adachi | Isamu | M | Japan | 1993 | 1996 | Breast cancer | 1 | 1 | 0 | 0 | 6 | 6 | 1 | |||||
Adachi | Susumu | M | 2001 | 2008 | Malignant pleural mesothelioma | 2 | 0 | 1 | 0 | 23 | 21 | 1 | ||||||
Adak | Sudeshna | F | USA | 1991 | 2001 | ECOG | Non-small cell lung cancer; Small cell lung cancer | 2 | 0 | 2 | 0 | 12 | 11 | 1 | ||||
Adam | H. | CBD | 1982 | 1994 | SAKK | Breast cancer | 1 | 0 | 1 | 0 | 17 | 17 | 1 | |||||
Adam | Rene | M | France | 1994 | 2017 | SARAH Trial Group | Colorectal cancer; Hepatocellular carcinoma | 2 | 0 | 2 | 0 | 52 | 52 | 1 | ||||
Adam | Zdenek | M | 2001 | 2013 | Multiple myeloma | 4 | 1 | 1 | 0 | 45 | 24 | 1 | ||||||
Adamchuk | Hryhoriy | Not yet determined | Ukraine | 2008 | 2019 | Breast cancer | 1 | 0 | 1 | 0 | 24 | 24 | 1 | |||||
Adami | Bernd | M | 2001 | 2009 | Colorectal cancer | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Adami | Fausto | M | Italy | 1999 | 2017 | Light-chain (AL) amyloidosis; POEMS syndrome | 2 | 0 | 0 | 0 | 17 | 16 | 1 | |||||
Adami | Francesca | F | Italy | 1996 | 2016 | GONO | Breast cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||
Adami | Hans Olov | M | Sweden; USA | 1989 | 2018 | SPCG | Prostate cancer | 6 | 0 | 1 | 0 | 78 | 22 | 1 | ||||
Adamkewicz | Joanne I. | F | USA | 2018 | 2018 | Inherited coagulopathy | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Adamo | Francesco | M | 1995 | 2006 | EORTC; FIL; GIMEMA | Acute myeloid leukemia; Hodgkin lymphoma | 2 | 0 | 1 | 0 | 37 | 36 | 1 | |||||
Adamo | Vincenzo | M | 1983 | 2005 | Italian Lung Cancer Project; Italian Multicentre Breast Study with Epirubicin | Breast cancer; Colon cancer; Non-small cell lung cancer; Ovarian cancer | 5 | 0 | 4 | 0 | 138 | 121 | 1 | |||||
Adamou | Adamos | M | 1992 | 2009 | HeCOG; HORG | Breast cancer | 2 | 0 | 2 | 0 | 35 | 34 | 1 | |||||
Adams | Bonne | Not yet determined | USA | 2017 | 2022 | Vascular sarcoma | 1 | 0 | 1 | 0 | 15 | 15 | 1 | |||||
Adams | George L. | M | 1989 | 2003 | Head and neck cancer; Nasopharyngeal carcinoma | 2 | 0 | 3 | 0 | 17 | 14 | 1 | ||||||
Adams | Grenfell | M | 1984 | 2004 | NCIC-CTG | Diffuse large B-cell lymphoma; Hodgkin lymphoma | 2 | 0 | 1 | 0 | 28 | 27 | 1 | |||||
Adams | Hans Peter | M | 1995 | 2003 | AGO | Ovarian cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Adams | Julian | M | USA | 2001 | 2004 | Follicular lymphoma; Mantle cell lymphoma; Multiple myeloma | 3 | 0 | 0 | 1 | 49 | 34 | 1 | |||||
Adams | M. | CBD | 1995 | 2002 | ICON | Ovarian cancer | 1 | 0 | 1 | 0 | 20 | 20 | 1 | |||||
Adams | Paul T. | M | USA | 2007 | 2015 | NSABP | Breast cancer | 2 | 0 | 1 | 0 | 39 | 21 | 1 | ||||
Adams | Richard A. | M | United Kingdom | 2005 | 2021 | MRC | Anal cancer; Colorectal cancer | 5 | 2 | 5 | 0 | 99 | 79 | 1 | ||||
Adams | Sylvia | F | USA | 2015 | 2021 | Breast cancer | 3 | 0 | 1 | 1 | 47 | 22 | 1 | |||||
Adamska | Krystyna | F | Poland | 2008 | 2014 | Canadian Brain Tumor Consortium; CENTRIC study team; EORTC | Glioblastoma | 1 | 0 | 1 | 0 | 36 | 36 | 1 | ||||
Adamski | Henri | M | 2011 | 2011 | Cutaneous squamous cell carcinoma | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Adamson | Peter C. | M | USA | 2008 | 2020 | Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma | Anaplastic large cell lymphoma pediatric; B-cell acute lymphoblastic leukemia pediatric; Non-Hodgkin lymphoma pediatric | 3 | 0 | 2 | 3 | 50 | 50 | 1 | ||||
Adamus | Jerzy | M | 1974 | 1982 | Melanoma | 1 | 0 | 1 | 0 | 25 | 25 | 1 | ||||||
Addamo | B. | CBD | 1998 | 2004 | AML Study Group Ulm | Acute myeloid leukemia | 1 | 0 | 1 | 0 | 24 | 24 | 1 | |||||
Adde | Magdalena | F | Sweden | 2001 | 2006 | Burkitt lymphoma; Diffuse large B-cell lymphoma; HIV-associated lymphoma | 2 | 1 | 0 | 0 | 15 | 15 | 1 | |||||
Addeo | Raffaele | M | Italy | 2003 | 2009 | Bladder cancer | 1 | 1 | 1 | 0 | 11 | 11 | 1 | |||||
Addison | Alicia | F | USA | 2013 | 2015 | Mantle cell lymphoma | 1 | 0 | 0 | 0 | 24 | 24 | 1 | |||||
Adebamowo | Clement | M | Nigeria | 2004 | 2016 | Breast cancer | 1 | 0 | 1 | 0 | 29 | 29 | 1 | |||||
Adelman | Carrie A. | F | United Kingdom | 2020 | 2020 | Prostate cancer | 2 | 0 | 0 | 0 | 38 | 23 | 1 | |||||
Adelson | Mark D. | M | USA | 1985 | 1999 | GOG | Endometrial cancer; Ovarian cancer | 2 | 0 | 2 | 0 | 18 | 18 | 1 | ||||
Adelstein | David J. | M | USA | 1988 | 2018 | RTOG; SWOG | Diffuse large B-cell lymphoma; Head and neck cancer; Oropharyngeal cancer | 6 | 4 | 4 | 0 | 62 | 56 | 1 | ||||
Ademokun | Debo | Not yet determined | United Kingdom | 2008 | 2019 | National Cancer Research Institute Haemato-oncology Clinical Studies Group | Multiple myeloma | 1 | 0 | 2 | 0 | 21 | 21 | 1 | ||||
Ademuyiwa | Foluso | Not yet determined | USA | 2013 | 2017 | Breast cancer | 1 | 0 | 0 | 0 | 33 | 33 | 1 | |||||
Adeniran | Adebowale | Not yet determined | USA | 2016 | 2021 | SWOG | Papillary renal cell carcinoma | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||
Adenis | Antoine | M | France | 1992 | 2022 | EORTC; FFCD; FNCLCC; French Sarcoma Group; GI Group of the French Anti-Cancer Centers; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO); UNICANCER | Anal cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastrointestinal stromal tumor; Pancreatic cancer | 18 | 2 | 12 | 5 | 322 | 225 | 1 | ||||
Ades | Lionel | M | France | 1993 | 2022 | EAPLG; European APL Group; French Belgian Swiss APL group; Groupe Francophone des Myelodysplasies; PETHEMA | Acute myeloid leukemia; Acute promyelocytic leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome | 8 | 7 | 6 | 1 | 182 | 121 | 1 | ||||
Adeva | Jorge | M | Spain | 2017 | 2021 | Cholangiocarcinoma | 2 | 0 | 1 | 1 | 51 | 28 | 1 | |||||
Adewoye | Adeboye H. | M | USA | 2012 | 2017 | Chronic lymphocytic leukemia | 1 | 0 | 1 | 0 | 22 | 22 | 1 | |||||
Adhoute | X. | CBD | France | 2003 | 2015 | FFCD | Colorectal cancer | 1 | 0 | 1 | 0 | 23 | 23 | 1 | ||||
Adib | Deyaa | M | USA | 2015 | 2020 | Follicular lymphoma | 1 | 0 | 0 | 1 | 20 | 20 | 1 | |||||
Adibi | Mehrad | Not yet determined | USA | 2017 | 2020 | Upper tract urothelial carcinoma | 1 | 0 | 0 | 0 | 35 | 35 | 1 | |||||
Adie | Sam | M | Australia | 2022 | 2022 | Venous thromboembolism | 1 | 0 | 1 | 0 | 45 | 45 | 1 | |||||
Adiguzel | Ibrahim | M | 2007 | 2011 | Small cell lung cancer | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Adinin | Rosnie B. | UNMATCHED | 2001 | 2008 | Breast cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Adjei | Alex A. | M | USA | 1999 | 2017 | ECOG-ACRIN; NCCTG | Non-small cell lung cancer | 2 | 0 | 2 | 0 | 38 | 38 | 1 | ||||
Adkins | Douglas | M | USA | 2004 | 2021 | Head and neck cancer; Soft tissue sarcoma; Thyroid cancer | 3 | 0 | 1 | 2 | 54 | 54 | 1 | |||||
Adler Reichel | S. | Not yet determined | Germany | 2001 | 2016 | Multiple myeloma | 1 | 0 | 1 | 0 | 34 | 34 | 1 | |||||
Adler | Brian | M | 1992 | 2003 | Sickle cell anemia | 1 | 0 | 1 | 0 | 26 | 26 | 1 | ||||||
Adler | Mathias | M | Germany | 1991 | 2011 | CONKO; GHSG | Hodgkin lymphoma; Pancreatic cancer | 3 | 0 | 2 | 0 | 66 | 59 | 1 | ||||
Adotevi | Olivier | M | France | 2014 | 2018 | Anal cancer | 1 | 0 | 0 | 0 | 26 | 26 | 1 | |||||
Adrian | Nicole | F | Germany | 2012 | 2016 | Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 12 | 12 | 1 | |||||
Adrover | Encarna | F | Spain | 1999 | 2015 | GEICAM | Breast cancer | 5 | 0 | 5 | 0 | 122 | 74 | 1 | ||||
Advani | Anjali S. | F | USA | 2006 | 2019 | CALGB; SWOG | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Diffuse large B-cell lymphoma; Follicular lymphoma; Myelodysplastic syndrome | 7 | 3 | 1 | 1 | 112 | 91 | 1 | ||||
Advani | Ranjana H. | F | USA | 1995 | 2022 | ECOG; WMCTG | Acute myeloid leukemia; Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant; Mantle cell lymphoma; Mediastinal gray-zone lymphoma; Peripheral T-cell lymphoma; Primary mediastinal B-cell lymphoma; Waldenstroem macroglobulinemia | 38 | 6 | 5 | 5 | 607 | 314 | 1 | ||||
Advani | Suresh H. | M | 1996 | 2005 | Breast cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Aeberhard | Peter | M | 1981 | 2008 | SAKK | Colon cancer | 2 | 0 | 2 | 0 | 12 | 9 | 1 | |||||
Aebersold | Daniel M. | M | 1994 | 2011 | SAKK | Head and neck cancer | 1 | 1 | 1 | 0 | 10 | 10 | 1 | |||||
Aebi | Stefan | M | Switzerland | 1993 | 2021 | BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; SAKK | Breast cancer | 9 | 2 | 5 | 0 | 179 | 83 | 1 | ||||
Aerts | Joachim G. J. V. | M | Netherlands | 2007 | 2021 | Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer | 9 | 1 | 6 | 1 | 152 | 125 | 1 | |||||
Afable | Manuel | M | 2012 | 2012 | Myelodysplastic syndrome | 1 | 0 | 0 | 0 | 16 | 16 | 1 | ||||||
Afanasyev | Boris V. | M | Russian Federation | 2003 | 2020 | SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network | Acute myeloid leukemia; Chronic lymphocytic leukemia; Mantle cell lymphoma; Myelodysplastic syndrome | 4 | 0 | 3 | 2 | 95 | 95 | 1 | ||||
Afchain | Pauline | F | 2004 | 2009 | Colorectal cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | ||||||
Afenjar | Karen | F | France | 2008 | 2019 | Breast cancer; Gastric cancer | 3 | 0 | 2 | 0 | 62 | 47 | 1 | |||||
Afflitto | Anthony J. | M | USA | 2013 | 2018 | Hepatocellular carcinoma | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Affronti | M. L. | Not yet determined | 1992 | 2006 | Breast cancer | 1 | 0 | 1 | 0 | 11 | 11 | 1 | ||||||
Afra | Denes | M | 1988 | 2008 | EORTC | Anaplastic glioma | 1 | 0 | 1 | 0 | 9 | 9 | 1 | |||||
Afrin | Lawrence B. | M | USA | 2009 | 2017 | Systemic mastocytosis | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Aft | Rebecca | F | USA | 2013 | 2017 | Breast cancer | 1 | 0 | 0 | 0 | 33 | 33 | 1 | |||||
Aftab | Dana T. | F | USA | 2013 | 2016 | Renal cell carcinoma | 1 | 0 | 1 | 1 | 22 | 22 | 1 | |||||
Aftimos | Philippe | M | Belgium | 2017 | 2022 | Breast cancer | 2 | 0 | 2 | 1 | 57 | 54 | 1 | |||||
Agajanian | Richy | M | USA | 2012 | 2016 | Multiple myeloma | 1 | 0 | 0 | 0 | 16 | 16 | 1 | |||||
Agaram | Narasimhan P. | M | USA | 2014 | 2018 | Alliance | Desmoid tumor | 1 | 0 | 1 | 0 | 24 | 24 | 1 | ||||
Agarwal | Archi | Not yet determined | India | 2012 | 2019 | Head and neck cancer | 1 | 0 | 1 | 0 | 50 | 50 | 1 | |||||
Agarwal | Jaiprakash | M | India | 2000 | 2019 | Head and neck cancer | 3 | 1 | 3 | 0 | 87 | 54 | 1 | |||||
Agarwal | Mohan B. | M | India | 2007 | 2011 | Chronic myeloid leukemia | 1 | 0 | 1 | 1 | 19 | 19 | 1 | |||||
Agarwal | Neeraj | M | USA | 2006 | 2022 | SWOG | Bladder cancer; Prostate cancer; Renal cell carcinoma | 15 | 2 | 8 | 3 | 299 | 211 | 1 | ||||
Agarwal | Prasheen | M | USA | 2004 | 2007 | Chronic myeloid leukemia | 2 | 0 | 0 | 0 | 32 | 25 | 1 | |||||
Agarwal | Rishu | F | Australia | 2015 | 2018 | Mantle cell lymphoma | 1 | 0 | 0 | 0 | 16 | 16 | 1 | |||||
Agarwal | Shefali | F | USA | 2013 | 2020 | Epithelioid sarcoma; Follicular lymphoma; Ovarian cancer | 3 | 0 | 1 | 3 | 71 | 71 | 1 | |||||
Agarwal | Suresh K. | M | USA | 2012 | 2019 | Acute myeloid leukemia; Chronic lymphocytic leukemia; Multiple myeloma | 4 | 0 | 0 | 3 | 71 | 60 | 1 | |||||
Agarwala | A. | Not yet determined | 2002 | 2011 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||||
Agarwala | Sanjiv S. | M | USA | 1974 | 2017 | ECOG; EORTC | Head and neck cancer; Melanoma | 16 | 5 | 13 | 3 | 268 | 198 | 1 | ||||
Agate | Laura | F | 2014 | 2014 | Thyroid cancer differentiated; Thyroid cancer medullary | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Agathocleous | Agathoclis | M | United Kingdom | 2010 | 2010 | Follicular lymphoma | 1 | 1 | 0 | 0 | 11 | 11 | 1 | |||||
Agbalika | Felix | M | 2007 | 2007 | Castleman disease | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Agelaki | Sophia | F | Greece | 2001 | 2017 | HORG | Breast cancer; Colorectal cancer; Non-small cell lung cancer; Small cell lung cancer | 5 | 0 | 4 | 0 | 65 | 39 | 1 | ||||
Agelidou | Athina | F | Greece | 1999 | 2011 | HORG | Non-small cell lung cancer; Small cell lung cancer | 8 | 0 | 7 | 0 | 99 | 47 | 1 | ||||
Agelidou | Maria | F | Greece | 2000 | 2013 | HORG | Non-small cell lung cancer; Small cell lung cancer | 6 | 0 | 5 | 0 | 79 | 42 | 1 | ||||
Ageno | Walter | M | Italy | 2008 | 2018 | Venous thromboembolism | 3 | 0 | 3 | 0 | 30 | 30 | 1 | |||||
Ager | Phyllis Joyce | F | 1984 | 1990 | NSABP | Breast cancer | 1 | 0 | 1 | 1 | 19 | 19 | 1 | |||||
Agerbaek | Mads | M | Denmark | 2002 | 2021 | EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group | Bladder cancer | 2 | 0 | 2 | 1 | 56 | 55 | 1 | ||||
Aggarwal | Charu | F | USA | 2011 | 2015 | Non-small cell lung cancer | 1 | 0 | 0 | 0 | 26 | 26 | 1 | |||||
Aggarwal | Sanjay | M | USA | 2012 | 2016 | Multiple myeloma | 2 | 0 | 1 | 1 | 37 | 37 | 1 | |||||
Aggerholm | Anni | F | 2004 | 2010 | Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Agha | Mounzer E. | UNMATCHED | USA | 2008 | 2022 | Multiple myeloma | 3 | 0 | 1 | 1 | 104 | 100 | 1 | |||||
Aghajanian | Carol A. | F | USA | 2005 | 2021 | GOG | Endometrial cancer; Leiomyosarcoma; Low-grade serous ovarian cancer; Ovarian cancer | 19 | 3 | 11 | 6 | 375 | 215 | 1 | ||||
Aghemo | E. | CBD | Italy | 2010 | 2016 | Multiple myeloma | 1 | 0 | 0 | 0 | 29 | 29 | 1 | |||||
Agis | Hermine | F | Austria | 2000 | 2006 | Chronic myeloid leukemia | 1 | 0 | 1 | 1 | 31 | 31 | 1 | |||||
Aglietta | Massimo | M | Italy | 1998 | 2022 | Italian Group for the Study of Gastrointestinal Cancer | Colorectal cancer; Multiple myeloma; Osteosarcoma; Soft tissue sarcoma | 8 | 1 | 4 | 2 | 138 | 119 | 1 | ||||
Agnelli | Giancarlo | M | Italy | 2010 | 2020 | Venous thromboembolism | 6 | 3 | 6 | 0 | 81 | 51 | 1 | |||||
Agnelli | L. | CBD | Italy | 2013 | 2013 | Plasma cell leukemia | 1 | 0 | 0 | 0 | 29 | 29 | 1 | |||||
Agodoa | Irene | F | USA | 2017 | 2021 | Sickle cell anemia | 1 | 0 | 1 | 0 | 11 | 11 | 1 | |||||
Agopian | Julie | F | France | 2009 | 2017 | Systemic mastocytosis | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Agostara | Biagio | M | 1997 | 2010 | GOIM; Gruppo Oncologico Italia Meridionale | Breast cancer; Colorectal cancer; Non-small cell lung cancer | 3 | 0 | 3 | 0 | 53 | 46 | 1 | |||||
Agostinelli | Claudio | M | Italy | 2006 | 2017 | Diffuse large B-cell lymphoma | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Agostini | Cecile | F | 2000 | 2007 | Breast cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | ||||||
Agrawal | Manish | M | USA | 2014 | 2017 | Bladder cancer | 1 | 0 | 0 | 1 | 17 | 17 | 1 | |||||
Agrawal | Rajiv K. | M | United Kingdom | 1996 | 2019 | NEAT Investigators and the SCTBG; tAnGo trial collaborators | Breast cancer | 5 | 0 | 5 | 0 | 120 | 71 | 1 | ||||
Agrawal | Samir | M | 2006 | 2012 | NCRI | Chronic lymphocytic leukemia; Multiple myeloma; Stem cell mobilization | 2 | 0 | 0 | 0 | 34 | 34 | 1 | |||||
Agrawal | Shruti | F | USA | 2006 | 2021 | Chronic myeloid leukemia pediatric; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | 2 | 0 | 1 | 2 | 42 | 42 | 1 | |||||
Agresta | Samuel V. | M | USA | 2013 | 2019 | Acute myeloid leukemia | 4 | 0 | 0 | 2 | 109 | 54 | 1 | |||||
Agricola | Karen | F | USA | 2007 | 2015 | Subependymal giant cell astrocytoma | 3 | 0 | 0 | 1 | 23 | 14 | 1 | |||||
Aguado Fraile | Elia | F | USA | 2017 | 2021 | Cholangiocarcinoma | 1 | 0 | 1 | 1 | 26 | 26 | 1 | |||||
Aguado | M. Jose | M | 1999 | 1999 | Hodgkin lymphoma | 1 | 0 | 0 | 0 | 5 | 5 | 1 | ||||||
Aguggini | S. | CBD | 1997 | 2005 | Breast cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | ||||||
Aguiar | Melanie | Not yet determined | United Kingdom | 2012 | 2022 | B-cell acute lymphoblastic leukemia | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Aguiar | Ricardo C. T. | M | USA | 2014 | 2014 | Hypereosinophilic syndrome | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Aguilera | Nadia | F | Cuba | 2006 | 2016 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | |||||
Aguilo | Rafael | M | 2000 | 2010 | Spanish Lung Cancer Group | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Agulnik | Jason | M | Canada | 2008 | 2016 | Non-small cell lung cancer nonsquamous | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Agulnik | Mark B. | M | USA | 2004 | 2020 | Epithelioid sarcoma; Head and neck cancer; Osteosarcoma; Soft tissue sarcoma; Vascular sarcoma | 7 | 1 | 3 | 2 | 132 | 100 | 1 | |||||
Agunwamba | Blessing U. | F | USA | 2009 | 2013 | Melanoma | 1 | 0 | 0 | 0 | 23 | 23 | 1 | |||||
Agura | Edward | M | USA | 1997 | 2018 | Acute myeloid leukemia; Allogeneic HSCT; Chronic lymphocytic leukemia; Hodgkin lymphoma | 8 | 1 | 1 | 1 | 131 | 83 | 1 | |||||
Agus | David B. | M | USA | 1993 | 2015 | Diffuse large B-cell lymphoma; Prostate cancer | 2 | 0 | 1 | 0 | 38 | 38 | 1 | |||||
Aguzzi | Rasha | Not yet determined | USA | 2018 | 2018 | Paroxysmal nocturnal hemoglobinuria | 1 | 0 | 1 | 1 | 13 | 13 | 1 | |||||
Ah See | Antoinne K. | M | 2002 | 2002 | Breast cancer | 1 | 0 | 1 | 0 | 11 | 11 | 1 | ||||||
Ah See | Mei Lin | Not yet determined | United Kingdom | 2007 | 2019 | Breast cancer | 1 | 0 | 1 | 0 | 31 | 31 | 1 | |||||
Ahern | Charlotte | F | USA | 2009 | 2013 | COG | Anaplastic large cell lymphoma pediatric | 1 | 0 | 0 | 1 | 13 | 13 | 1 | ||||
Ahlberg | Lucia | F | 2002 | 2013 | Multiple myeloma | 2 | 0 | 2 | 0 | 48 | 37 | 1 | ||||||
Ahlborn | Miriam | F | Germany | 2012 | 2021 | GHSG | Hodgkin lymphoma | 1 | 0 | 2 | 0 | 35 | 35 | 1 | ||||
Ahlgren | Goeran M. | M | Sweden | 2005 | 2018 | SPCG | Prostate cancer | 2 | 1 | 2 | 0 | 30 | 29 | 1 | ||||
Ahlgren | James D. | M | 1984 | 1989 | MAOP | Colorectal cancer | 1 | 0 | 1 | 0 | 4 | 4 | 1 | |||||
Ahlgren | Johan | M | Sweden | 2004 | 2022 | Breast cancer | 3 | 0 | 1 | 0 | 57 | 27 | 1 | |||||
Ahlgren | Tomas | M | Sweden | 2002 | 2015 | Nordic Lymphoma Group | Follicular lymphoma | 1 | 0 | 1 | 0 | 12 | 12 | 1 | ||||
Ahlman | Hakan | M | 1979 | 2010 | Adrenocortical carcinoma | 1 | 1 | 0 | 0 | 8 | 8 | 1 | ||||||
Ahlmann | Martina | F | Germany | 2020 | 2020 | Hemophagocytic lymphohistiocytosis | 1 | 0 | 0 | 1 | 19 | 19 | 1 | |||||
Ahluwalia | Manmeet S. | M | USA | 2009 | 2020 | Glioblastoma | 2 | 0 | 2 | 0 | 47 | 46 | 1 | |||||
Ahmad | Chaudhary E. | Not yet determined | Canada | 2016 | 2020 | NCIC-CTG | Colorectal cancer | 1 | 0 | 0 | 0 | 20 | 20 | 1 | ||||
Ahmad | Rizvana | F | United Kingdom | 2009 | 2015 | Breast cancer | 1 | 0 | 1 | 0 | 20 | 20 | 1 | |||||
Ahmad | Shaharyar | UNMATCHED | 2013 | 2013 | Hodgkin lymphoma | 1 | 0 | 0 | 0 | 3 | 3 | 1 | ||||||
Ahmadi | Jamshid | M | USA | 1992 | 2015 | SWOG | Meningioma | 1 | 0 | 1 | 0 | 12 | 12 | 1 | ||||
Ahmadi | Tahamtan | M | USA | 2008 | 2021 | Follicular lymphoma; Light-chain (AL) amyloidosis; Mantle cell lymphoma; Multiple myeloma | 16 | 1 | 6 | 9 | 409 | 214 | 1 | |||||
Ahmann | David L. | M | USA | 1977 | 1995 | Breast cancer; Melanoma | 7 | 2 | 7 | 1 | 54 | 30 | 1 | |||||
Ahmann | Frederick R. | M | 2002 | 2007 | Prostate cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||||
Ahmann | Gregory J. | M | USA | 2004 | 2018 | ECOG | Multiple myeloma | 2 | 0 | 1 | 1 | 42 | 39 | 1 | ||||
Ahmed | Asra | F | 2005 | 2012 | Multiple myeloma | 2 | 0 | 0 | 0 | 28 | 25 | 1 | ||||||
Ahmed | Atif A. | Not yet determined | USA | 2010 | 2021 | COG | Ewing sarcoma | 1 | 0 | 1 | 0 | 23 | 23 | 1 | ||||
Ahmed | Ikhlaaq | Not yet determined | United Kingdom | 1998 | 2019 | Breast cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Ahmed | Nazma | F | Switzerland | 2006 | 2015 | Head and neck cancer | 1 | 0 | 1 | 0 | 24 | 24 | 1 | |||||
Ahmed | Sairah | F | USA | 2009 | 2014 | Allogeneic HSCT; Mantle cell lymphoma; Transformed lymphoma | 1 | 0 | 0 | 0 | 13 | 13 | 1 | |||||
Ahn | Chul | M | USA | 2013 | 2014 | Blastic plasmacytoid dendritic cell neoplasm | 1 | 0 | 0 | 0 | 14 | 14 | 1 | |||||
Ahn | Daniel H. | M | USA | 2015 | 2019 | Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer | 2 | 0 | 0 | 0 | 31 | 30 | 1 | |||||
Ahn | Hanjong | Not yet determined | South Korea | 2014 | 2022 | Prostate cancer | 1 | 0 | 1 | 0 | 8 | 8 | 1 | |||||
Ahn | Inhye E. | Not yet determined | USA | 2015 | 2020 | Chronic lymphocytic leukemia | 1 | 1 | 0 | 0 | 16 | 16 | 1 | |||||
Ahn | Jae Sook | M | South Korea | 2009 | 2015 | Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology | B-cell acute lymphoblastic leukemia; CNS leukemia | 1 | 0 | 0 | 0 | 36 | 36 | 1 | ||||
Ahn | Jin Hee | F | South Korea | 2007 | 2022 | KCSG | Breast cancer | 4 | 0 | 4 | 1 | 79 | 66 | 1 | ||||
Ahn | Jin Seok | M | South Korea | 2002 | 2020 | KCSG | Breast cancer; CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Small cell lung cancer | 15 | 1 | 10 | 4 | 230 | 152 | 1 | ||||
Ahn | Joong Bae | M | South Korea | 2008 | 2019 | Colorectal cancer; Rectal cancer | 6 | 0 | 3 | 1 | 103 | 65 | 1 | |||||
Ahn | Myung Ju | F | South Korea | 2002 | 2021 | KCSG | CNS carcinoma; Esophageal squamous cell carcinoma; Head and neck cancer; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; NTRK; Small cell lung cancer | 41 | 4 | 20 | 11 | 735 | 423 | 1 | ||||
Ahn | Sei Hyun | Not yet determined | South Korea | 2012 | 2020 | Breast cancer | 1 | 1 | 1 | 0 | 9 | 8 | 1 | |||||
Ahn | Sung Ja | Not yet determined | 2005 | 2013 | Non-small cell lung cancer | 1 | 1 | 1 | 0 | 11 | 11 | 1 | ||||||
Ahn | Yeon S. | Not yet determined | 1983 | 1983 | Immune thrombocytopenia | 1 | 1 | 0 | 0 | 5 | 5 | 1 | ||||||
Ahn | Yong Chan | M | South Korea | 2003 | 2015 | Consortium for Improving Survival of Lymphoma; KCSG | Extranodal NK- and T-cell lymphoma nasal type; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer | 4 | 1 | 3 | 0 | 69 | 60 | 1 | ||||
Ahren | Bo | M | 1991 | 2003 | Neuroendocrine tumor | 1 | 1 | 0 | 0 | 3 | 3 | 1 | ||||||
Ahrens | S. | CBD | 2001 | 2001 | Ewing sarcoma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Ahsan | S. | Not yet determined | USA | 2011 | 2019 | Melanoma | 1 | 0 | 0 | 0 | 19 | 19 | 1 | |||||
Ahsan | Sama | F | United Kingdom; USA | 2015 | 2022 | SWOG | Melanoma | 2 | 0 | 2 | 1 | 57 | 54 | 1 | ||||
Ahuja | Harish | M | 2005 | 2005 | Esophageal cancer | 1 | 0 | 0 | 0 | 10 | 10 | 1 | ||||||
Ai | Ping | F | China | 2011 | 2019 | Nasopharyngeal carcinoma | 2 | 0 | 2 | 0 | 67 | 34 | 1 | |||||
Ai | Weiyun | F | USA | 2018 | 2021 | Diffuse large B-cell lymphoma; Transformed lymphoma | 1 | 0 | 0 | 1 | 17 | 17 | 1 | |||||
Ai | Xinghao | Not yet determined | China | 2018 | 2021 | Non-small cell lung cancer nonsquamous; Small cell lung cancer | 2 | 1 | 2 | 0 | 57 | 51 | 1 | |||||
Aiba | Keisuke | Not yet determined | Japan | 2010 | 2021 | Colon cancer | 2 | 0 | 1 | 0 | 41 | 30 | 1 | |||||
Aiello | Maria | F | USA | 2012 | 2014 | Chronic lymphocytic leukemia | 1 | 0 | 1 | 1 | 26 | 26 | 1 | |||||
Aieta | Michele | M | Italy | 2007 | 2018 | Reader study level-I and level-II Groups | Breast cancer; Testicular cancer | 2 | 0 | 1 | 0 | 40 | 40 | 1 | ||||
Aihara | Satomi | Not yet determined | Japan | 2015 | 2021 | Ovarian cancer | 1 | 0 | 1 | 0 | 41 | 41 | 1 | |||||
Aihara | Tomohiko | M | Japan | 2002 | 2010 | Breast cancer | 1 | 1 | 1 | 0 | 20 | 20 | 1 | |||||
Aikata | Hiroshi | M | Japan | 2008 | 2018 | Hepatocellular carcinoma | 2 | 0 | 2 | 0 | 35 | 32 | 1 | |||||
Aikawa | Keiko | Not yet determined | Japan | 1995 | 2010 | JCOG | Adult T-cell leukemia-lymphoma; Diffuse large B-cell lymphoma | 2 | 0 | 1 | 0 | 32 | 25 | 1 | ||||
Aiken | Robert | Not yet determined | USA | 2007 | 2018 | Glioblastoma | 1 | 0 | 1 | 0 | 68 | 68 | 1 | |||||
Ailawadhi | Sikander | M | USA | 2012 | 2018 | Chronic myeloid leukemia; Multiple myeloma | 3 | 0 | 0 | 1 | 70 | 51 | 1 | |||||
Aimone | Paola | F | Switzerland | 2007 | 2021 | Chronic myeloid leukemia; Chronic myeloid leukemia pediatric; Head and neck cancer; Renal cell carcinoma | 7 | 0 | 3 | 4 | 146 | 116 | 1 | |||||
Airatovich Gafanov | Rustem | M | Russian Federation | 2016 | 2021 | Clear cell renal cell carcinoma; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma | 5 | 0 | 2 | 1 | 107 | 78 | 1 | |||||
Aird | William | M | 1990 | 2000 | Acute myeloid leukemia | 1 | 0 | 0 | 0 | 6 | 6 | 1 | ||||||
Airewele | Gladstone | Not yet determined | USA | 2004 | 2014 | Acute myeloid leukemia pediatric; Sickle cell anemia | 2 | 0 | 1 | 0 | 56 | 56 | 1 | |||||
Airoma | G. | CBD | 1990 | 1996 | GOSCI | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Aisa | Yoshinobu | M | 2015 | 2015 | Follicular lymphoma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Aisner | D. L. | CBD | USA | 2011 | 2015 | Pancreatic cancer | 1 | 0 | 0 | 0 | 30 | 30 | 1 | |||||
Aisner | Joseph A. | M | USA | 1976 | 2003 | CALGB | Breast cancer; Head and neck cancer; Soft tissue sarcoma; Thymoma | 9 | 3 | 6 | 0 | 93 | 65 | 1 | ||||
Aisner | Seena C. | F | USA | 1982 | 2017 | ECOG; ECOG-ACRIN; SECSG; SWOG | Non-small cell lung cancer; Small cell lung cancer; Thymoma | 8 | 0 | 3 | 0 | 72 | 56 | 1 | ||||
Aitchison | Michael A. | M | United Kingdom | 1998 | 2018 | EORTC; MRC | Renal cell carcinoma | 3 | 1 | 3 | 0 | 48 | 47 | 1 | ||||
Aitini | Enrico | M | Italy | 1987 | 2014 | GERCOR; GISCAD; Italian Group for the Study of Digestive Tract Cancer; Mammella InterGruppo | Breast cancer; Colorectal cancer; Diffuse large B-cell lymphoma; Gastric cancer; Malignant pleural mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer | 13 | 0 | 10 | 0 | 216 | 176 | 1 | ||||
Aitken | Casey N. | UNMATCHED | USA | 2017 | 2017 | Transformed lymphoma | 1 | 0 | 0 | 0 | 34 | 34 | 1 | |||||
Aivado | Manuel | M | 2010 | 2010 | Immune thrombocytopenia | 1 | 0 | 1 | 0 | 8 | 8 | 1 | ||||||
Aix | Santiago Ponce | Not yet determined | Spain | 2014 | 2020 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Aizawa | Masataka | Not yet determined | 2005 | 2013 | Bladder cancer; Upper tract urothelial carcinoma | 1 | 0 | 0 | 0 | 22 | 22 | 1 | ||||||
Ajani | Jaffer A. | M | USA | 1990 | 2022 | RTOG; USA Intergroup | Anal cancer; Esophageal adenocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer | 21 | 11 | 13 | 5 | 316 | 237 | 1 | ||||
Ajaz | Mazhar | Not yet determined | United Kingdom | 2016 | 2019 | Melanoma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Akabane | Hiromitsu | M | Japan | 2006 | 2021 | Breast cancer | 2 | 0 | 2 | 0 | 21 | 19 | 1 | |||||
Akaike | Makoto | M | Japan | 2003 | 2014 | JCOG | Colorectal cancer | 1 | 0 | 1 | 0 | 17 | 17 | 1 | ||||
Akaike | Tomoko | F | USA | 2015 | 2021 | Merkel cell carcinoma | 1 | 0 | 0 | 1 | 28 | 28 | 1 | |||||
Akamaru | Yusuke | M | Japan | 2007 | 2015 | Gastric cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Akamatsu | Hiroaki | M | Japan | 2014 | 2021 | CNS carcinoma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | 3 | 0 | 2 | 1 | 53 | 42 | 1 | |||||
Akamatsu | Hiroki | Not yet determined | Japan | 2011 | 2017 | Rectal cancer | 1 | 0 | 1 | 0 | 12 | 12 | 1 | |||||
Akapame | Sydney | M | USA | 2015 | 2022 | Bladder cancer | 1 | 0 | 0 | 1 | 18 | 18 | 1 | |||||
Akard | Luke | M | USA | 2006 | 2015 | Chronic myeloid leukemia; Testicular cancer | 3 | 0 | 0 | 2 | 40 | 34 | 1 | |||||
Akaza | Hideyuki | M | Japan | 2000 | 2020 | Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer | Prostate cancer | 6 | 3 | 5 | 1 | 66 | 57 | 1 | ||||
Akazawa | Kohei | M | Japan | 2010 | 2018 | Hepatocellular carcinoma | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
Akazawa | Rio | F | Japan | 2013 | 2018 | Prostate cancer | 1 | 0 | 1 | 0 | 11 | 11 | 1 | |||||
Akbulut | Hakan | M | 1992 | 2005 | Turkish Oncology Group | Breast cancer | 2 | 0 | 2 | 0 | 25 | 21 | 1 | |||||
Akdas | Atif | M | Turkey | 1997 | 2009 | EORTC | Prostate cancer | 1 | 0 | 1 | 0 | 15 | 15 | 1 | ||||
Aker | Memet | M | 1998 | 1998 | Allogeneic HSCT; Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Akerley | Wallace | M | USA | 1998 | 2016 | CALGB | Melanoma; Non-small cell lung cancer; Small cell lung cancer | 4 | 0 | 4 | 1 | 74 | 72 | 1 | ||||
Akerman | Maans | M | 1989 | 2008 | Nordic Lymphoma Group | Autologous HSCT; Diffuse large B-cell lymphoma; Mantle cell lymphoma | 2 | 1 | 1 | 0 | 30 | 28 | 1 | |||||
Akewanlop | Charuwan | F | Thailand | 2015 | 2020 | Non-small cell lung cancer | 1 | 0 | 1 | 1 | 23 | 23 | 1 | |||||
Akhter | Chameli | Not yet determined | Bangladesh | 2004 | 2016 | Breast cancer | 1 | 0 | 1 | 0 | 29 | 29 | 1 | |||||
Akilov | Oleg E. | M | USA | 2012 | 2021 | Cutaneous T-cell lymphoma | 2 | 0 | 1 | 1 | 57 | 37 | 1 | |||||
Akimasa | Nakao | UNMATCHED | 2003 | 2007 | Chubu Clinical Cancer Group | Gastric cancer | 1 | 1 | 0 | 0 | 12 | 12 | 1 | |||||
Akimov | Mikhail | M | Switzerland | 2020 | 2020 | Non-small cell lung cancer | 1 | 0 | 0 | 1 | 31 | 31 | 1 | |||||
Akin | Cem | M | USA | 2003 | 2016 | Hypereosinophilic syndrome; Systemic mastocytosis | 3 | 0 | 0 | 1 | 34 | 34 | 1 | |||||
Akinaga | Shiro | M | Japan | 2010 | 2015 | Adult T-cell leukemia-lymphoma; CNS leukemia; Cutaneous T-cell lymphoma; Non-small cell lung cancer; Peripheral T-cell lymphoma | 3 | 0 | 1 | 0 | 54 | 47 | 1 | |||||
Akita | Hirotoshi | M | 1992 | 1992 | Small cell lung cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Akiya | Toshikazu | M | 2002 | 2008 | Gastric cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | ||||||
Akiyama | Hideki | M | 1993 | 2013 | JALSG | B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia | 2 | 0 | 1 | 1 | 35 | 35 | 1 | |||||
Akiyoshi | Kohei | Not yet determined | Japan | 2019 | 2019 | Carcinoma of unknown primary | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Akkermans Vogelaar | Janine M. | F | Netherlands | 2013 | 2022 | Dutch Pancreatic Cancer Group | Pancreatic cancer | 2 | 0 | 1 | 0 | 60 | 31 | 1 | ||||
Akopov | Audrey | F | Russian Federation | 2015 | 2021 | Non-small cell lung cancer | 1 | 0 | 1 | 1 | 20 | 20 | 1 | |||||
Akpek | Gorgun | UNMATCHED | USA | 2016 | 2016 | BMT CTN | Autologous HSCT; HIV-associated lymphoma | 1 | 0 | 0 | 0 | 21 | 21 | 1 | ||||
Akram Hussain | Syed Md | Not yet determined | Bangladesh | 2004 | 2016 | Breast cancer | 1 | 0 | 1 | 0 | 29 | 29 | 1 | |||||
Akram | Muhammed | M | USA | 2018 | 2021 | Multiple myeloma | 1 | 0 | 0 | 1 | 35 | 35 | 1 | |||||
Aksnes | Anne Kirsti | F | Norway | 2008 | 2014 | Prostate cancer | 1 | 0 | 1 | 1 | 12 | 12 | 1 | |||||
Aktan | Gursel | M | USA | 2005 | 2022 | NeoALTTO Study Team | Breast cancer | 6 | 0 | 5 | 2 | 123 | 95 | 1 | ||||
Aktan | Melih | M | Turkey | 2010 | 2018 | Chronic lymphocytic leukemia | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Aktas | Bahriye | F | Germany | 2000 | 2019 | GBG | Breast cancer | 7 | 0 | 5 | 0 | 144 | 87 | 1 | ||||
Akusawa | Hiroshi | M | 1987 | 1996 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 7 | 7 | 1 | ||||||
Al Akash | Samhar I. | Not yet determined | USA | 2016 | 2016 | Atypical hemolytic uremic syndrome | 1 | 0 | 0 | 0 | 14 | 14 | 1 | |||||
Al Ali | Haifa Kathrin | F | Germany | 1997 | 2017 | OSHO | Acute myeloid leukemia; Allogeneic HSCT; Autologous HSCT; Chronic lymphocytic leukemia; CNS lymphoma; Follicular lymphoma; Myelofibrosis | 10 | 1 | 5 | 1 | 165 | 117 | 1 | ||||
Al Batran | Salah Eddin | M | Germany | 2000 | 2020 | AIO | Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Esophageal squamous cell carcinoma; Follicular lymphoma; Gastric cancer; Gastrointestinal stromal tumor; Mantle cell lymphoma; Marginal zone lymphoma; MSI-H or dMMR; Waldenstroem macroglobulinemia | 19 | 6 | 10 | 2 | 415 | 280 | 1 | ||||
Al Booz | Hoda | F | United Kingdom | 2012 | 2018 | De-ESCALaTE HPV Trial Group | Oropharyngeal cancer | 1 | 0 | 1 | 0 | 30 | 30 | 1 | ||||
Al Dewik | Nader | M | Qatar | 2015 | 2015 | Essential thrombocythemia | 1 | 0 | 0 | 0 | 13 | 13 | 1 | |||||
Al Fayoumi | Suliman | M | USA | 2014 | 2018 | Myelofibrosis | 1 | 0 | 1 | 1 | 18 | 18 | 1 | |||||
Al Ghuzlan | Abir | Not yet determined | France | 2013 | 2022 | Thyroid cancer differentiated | 1 | 0 | 1 | 0 | 33 | 33 | 1 | |||||
Al Kali | Aref | M | USA | 2010 | 2016 | Myelodysplastic syndrome | 1 | 0 | 1 | 0 | 20 | 20 | 1 | |||||
Al Kateb | Hussam | Not yet determined | USA | 2013 | 2017 | Breast cancer | 1 | 0 | 0 | 0 | 33 | 33 | 1 | |||||
Al Rajabi | Raed | M | USA | 2015 | 2020 | Cholangiocarcinoma; Esophageal cancer; Esophageal squamous cell carcinoma | 2 | 0 | 1 | 2 | 44 | 44 | 1 | |||||
Al Sakaff | Nedal | M | Switzerland | 2001 | 2019 | Herceptin Adjuvant (HERA) Trial Study Team | Breast cancer | 2 | 0 | 2 | 2 | 26 | 25 | 1 | ||||
al Sarraf | Muhyi | M | USA | 1977 | 1999 | Radiation Therapy Oncology Group; RTOG; SWOG | Esophageal cancer; Glioblastoma; Melanoma; Nasopharyngeal carcinoma; Prostate cancer | 7 | 2 | 6 | 1 | 70 | 53 | 1 | ||||
Al Sawaf | Othman | M | Germany | 2005 | 2022 | GCLLSG | Chronic lymphocytic leukemia | 6 | 2 | 4 | 1 | 148 | 80 | 1 | ||||
Al Shukri | Salman | M | Russian Federation | 2010 | 2016 | Renal cell carcinoma | 2 | 0 | 1 | 0 | 17 | 11 | 1 | |||||
Al Toubah | Taymeyah E. | Not yet determined | USA | 2016 | 2020 | Cholangiocarcinoma | 1 | 0 | 0 | 0 | 10 | 10 | 1 | |||||
Al Tweigeri | Taher | M | Canada | 1997 | 2005 | BCIRG | Breast cancer | 1 | 0 | 1 | 1 | 31 | 31 | 1 | ||||
Al Zoubi | Ammar | M | 2005 | 2012 | Multiple myeloma | 2 | 0 | 0 | 0 | 28 | 25 | 1 | ||||||
Alabiso | O. | CBD | 2007 | 2007 | Malignant pleural mesothelioma | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Alakel | N. | CBD | Germany | 2012 | 2015 | Acute myeloid leukemia; Allogeneic HSCT | 1 | 0 | 0 | 0 | 25 | 25 | 1 | |||||
Alakl | May | F | France | 1994 | 2010 | EORTC | Breast cancer; Colorectal cancer; Light-chain (AL) amyloidosis | 5 | 0 | 3 | 3 | 82 | 81 | 1 | ||||
Alam | A. | CBD | 2005 | 2005 | Follicular lymphoma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Alam | Rafeul | M | USA | 2001 | 2003 | Hypereosinophilic syndrome | 1 | 0 | 0 | 0 | 25 | 25 | 1 | |||||
Alam | Yasmin | F | Italy | 2006 | 2012 | Non-small cell lung cancer | 3 | 0 | 1 | 0 | 70 | 47 | 1 | |||||
Alama | A. | CBD | 1983 | 1987 | Breast cancer | 1 | 0 | 1 | 0 | 15 | 15 | 1 | ||||||
Alamoudi | Sameer | M | Canada | 2003 | 2015 | NCIC-CTG | Transformed lymphoma | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||
Alamouti | Sepideh | F | Canada | 2010 | 2016 | Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 23 | 23 | 1 | |||||
Alanko | Tuomo | M | Finland | 2000 | 2009 | Breast cancer | 3 | 0 | 2 | 0 | 56 | 34 | 1 | |||||
Alao | Hawwa | Not yet determined | USA | 2014 | 2019 | Hypereosinophilic syndrome | 1 | 0 | 0 | 0 | 24 | 24 | 1 | |||||
Alapi | Krisztina Zuborne | Not yet determined | United Kingdom | 2012 | 2022 | B-cell acute lymphoblastic leukemia | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Alarcon | Jesus | M | 2007 | 2007 | Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Alashkar | Ferras | Not yet determined | Germany | 2021 | 2021 | Paroxysmal nocturnal hemoglobinuria | 1 | 0 | 0 | 0 | 14 | 14 | 1 | |||||
Alatorre Alexander | Jorge | M | Mexico | 2016 | 2021 | Small cell lung cancer | 1 | 0 | 1 | 1 | 19 | 19 | 1 | |||||
Alattar | Mona Lisa | F | 2011 | 2013 | Acute myeloid leukemia | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Alavi | Jane | F | 2003 | 2003 | CNS lymphoma | 1 | 0 | 0 | 0 | 7 | 7 | 1 | ||||||
Alba | Emilio | M | Spain | 1995 | 2021 | GEICAM | Breast cancer | 13 | 3 | 12 | 1 | 280 | 186 | 1 | ||||
Albain | Kathy S. | F | USA | 1989 | 2021 | Breast Cancer Intergroup of North America; NCIC-CTG; NSABP; RTOG; SWOG | Breast cancer; Non-small cell lung cancer | 19 | 4 | 12 | 3 | 361 | 250 | 1 | ||||
Albala | Maurice M. | M | 1968 | 1968 | Head and neck cancer | 1 | 0 | 0 | 0 | 2 | 2 | 1 | ||||||
Albanell | Juan | M | Spain | 1987 | 2014 | GEICAM | Breast cancer | 3 | 0 | 2 | 0 | 38 | 38 | 1 | ||||
Albano | Edythe | F | USA | 2002 | 2006 | B-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 0 | 1 | 19 | 19 | 1 | |||||
Albano | Francesco | M | Italy | 2004 | 2019 | GIMEMA | Acute promyelocytic leukemia; Chronic myeloid leukemia | 3 | 0 | 3 | 1 | 113 | 69 | 1 | ||||
Alberici | Federico | M | Italy | 1994 | 2015 | GOIRC; POLAR-01 Trial Investigators | Erdheim-Chester disease; Renal cell carcinoma | 2 | 0 | 1 | 0 | 34 | 32 | 1 | ||||
Alberola | Vincente | M | Spain | 1989 | 2012 | Spanish Lung Cancer Group | Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | 6 | 1 | 6 | 2 | 109 | 85 | 1 | ||||
Albers | Gregory W. | M | USA | 2018 | 2018 | Venous thromboembolism | 1 | 0 | 1 | 0 | 12 | 12 | 1 | |||||
Albers | Mary E. | F | USA | 1990 | 1998 | Head and neck cancer | 1 | 0 | 1 | 0 | 8 | 8 | 1 | |||||
Albers | Peter | M | Germany | 1994 | 2021 | AUO; EORTC; German Association of Urologic Oncology; Groupe d'Etude des Tumeurs Urogenitales; National Cancer Institute of Canada Clinical Trials Group; National Cancer Research Institute Bladder Cancer Study Group | Bladder cancer; Prostate cancer; Testicular cancer | 9 | 3 | 8 | 0 | 156 | 127 | 1 | ||||
Albert | Catherine M. | F | USA | 2015 | 2020 | NTRK | 1 | 0 | 0 | 3 | 28 | 28 | 1 | |||||
Albert | Donald | M | 2002 | 2008 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 7 | 7 | 1 | ||||||
Albert | Istvan | M | Hungary | 2006 | 2019 | Non-small cell lung cancer | 4 | 0 | 4 | 1 | 74 | 64 | 1 | |||||
Albert | Michael H. | M | Germany | 2003 | 2015 | Allogeneic HSCT; B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 0 | 0 | 22 | 22 | 1 | |||||
Albert | Paul S. | M | USA | 2006 | 2008 | Glioblastoma | 1 | 0 | 0 | 1 | 12 | 12 | 1 | |||||
Albert | Ute Susann | F | 1998 | 2009 | Breast cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | ||||||
Alberti | Daniele | UNMATCHED | 1996 | 2002 | Breast cancer | 1 | 0 | 1 | 0 | 9 | 9 | 1 | ||||||
Albertini | Mark R. | M | USA | 1998 | 2019 | ECOG | Melanoma; Uveal melanoma | 3 | 0 | 2 | 0 | 67 | 58 | 1 | ||||
Alberto | Pierre | M | 1979 | 1994 | SAKK | Breast cancer | 2 | 1 | 2 | 0 | 22 | 19 | 1 | |||||
Alberts | David S. | M | USA | 1974 | 2019 | GOG; GRACES Clinical Trial Consortium; Gynecologic Cancer Intergroup; SWOG | Cervical cancer; Multiple myeloma; Ovarian cancer | 16 | 13 | 11 | 1 | 144 | 105 | 1 | ||||
Alberts | Steven R. | M | USA | 1997 | 2017 | CALGB; ECOG; NCCTG; SWOG | Cholangiocarcinoma; Colon cancer; Colorectal cancer; Gallbladder cancer; Gastric cancer; Pancreatic cancer | 10 | 2 | 8 | 2 | 121 | 97 | 1 | ||||
Albertsen | Birgitte Klug | F | Denmark | 2008 | 2019 | B-cell acute lymphoblastic leukemia pediatric | 1 | 1 | 1 | 0 | 9 | 9 | 1 | |||||
Albertson | Tina M. | F | USA | 2016 | 2020 | Diffuse large B-cell lymphoma; Primary mediastinal B-cell lymphoma; Transformed lymphoma | 1 | 0 | 0 | 1 | 21 | 21 | 1 | |||||
Albertsson | Maria | F | Sweden | 1991 | 2015 | Nordic Gastrointestinal Tumour Adjuvant Therapy Group | Colon cancer; Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma | 4 | 1 | 3 | 0 | 34 | 30 | 1 | ||||
Albiges | Laurence | M | France; USA | 2004 | 2022 | GETUG | Non-clear cell renal cell carcinoma; Papillary renal cell carcinoma; Prostate cancer; Renal cell carcinoma | 9 | 3 | 7 | 2 | 187 | 143 | 1 | ||||
Albitar | Maher | M | USA | 1998 | 2009 | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; CNS leukemia; Hypereosinophilic syndrome; Myelodysplastic syndrome; Systemic mastocytosis | 7 | 0 | 2 | 3 | 98 | 74 | 1 | |||||
Albo | Vincent C. | M | 1988 | 1988 | CCG | T-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 0 | 0 | 11 | 11 | 1 | |||||
Albright | A. L. | Not yet determined | 1999 | 1999 | CCG | Medulloblastoma | 1 | 0 | 0 | 0 | 15 | 15 | 1 | |||||
Albright | Robert E. | M | USA | 1999 | 2000 | Temodal Brain Tumor Group | Anaplastic glioma; Glioblastoma | 2 | 0 | 0 | 1 | 36 | 27 | 1 | ||||
Albritton | Karen | F | 2004 | 2004 | Ewing sarcoma | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Albuquerque | Marco | M | Canada | 2010 | 2016 | Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 23 | 23 | 1 | |||||
Alcaide | Julia | F | Spain | 2010 | 2018 | TTD | Colorectal cancer | 1 | 0 | 0 | 0 | 26 | 26 | 1 | ||||
Alcaide | Miguel | M | Canada | 2010 | 2016 | Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 23 | 23 | 1 | |||||
Alcaraz | Antonio | M | Spain | 2011 | 2022 | Prostate cancer | 3 | 0 | 2 | 1 | 50 | 38 | 1 | |||||
Alcedo | Juan Carlos | M | Panama | 2002 | 2016 | Breast cancer; Cervical cancer | 2 | 0 | 3 | 0 | 26 | 26 | 1 | |||||
Alcindor | Thierry | M | Canada | 2003 | 2019 | EORTC | Gastric cancer; Liposarcoma; Soft tissue sarcoma; Tenosynovial giant cell tumor | 7 | 0 | 6 | 2 | 138 | 107 | 1 | ||||
Aldaoud | Ali | M | Germany | 1996 | 2017 | European Mantle Cell Lymphoma Network; GCLLSG; GLSG | Autologous HSCT; Chronic lymphocytic leukemia; Follicular lymphoma; Mantle cell lymphoma; Stem cell mobilization | 6 | 0 | 6 | 1 | 111 | 75 | 1 | ||||
Aldape | Kenneth D. | M | Canada; USA | 2002 | 2017 | Canadian Brain Tumor Consortium; CENTRIC study team; EORTC; RTOG | Anaplastic glioma; Glioblastoma | 5 | 0 | 6 | 0 | 137 | 102 | 1 | ||||
Alderdice | M. | CBD | 1995 | 2002 | Breast cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | ||||||
Alderete | Daniel | M | 1987 | 1997 | Hodgkin lymphoma | 1 | 0 | 1 | 0 | 9 | 9 | 1 | ||||||
Alderson | Derek | M | United Kingdom | 1989 | 2017 | MRC | Colorectal cancer; Esophageal adenocarcinoma | 3 | 1 | 4 | 0 | 42 | 33 | 1 | ||||
Alderuccio | Juan Pablo | M | USA | 2018 | 2021 | Diffuse large B-cell lymphoma; Transformed lymphoma | 1 | 0 | 0 | 1 | 17 | 17 | 1 | |||||
Aldrighetti | Daniela | F | 1996 | 2004 | GONO | Breast cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Aldrighetti | Luca | M | 2000 | 2005 | Pancreatic cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | ||||||
Aledo | Alexander | M | USA | 2002 | 2014 | COG | B-cell acute lymphoblastic leukemia pediatric | 2 | 0 | 0 | 1 | 37 | 20 | 1 | ||||
Aledort | Louis M. | M | 1991 | 2008 | Immune thrombocytopenia | 2 | 1 | 2 | 0 | 35 | 34 | 1 | ||||||
Alegakis | Athanasios | M | 2004 | 2004 | Non-small cell lung cancer | 1 | 1 | 1 | 0 | 14 | 14 | 1 | ||||||
Alegre | Adrian | M | Spain | 2004 | 2021 | GEM; PETHEMA | Multiple myeloma | 8 | 0 | 3 | 2 | 199 | 112 | 1 | ||||
Aleinikova | Olga | F | Belarus | 2001 | 2020 | EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group | Acute myeloid leukemia; Acute myeloid leukemia pediatric; Allogeneic HSCT | 2 | 0 | 3 | 0 | 49 | 49 | 1 | ||||
Alekar | Shilpa | F | USA | 2014 | 2014 | B-cell acute lymphoblastic leukemia | 1 | 0 | 0 | 0 | 19 | 19 | 1 | |||||
Aleksandrovic | Jasna | F | 1991 | 2000 | Head and neck cancer | 1 | 0 | 1 | 0 | 7 | 7 | 1 | ||||||
Alekseev | Boris Yakovlevich | M | Russian Federation | 2010 | 2022 | Bladder cancer; Non-clear cell renal cell carcinoma; Prostate cancer; Renal cell carcinoma | 22 | 0 | 15 | 8 | 482 | 310 | 1 | |||||
Alekseev | Sergey | M | Russian Federation | 2012 | 2021 | Hodgkin lymphoma | 3 | 0 | 1 | 1 | 79 | 38 | 1 | |||||
Alekseeva | Yulia | F | Russian Federation | 2017 | 2022 | Multiple myeloma | 1 | 0 | 1 | 0 | 27 | 27 | 1 | |||||
Aleman | Berthe M. P. | F | Netherlands | 1988 | 2017 | EORTC; GELA | Hodgkin lymphoma | 3 | 1 | 5 | 0 | 75 | 56 | 1 | ||||
Aleman | Karen | F | USA | 2012 | 2016 | Kaposi sarcoma | 2 | 0 | 0 | 1 | 27 | 20 | 1 | |||||
Alencar | Alvaro | Not yet determined | USA | 2014 | 2019 | Blood Cancer Research Partnership of the Leukemia and Lymphoma Society | Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 22 | 22 | 1 | ||||
Alese | Olatunji B. | Not yet determined | USA | 2016 | 2020 | Cholangiocarcinoma | 1 | 0 | 0 | 0 | 10 | 10 | 1 | |||||
Alessandri | S. | CBD | 1982 | 1986 | Ovarian cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | ||||||
Alessandrino | Emilio Paolo | M | Italy | 1996 | 2015 | Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma; Stem cell mobilization | 3 | 0 | 1 | 0 | 77 | 60 | 1 | |||||
Alessandroni | Paolo | M | 2006 | 2012 | Colorectal cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Alexander | Eben | M | USA | 1969 | 1980 | BTSG | Glioblastoma | 2 | 0 | 2 | 0 | 27 | 18 | 1 | ||||
Alexander | Sarah | F | Canada | 2011 | 2021 | Children's Oncology Group; COG; European Intergroup for Childhood Non-Hodgkin Lymphoma | Anaplastic large cell lymphoma pediatric; Non-Hodgkin lymphoma pediatric | 3 | 1 | 1 | 1 | 38 | 33 | 1 | ||||
Alexandre | Jerome | M | Canada | 2006 | 2016 | JGOG | Ovarian cancer | 1 | 0 | 1 | 0 | 23 | 23 | 1 | ||||
Alexandris | Ekaterine | F | USA | 2010 | 2014 | Non-small cell lung cancer | 1 | 0 | 1 | 1 | 25 | 25 | 1 | |||||
Alexandru | Aurelia | F | Romania | 2015 | 2021 | Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | 3 | 0 | 2 | 2 | 77 | 52 | 1 | |||||
Alexanian | Raymond | M | USA | 1965 | 2008 | SWOG | Multiple myeloma | 14 | 10 | 3 | 2 | 90 | 48 | 1 | ||||
Alexeeva | Julia A. | F | Russian Federation | 2004 | 2016 | SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network | Acute myeloid leukemia; Mantle cell lymphoma | 3 | 0 | 2 | 1 | 65 | 63 | 1 | ||||
Alexis Vigier | Magda | F | France | 1990 | 2021 | France Intergroupe des Leucemies Myeloides Chroniques; GOELAMS | Chronic myeloid leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Mantle cell lymphoma | 4 | 0 | 2 | 0 | 106 | 96 | 1 | ||||
Alexopoulos | Athanasios | M | 1997 | 2003 | Greek Oncology Cooperative Group (GOCG) for Lung Cancer; HORG | Non-small cell lung cancer | 2 | 0 | 2 | 0 | 19 | 18 | 1 | |||||
Alexopoulos | Constantinos G. | M | 1990 | 2007 | ELCWP | Non-small cell lung cancer | 4 | 0 | 4 | 0 | 51 | 23 | 1 | |||||
Alfaro | Elizabeth | F | 1987 | 1997 | Hodgkin lymphoma | 1 | 0 | 1 | 0 | 9 | 9 | 1 | ||||||
Alfaro | Vicente | M | Spain | 2008 | 2021 | Multiple myeloma; Ovarian cancer; Small cell lung cancer; Soft tissue sarcoma | 4 | 0 | 3 | 1 | 84 | 76 | 1 | |||||
Alfieri | Sergio | M | Italy | 2005 | 2019 | Rectal cancer | 1 | 0 | 1 | 0 | 27 | 27 | 1 | |||||
Alfonsi | Marc | M | France | 1994 | 2020 | GORTEC | Head and neck cancer | 9 | 0 | 8 | 0 | 162 | 84 | 1 | ||||
Algarra | Lorenzo | M | Spain | 2014 | 2021 | PETHEMA Group | Acute myeloid leukemia | 1 | 0 | 1 | 0 | 32 | 32 | 1 | ||||
Algazi | Alain P. | M | USA | 2010 | 2021 | CNS melanoma; Melanoma | 7 | 0 | 0 | 1 | 166 | 91 | 1 | |||||
Algeri | Renato | M | 1991 | 2000 | Breast cancer | 1 | 0 | 1 | 0 | 9 | 9 | 1 | ||||||
Algul | Hana | F | Germany | 2015 | 2019 | Pancreatic cancer | 1 | 0 | 1 | 1 | 18 | 18 | 1 | |||||
Ali | Adnan | Not yet determined | United Kingdom | 2005 | 2019 | Prostate cancer | 1 | 0 | 1 | 0 | 49 | 49 | 1 | |||||
Ali | Arif N. | M | USA | 1990 | 2018 | RTOG | Glioblastoma | 1 | 1 | 1 | 0 | 17 | 17 | 1 | ||||
Ali | Haris | M | USA | 2016 | 2020 | Graft versus host disease | 1 | 0 | 0 | 1 | 12 | 12 | 1 | |||||
Ali | Haythem | M | USA | 2008 | 2017 | Thyroid cancer medullary | 2 | 0 | 1 | 1 | 36 | 21 | 1 | |||||
Ali | Kulsam | M | 2003 | 2009 | Small cell lung cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Ali | Marco | M | Italy | 2017 | 2017 | Thymoma | 1 | 0 | 0 | 0 | 23 | 23 | 1 | |||||
Ali | Nasim | M | United Kingdom | 2010 | 2020 | Gastrointestinal stromal tumor; Leiomyosarcoma; Soft tissue sarcoma | 2 | 0 | 1 | 0 | 38 | 37 | 1 | |||||
Ali | Ridvan | M | 2006 | 2010 | Multiple myeloma | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||||
Ali | Saad | M | United Kingdom | 2015 | 2018 | Endometrial cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | |||||
Ali | Sahra | F | United Kingdom | 2006 | 2017 | MRC; UK NCRI | Acute myeloid leukemia; Essential thrombocythemia; Myelofibrosis | 4 | 0 | 1 | 0 | 53 | 42 | 1 | ||||
Ali | Shamshad | M | USA | 1992 | 2014 | GOG | Cervical cancer; Vulvar cancer | 3 | 0 | 2 | 0 | 24 | 24 | 1 | ||||
Ali | Shyanne | F | USA | 2009 | 2014 | Breast cancer | 1 | 0 | 1 | 0 | 22 | 22 | 1 | |||||
Ali | Siraj M. | M | USA | 2017 | 2022 | Bladder cancer; Non-small cell lung cancer | 4 | 0 | 1 | 0 | 121 | 106 | 1 | |||||
Aliberti | Camillo | M | 2006 | 2012 | Colorectal cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Aliberti | Sandra | F | 2009 | 2009 | Osteosarcoma | 1 | 0 | 0 | 0 | 8 | 8 | 1 | ||||||
Alietti | Alessandra | F | 2008 | 2014 | Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 39 | 39 | 1 | ||||||
Alimam | Samah | F | United Kingdom | 2012 | 2017 | Essential thrombocythemia | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Alimena | Giuliana | F | Italy | 2001 | 2016 | EORTC; GIMEMA; GIMEMA CML Working Party | Acute myeloid leukemia; Chronic myeloid leukemia | 8 | 0 | 3 | 2 | 171 | 108 | 1 | ||||
Alinari | Lapo | M | 1996 | 2010 | Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma | 3 | 0 | 2 | 0 | 51 | 39 | 1 | ||||||
Aljijakli | Ahmad | M | France | 2008 | 2012 | ALFA | Acute myeloid leukemia | 1 | 0 | 1 | 1 | 21 | 21 | 1 | ||||
Aljitawi | Omar S. | M | 2011 | 2011 | BMT CTN | Allogeneic HSCT | 1 | 0 | 0 | 0 | 13 | 13 | 1 | |||||
Aljumaily | Raid | M | USA | 2014 | 2017 | Bladder cancer | 1 | 0 | 0 | 1 | 17 | 17 | 1 | |||||
Alkan | Serhan | M | 2008 | 2008 | Acute myeloid leukemia | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Alkhouri | Naim | Not yet determined | USA | 2013 | 2020 | Thrombocytopenia in liver disease | 1 | 1 | 2 | 0 | 7 | 7 | 1 | |||||
Alkindi | Salam | Not yet determined | Oman | 2017 | 2019 | Sickle cell anemia | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
Alkuzweny | Baha | M | 2004 | 2004 | Follicular lymphoma | 1 | 0 | 0 | 0 | 4 | 4 | 1 | ||||||
Allaham | Wassim | M | France | 2011 | 2017 | SARAH Trial Group | Hepatocellular carcinoma | 1 | 0 | 1 | 0 | 36 | 36 | 1 | ||||
Allal | Abdelkarim S. | M | 1994 | 2011 | SAKK | Head and neck cancer | 2 | 0 | 1 | 0 | 28 | 24 | 1 | |||||
Allan | John N. | M | USA | 2021 | 2021 | Waldenstroem macroglobulinemia | 1 | 0 | 0 | 0 | 22 | 22 | 1 | |||||
Allan | Karen | F | United Kingdom | 2008 | 2018 | Colorectal cancer | 1 | 0 | 1 | 0 | 35 | 35 | 1 | |||||
Allan | Norman C. | M | United Kingdom | 1986 | 1995 | MRC | Chronic myeloid leukemia | 1 | 1 | 1 | 0 | 2 | 2 | 1 | ||||
Alland | Leila | F | USA | 1998 | 2006 | B-cell acute lymphoblastic leukemia; Breast cancer; Chronic myeloid leukemia; Hypereosinophilic syndrome; Systemic mastocytosis | 3 | 0 | 2 | 1 | 43 | 41 | 1 | |||||
Allangba | Olivier | M | France | 2013 | 2018 | IFM | Multiple myeloma | 2 | 0 | 1 | 0 | 77 | 54 | 1 | ||||
Allard | Christian | M | France | 2003 | 2010 | Intergroupe Francais des Leucemies Myeloides Chroniques; SPIRIT Investigators | Chronic myeloid leukemia | 1 | 0 | 1 | 0 | 22 | 22 | 1 | ||||
Allegra | Carmen J. | M | USA | 1991 | 2020 | NSABP; SWOG | Colon cancer; Colorectal cancer; Rectal cancer | 11 | 6 | 6 | 1 | 153 | 82 | 1 | ||||
Allegrini | Giacomo | M | Italy | 2001 | 2015 | GONO | Colorectal cancer | 4 | 0 | 3 | 0 | 75 | 48 | 1 | ||||
Allen Mersh | T. G. | Not yet determined | United Kingdom | 1988 | 1994 | Colorectal cancer | 1 | 1 | 1 | 0 | 4 | 4 | 1 | |||||
Allen | Aaron M. | M | Israel | 2008 | 2022 | Prostate cancer | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
Allen | Andrew R. | M | USA | 2013 | 2016 | Ovarian cancer | 1 | 0 | 0 | 1 | 30 | 30 | 1 | |||||
Allen | Carl | M | USA | 2020 | 2020 | Hemophagocytic lymphohistiocytosis | 1 | 0 | 0 | 1 | 19 | 19 | 1 | |||||
Allen | Jeffrey C. | M | 1985 | 1999 | CCG | High-grade glioma pediatric; Low-grade glioma; Medulloblastoma | 3 | 0 | 1 | 0 | 47 | 36 | 1 | |||||
Allen | Jennifer L. | F | United Kingdom | 2015 | 2018 | Endometrial cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | |||||
Allen | Jill N. | F | USA | 2006 | 2018 | Cholangiocarcinoma; Gallbladder cancer; Hepatocellular carcinoma; Pancreatic cancer | 3 | 0 | 0 | 0 | 56 | 44 | 1 | |||||
Allen | John | M | USA | 1995 | 2014 | Hodgkin lymphoma; Hodgkin lymphoma nodular lymphocyte-predominant | 2 | 0 | 0 | 0 | 14 | 10 | 1 | |||||
Allen | L. | CBD | United Kingdom | 1984 | 1985 | Prostate cancer | 1 | 0 | 1 | 0 | 5 | 5 | 1 | |||||
Allen | Lee F. | M | USA | 2006 | 2018 | Cutaneous T-cell lymphoma; Immune thrombocytopenia; Peripheral T-cell lymphoma; Thrombocytopenia in liver disease | 4 | 1 | 3 | 1 | 47 | 42 | 1 | |||||
Allen | Mary S. | F | USA | 2014 | 2014 | Autologous HSCT | 1 | 0 | 0 | 0 | 6 | 6 | 1 | |||||
Allen | Peter J. | M | USA | 2007 | 2016 | Hepatocellular carcinoma | 1 | 0 | 0 | 0 | 19 | 19 | 1 | |||||
Allen | Roberta S. | F | USA | 1998 | 2002 | Follicular lymphoma | 1 | 0 | 0 | 1 | 11 | 11 | 1 | |||||
Allen | Steven L. | M | USA | 1977 | 2015 | CALGB | Acute myeloid leukemia; Acute promyelocytic leukemia; Adult T-cell leukemia-lymphoma; Breast cancer; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma | 9 | 0 | 3 | 1 | 128 | 100 | 1 | ||||
Allepuz | Alex | M | Switzerland | 2013 | 2021 | Chronic myeloid leukemia; Chronic myeloid leukemia pediatric | 3 | 0 | 1 | 2 | 63 | 45 | 1 | |||||
Allerton | Rozenn | F | United Kingdom | 2009 | 2015 | Breast cancer; CNS carcinoma | 1 | 0 | 1 | 0 | 20 | 20 | 1 | |||||
Allevi | G. | CBD | 1997 | 2005 | Breast cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | ||||||
Allewelt | Heather | F | USA | 2014 | 2022 | Marginal zone lymphoma | 1 | 0 | 0 | 1 | 13 | 13 | 1 | |||||
Allgeier | Anouk | F | Belgium | 1988 | 2012 | EORTC; NCIC-CTG | Anaplastic glioma; Glioblastoma | 5 | 0 | 3 | 1 | 84 | 43 | 1 | ||||
Allietta | Nathalie | F | France | 2006 | 2013 | Multiple myeloma | 2 | 0 | 0 | 1 | 20 | 17 | 1 | |||||
Allione | Bernardino | M | Italy | 1993 | 2020 | EORTC | Acute myeloid leukemia; Chronic myelomonocytic leukemia; HIV-associated lymphoma; Multiple myeloma | 4 | 0 | 2 | 0 | 81 | 80 | 1 | ||||
Allis | Simona | F | 1992 | 2010 | Head and neck cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | ||||||
Allison | James | M | USA | 2015 | 2017 | Anal cancer | 1 | 0 | 0 | 0 | 28 | 28 | 1 | |||||
Allison | Mary Ann K. | F | USA | 2007 | 2013 | Breast cancer | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Allman | David | M | France | 1996 | 2001 | Colorectal cancer | 1 | 0 | 1 | 1 | 20 | 20 | 1 | |||||
Allmark | Christine | F | 2014 | 2021 | Gastric cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | ||||||
Allmer | Christine | F | 2004 | 2008 | NCCTG | Mantle cell lymphoma | 1 | 0 | 0 | 0 | 11 | 11 | 1 | |||||
Alloisio | M. | CBD | 1998 | 2002 | Bladder cancer | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Allolio | Bruno | M | Germany | 2004 | 2012 | Adrenocortical carcinoma | 1 | 0 | 1 | 0 | 36 | 36 | 1 | |||||
Allotey | David | M | United Kingdom | 2011 | 2021 | UK NCRI | Multiple myeloma | 1 | 0 | 1 | 0 | 22 | 22 | 1 | ||||
Allouache | Djelila | F | France | 1999 | 2022 | GINECO; Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) | Breast cancer; Carcinoma of unknown primary | 3 | 0 | 1 | 0 | 58 | 55 | 1 | ||||
Allouache | Nedla | Not yet determined | France | 2006 | 2019 | GETUG | Prostate cancer | 1 | 0 | 1 | 0 | 21 | 21 | 1 | ||||
Allred | Alicia J. | F | USA | 2010 | 2021 | Melanoma; Multiple myeloma | 2 | 0 | 0 | 1 | 60 | 59 | 1 | |||||
Allred | D. Craig | M | USA | 1989 | 2011 | ACOSOG | Breast cancer | 3 | 0 | 1 | 0 | 38 | 38 | 1 | ||||
Allred | Jacob B. | M | USA | 2004 | 2012 | Light-chain (AL) amyloidosis; Multiple myeloma; Myelofibrosis | 7 | 0 | 0 | 0 | 126 | 40 | 1 | |||||
Allsup | David J. | M | United Kingdom | 2006 | 2017 | NCRI | Chronic lymphocytic leukemia | 2 | 0 | 0 | 0 | 38 | 35 | 1 | ||||
Allum | William H. | M | United Kingdom | 1976 | 2017 | British Stomach Cancer Group; MAGIC Trial Participants; MRC | Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer | 5 | 3 | 5 | 0 | 40 | 33 | 1 | ||||
Ally | Mina S. | F | USA | 2009 | 2016 | Cutaneous basal cell carcinoma | 1 | 0 | 0 | 0 | 12 | 12 | 1 | |||||
Alm | Gunnar | M | Sweden | 1983 | 1983 | Neuroendocrine tumor | 1 | 1 | 0 | 0 | 2 | 2 | 1 | |||||
Almeida | Antonio | M | Portugal | 2010 | 2021 | Myelodysplastic syndrome | 2 | 0 | 2 | 0 | 48 | 39 | 1 | |||||
Almeida | M. S. S. | Not yet determined | Brazil | 2006 | 2015 | Multiple myeloma | 1 | 0 | 1 | 0 | 11 | 11 | 1 | |||||
Almenar | Daniel | M | 2000 | 2005 | Spanish Germ Cell Cancer Cooperative Group; Spanish Lung Cancer Group | Non-small cell lung cancer; Testicular cancer | 2 | 0 | 1 | 0 | 38 | 38 | 1 | |||||
Almenar | Sergio | M | Spain | 1999 | 2010 | GEICAM | Breast cancer | 2 | 0 | 2 | 0 | 64 | 49 | 1 | ||||
Almond | Jennifer P. | F | 1994 | 2001 | European Study Group for Pancreatic Cancer | Pancreatic cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Aloe | Alessandra | Not yet determined | 1996 | 2009 | Breast cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Aloj | Luigi | M | 2014 | 2014 | Hodgkin lymphoma | 1 | 0 | 0 | 0 | 16 | 16 | 1 | ||||||
Alonso Carrion | Lorenzo | M | Spain | 2021 | 2021 | Uveal melanoma | 1 | 0 | 0 | 0 | 13 | 13 | 1 | |||||
Alonso Garcia | Miriam | M | Spain | 1995 | 2021 | Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | 2 | 0 | 3 | 3 | 44 | 44 | 1 | |||||
Alonso Gordoa | Teresa | F | Spain | 2016 | 2021 | Clear cell renal cell carcinoma; Renal cell carcinoma | 2 | 0 | 1 | 1 | 56 | 55 | 1 | |||||
Alonso Orduna | Vicente | M | Spain | 2006 | 2012 | TTD | Colorectal cancer; Esophageal adenocarcinoma | 2 | 0 | 1 | 1 | 33 | 33 | 1 | ||||
Alonso | Carmen | F | Spain | 1994 | 2004 | Small cell lung cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Alonso | Guillermo | M | 2000 | 2010 | Spanish Lung Cancer Group | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Alonso | Liuba | F | Cuba | 2006 | 2016 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | |||||
Alonso | Maria Carmen | F | Spain | 1978 | 1995 | Breast cancer | 2 | 1 | 2 | 0 | 13 | 12 | 1 | |||||
Alonso | Mirta Garcia | F | Spain | 2009 | 2020 | Breast cancer | 1 | 0 | 1 | 1 | 30 | 30 | 1 | |||||
Alonso | Natalia | F | 2013 | 2013 | Burkitt lymphoma; HIV-associated lymphoma | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Alonso | Silvia | F | 2003 | 2009 | Bladder cancer | 1 | 0 | 0 | 0 | 8 | 8 | 1 | ||||||
Alonzo | Todd A. | M | USA | 1979 | 2014 | CCG; COG | Acute myeloid leukemia; Acute myeloid leukemia pediatric; Chronic myeloid leukemia pediatric | 4 | 1 | 4 | 1 | 46 | 37 | 1 | ||||
Alousi | Amin M. | M | USA | 2009 | 2020 | BMT CTN | Acute myeloid leukemia; Allogeneic HSCT; Follicular lymphoma; Graft versus host disease; Mantle cell lymphoma; Transformed lymphoma | 5 | 0 | 1 | 0 | 84 | 60 | 1 | ||||
Alpen | B. | Not yet determined | 1997 | 1997 | MALT lymphoma | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Alquati | Palmiro | M | 1991 | 2005 | Epirubicin-Lonidamine Group | Breast cancer | 3 | 0 | 3 | 0 | 46 | 37 | 1 | |||||
Alsayed | Yazan | M | 1998 | 2010 | Multiple myeloma | 4 | 0 | 0 | 0 | 59 | 28 | 1 | ||||||
Alsina Maqueda | Maria | F | Spain | 2011 | 2021 | Colorectal cancer; Esophageal cancer; Esophageal squamous cell carcinoma; Gastric cancer | 8 | 0 | 8 | 2 | 161 | 129 | 1 | |||||
Alsina | Melissa | F | USA | 2001 | 2022 | Multiple myeloma | 14 | 0 | 2 | 4 | 279 | 159 | 1 | |||||
Altavilla | Giuseppe | M | Italy | 1983 | 2012 | Associazione Italiana Oncologia Toracica; Groupe Francais de Pneumo-Cancerologie; Italian Lung Cancer Project; Italian Lung Cancer Task Force; Italian Multicentre Breast Study with Epirubicin; Spanish Lung Cancer Group | Breast cancer; Non-small cell lung cancer | 4 | 0 | 4 | 1 | 157 | 151 | 1 | ||||
Altenhofer | Petra | F | Austria | 2010 | 2016 | AGMT | Chronic lymphocytic leukemia | 1 | 0 | 1 | 0 | 34 | 34 | 1 | ||||
Alter | Robert S. | M | USA | 2015 | 2020 | Bladder cancer | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Alterio | D. | CBD | Italy | 2008 | 2017 | GSTTC | Head and neck cancer | 1 | 0 | 0 | 0 | 36 | 36 | 1 | ||||
Altermatt | Hans J. | M | 1998 | 2007 | BIG | Breast cancer | 1 | 0 | 1 | 1 | 18 | 18 | 1 | |||||
Altes | Albert | M | 2001 | 2008 | Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Althaus | Betsy L. | F | USA | 2009 | 2020 | Breast cancer; Gastric cancer | 3 | 0 | 1 | 0 | 42 | 42 | 1 | |||||
Althausen | Alex F. | M | USA | 1993 | 1993 | Bladder cancer | 1 | 0 | 0 | 0 | 5 | 5 | 1 | |||||
Altieri | Vincenzo | M | 2011 | 2011 | Penile cancer | 1 | 0 | 0 | 0 | 15 | 15 | 1 | ||||||
Altinbas | M. | CBD | 1997 | 2005 | Turkish Oncology Group | Breast cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Altinmakas | Emre | M | USA | 2010 | 2015 | Non-clear cell renal cell carcinoma | 1 | 0 | 0 | 0 | 15 | 15 | 1 | |||||
Altintas | Sevilay | F | Belgium | 2011 | 2016 | Ovarian cancer | 1 | 0 | 1 | 0 | 23 | 23 | 1 | |||||
Altman | Arnold | M | USA | 2002 | 2006 | B-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 0 | 1 | 19 | 19 | 1 | |||||
Altman | Jessica K. | F | USA | 2007 | 2022 | ECOG | Acute myeloid leukemia; Acute promyelocytic leukemia; Hairy cell leukemia; Myelodysplastic syndrome | 10 | 0 | 4 | 2 | 248 | 176 | 1 | ||||
Altman | Stanley J. | M | USA | 1979 | 1993 | COG; SWOG | Breast cancer; Soft tissue sarcoma; Testicular cancer | 3 | 0 | 3 | 0 | 26 | 26 | 1 | ||||
Altmann | Bettina | F | Germany | 2003 | 2021 | DSHNHL; FLYER Trial Investigators; German Lymphoma Alliance | Autologous HSCT; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma | 4 | 1 | 4 | 0 | 130 | 90 | 1 | ||||
Altorjai | Gabriela | F | 2004 | 2007 | Breast cancer | 1 | 0 | 0 | 0 | 8 | 8 | 1 | ||||||
Altorki | Nasser K. | M | USA | 2007 | 2021 | Non-small cell lung cancer | 2 | 0 | 2 | 1 | 35 | 35 | 1 | |||||
Altug | Sedat | M | Turkey | 2009 | 2014 | Non-small cell lung cancer nonsquamous | 1 | 0 | 1 | 0 | 11 | 11 | 1 | |||||
Altwein | Jens Erik | M | 1986 | 1991 | Prostate cancer | 2 | 0 | 2 | 0 | 12 | 12 | 1 | ||||||
Alu | Massimiliano | M | 1996 | 2002 | Breast cancer | 1 | 0 | 1 | 0 | 9 | 9 | 1 | ||||||
Alumkal | Joshi J. | M | USA | 2007 | 2017 | Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium | Prostate cancer | 3 | 0 | 0 | 0 | 40 | 35 | 1 | ||||
Alva | Ajjai S. | M | USA | 2012 | 2021 | SWOG | Bladder cancer; Clear cell renal cell carcinoma; Papillary renal cell carcinoma; Renal cell carcinoma | 4 | 1 | 3 | 2 | 100 | 92 | 1 | ||||
Alvarado | Gladys | F | 1995 | 2009 | Melanoma | 1 | 0 | 1 | 0 | 20 | 20 | 1 | ||||||
Alvarado | Yesid | M | USA | 2011 | 2020 | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Myelodysplastic syndrome | 4 | 0 | 0 | 0 | 115 | 66 | 1 | |||||
Alvarez Cabellos | Ruth | F | 2013 | 2013 | GOTEL | Follicular lymphoma | 1 | 0 | 0 | 0 | 11 | 11 | 1 | |||||
Alvarez de Celis | Isabel | F | Italy | 2004 | 2013 | Follicular lymphoma | 1 | 0 | 2 | 0 | 20 | 20 | 1 | |||||
Alvarez Larran | Alberto | M | 2005 | 2005 | Myelofibrosis | 1 | 0 | 0 | 0 | 4 | 4 | 1 | ||||||
Alvarez Secord | Angeles | F | USA | 1999 | 2022 | GOG | Endometrial cancer; Gestational trophoblastic neoplasia; Low-grade serous ovarian cancer; Ovarian cancer | 8 | 1 | 7 | 2 | 149 | 122 | 1 | ||||
Alvarez Twose | Ivan | M | Spain | 2018 | 2021 | Systemic mastocytosis | 1 | 0 | 0 | 1 | 23 | 23 | 1 | |||||
Alvarez Vicent | J. J. | CBD | 1996 | 2002 | Head and neck cancer | 1 | 0 | 0 | 0 | 10 | 10 | 1 | ||||||
Alvarez | Ana | F | Spain | 2005 | 2015 | Prostate cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Alvarez | Axxx | CBD | Argentina | 1991 | 1999 | Breast cancer | 1 | 0 | 1 | 0 | 9 | 9 | 1 | |||||
Alvarez | Elena | F | 1987 | 1999 | Breast cancer | 1 | 1 | 1 | 0 | 9 | 9 | 1 | ||||||
Alvarez | Isabel | F | Spain | 1995 | 2020 | ANZ BCTG; GEICAM; Intergroup Exemestane Study | Breast cancer; Diffuse large B-cell lymphoma | 9 | 0 | 9 | 1 | 230 | 159 | 1 | ||||
Alvarez | Ivan | M | Spain | 2006 | 2006 | Allogeneic HSCT; Hodgkin lymphoma | 1 | 1 | 0 | 0 | 17 | 17 | 1 | |||||
Alvarez | Jose Valero | M | 1999 | 2008 | GEICAM | Breast cancer | 1 | 0 | 1 | 0 | 34 | 34 | 1 | |||||
Alvarez | Ofelia A. | F | USA | 2013 | 2016 | Sickle cell anemia | 1 | 0 | 0 | 1 | 15 | 15 | 1 | |||||
Alvarez | Pablo | M | United Kingdom | 2007 | 2012 | Thyroid cancer differentiated | 1 | 0 | 1 | 0 | 27 | 27 | 1 | |||||
Alvarez | Ronald D. | M | 1985 | 2008 | GOG; GRACES Clinical Trial Consortium; SWOG | Cervical cancer; Endometrial cancer; Ovarian cancer | 5 | 1 | 4 | 0 | 39 | 36 | 1 | |||||
Alvarnas | Joseph C. | M | USA | 2016 | 2016 | BMT CTN | Autologous HSCT; HIV-associated lymphoma | 1 | 1 | 0 | 0 | 21 | 21 | 1 | ||||
Alvegaard | Thor | M | Sweden | 2004 | 2020 | Gastrointestinal stromal tumor | 3 | 0 | 1 | 1 | 58 | 29 | 1 | |||||
Aly | Abdalla | M | USA | 2009 | 2018 | Pancreatic cancer | 1 | 0 | 1 | 1 | 11 | 11 | 1 | |||||
Alyasova | Anna | F | Russian Federation | 2010 | 2021 | Head and neck cancer; Renal cell carcinoma | 4 | 0 | 2 | 1 | 95 | 89 | 1 | |||||
Alyea | Edwin P. | M | USA | 2003 | 2017 | BMT CTN; CALGB | Acute myeloid leukemia; Allogeneic HSCT; Multiple myeloma | 3 | 1 | 2 | 0 | 60 | 51 | 1 | ||||
Alzate | Stefanie | F | USA | 2012 | 2017 | Multiple myeloma | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Alzieu | Claude | M | 1984 | 2006 | FNCLCC | Head and neck cancer | 2 | 0 | 2 | 0 | 25 | 25 | 1 | |||||
Alzouebi | Mymoona | F | United Kingdom | 2005 | 2015 | Prostate cancer | 1 | 0 | 1 | 0 | 46 | 46 | 1 | |||||
Amabile | Marilina | F | 1994 | 2009 | GIMEMA; GIMEMA CML Working Party; Italian Cooperative Study Group on Myeloid Leukemia | Chronic myeloid leukemia | 3 | 0 | 1 | 0 | 51 | 32 | 1 | |||||
Amado | Rafael G. | M | USA | 2004 | 2008 | Colorectal cancer | 2 | 2 | 2 | 1 | 23 | 23 | 1 | |||||
Amador Barciela | Maria L. | F | Spain | 2014 | 2021 | PETHEMA Group | Acute myeloid leukemia | 1 | 0 | 1 | 0 | 32 | 32 | 1 | ||||
Amador | Rosa M. | F | Cuba | 2006 | 2016 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 33 | 33 | 1 | |||||
Amadori | Dino | M | Italy | 1981 | 2017 | GONO; International Collaborative Cancer Group | Bladder cancer; Breast cancer; Colorectal cancer; Gastric cancer; Hepatocellular carcinoma | 14 | 4 | 11 | 0 | 196 | 155 | 1 | ||||
Amadori | Sergio | M | Italy | 1984 | 2020 | AIEOP; EORTC; German-Austrian Acute Myeloid Leukemia Study Group; GIMEMA; Study Alliance Leukemia | Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; CNS leukemia; Diffuse large B-cell lymphoma; Multiple myeloma; Myelodysplastic syndrome | 30 | 7 | 21 | 3 | 594 | 249 | 1 | ||||
Amaducci | Laura | F | Italy | 1997 | 2021 | GIM; Reader study level-I and level-II Groups | Breast cancer | 3 | 0 | 3 | 0 | 77 | 71 | 1 | ||||
Amagai | Kenji | M | Japan | 2008 | 2018 | Tokyo Cooperative Oncology Group | Gastric cancer | 4 | 0 | 4 | 0 | 70 | 61 | 1 | ||||
Amam | Josif | M | Germany | 2005 | 2019 | FLYER Trial Investigators; German Lymphoma Alliance | Diffuse large B-cell lymphoma | 1 | 0 | 1 | 0 | 43 | 43 | 1 | ||||
Amann | G. | CBD | 2001 | 2001 | Ewing sarcoma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Amano | Hodaka | UNMATCHED | 1986 | 2002 | Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract | Periampullary adenocarcinoma | 1 | 0 | 1 | 0 | 7 | 7 | 1 | |||||
Amant | Frederic | M | Belgium | 1998 | 2010 | EORTC; NCIC-CTG | Breast cancer; Ovarian cancer | 2 | 0 | 2 | 0 | 32 | 32 | 1 | ||||
Amar | Avraham | M | 1998 | 1998 | Allogeneic HSCT; Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Amaravadi | Ravi K. | M | USA | 2009 | 2012 | Melanoma | 1 | 0 | 0 | 1 | 24 | 24 | 1 | |||||
Amare | Mammo | Not yet determined | 1977 | 1983 | SWOG | Multiple myeloma | 1 | 0 | 1 | 0 | 0 | 0 | 1 | |||||
Amato | Giovanni | M | Italy | 2013 | 2021 | CNS melanoma | 1 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Amato | Robert J. | M | USA | 1985 | 2010 | Bladder cancer; Penile cancer; Prostate cancer; Renal cell carcinoma; Testicular cancer | 5 | 2 | 3 | 0 | 39 | 35 | 1 | |||||
Amato | S. | CBD | Argentina | 1995 | 1999 | Breast cancer | 1 | 0 | 0 | 0 | 14 | 14 | 1 | |||||
Amatruda | Thomas T. | M | USA | 2006 | 2015 | NCCTG | Melanoma | 3 | 0 | 1 | 1 | 48 | 43 | 1 | ||||
Amatu | Alessio | M | Italy | 2012 | 2017 | Colorectal cancer; Non-small cell lung cancer; NTRK | 2 | 0 | 0 | 2 | 63 | 57 | 1 | |||||
Ambarkhane | Sumeet | M | Germany | 2016 | 2021 | Diffuse large B-cell lymphoma; Transformed lymphoma | 2 | 0 | 0 | 1 | 36 | 21 | 1 | |||||
Ambinder | Richard F. | M | USA | 1998 | 2018 | A5264/AMC-067 REACT-KS Team; AIDS Malignancy Consortium; BMT CTN | Autologous HSCT; Burkitt lymphoma; Diffuse large B-cell lymphoma; Graft versus host disease; HIV-associated lymphoma; Hodgkin lymphoma; Kaposi sarcoma | 9 | 2 | 4 | 0 | 136 | 109 | 1 | ||||
Ambo | Y. | CBD | Japan | 2007 | 2018 | Cholangiocarcinoma | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Ambros | Peter F. | M | Austria | 2002 | 2018 | SIOP Europe Neuroblastoma Group (SIOPEN) | Neuroblastoma | 2 | 0 | 1 | 0 | 50 | 32 | 1 | ||||
Ambrose | David | M | USA | 2015 | 2015 | Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 17 | 17 | 1 | |||||
Ambrosetti | Achille | M | Italy | 1995 | 2017 | FIL; IELSG | Chronic lymphocytic leukemia; CNS lymphoma; Hairy cell leukemia; Hodgkin lymphoma; MALT lymphoma; Mantle cell lymphoma | 7 | 0 | 1 | 0 | 211 | 166 | 1 | ||||
Ambrosini | Giovanni | M | Italy | 1983 | 2011 | Italian Multicentre Breast Study with Epirubicin | Breast cancer; Rectal cancer | 3 | 2 | 2 | 0 | 97 | 96 | 1 | ||||
Ambrosini | Grazia | F | USA | 2010 | 2014 | Uveal melanoma | 1 | 0 | 0 | 0 | 27 | 27 | 1 | |||||
Ambrosini | Maria Teresa | F | 2002 | 2007 | GIMEMA--Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto; Italian Multiple Myeloma Network | Multiple myeloma | 3 | 0 | 1 | 0 | 52 | 36 | 1 | |||||
Ambrosio | Francesca | F | Italy | 2009 | 2017 | GOIRC | Small cell lung cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||
Ambrun | Alexis | Not yet determined | France | 2016 | 2016 | Hereditary hemorrhagic telangiectasia | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Amellal | Nadia | F | Germany; USA | 1999 | 2008 | Head and neck cancer | 4 | 0 | 2 | 3 | 53 | 40 | 1 | |||||
Amendola | Angela | F | 2006 | 2006 | GIMEMA | Immune thrombocytopenia | 1 | 0 | 0 | 0 | 15 | 15 | 1 | |||||
Amenedo Gancedo | Margarita | F | Spain | 1999 | 2020 | GEICAM | Breast cancer; Ovarian cancer | 4 | 0 | 2 | 1 | 93 | 48 | 1 | ||||
Ames | Frederick C. | M | USA | 1977 | 2004 | Breast cancer | 5 | 0 | 5 | 0 | 65 | 36 | 1 | |||||
Ames | Patricia | F | 1998 | 2002 | Melanoma | 1 | 0 | 0 | 0 | 11 | 11 | 1 | ||||||
Ameye | Lieveke | F | Belgium | 1998 | 2015 | BIG | Breast cancer | 1 | 0 | 1 | 0 | 17 | 17 | 1 | ||||
Amiel | Jean Louis | M | 1969 | 1969 | B-cell acute lymphoblastic leukemia | 1 | 0 | 0 | 0 | 7 | 7 | 1 | ||||||
Amillano | Kepa | Not yet determined | Spain | 2015 | 2021 | Breast cancer | 1 | 0 | 1 | 0 | 39 | 39 | 1 | |||||
Amin | Amanda L. | F | USA | 2010 | 2016 | Breast cancer | 1 | 0 | 0 | 0 | 33 | 33 | 1 | |||||
Amin | Asim | M | USA | 2013 | 2020 | Renal cell carcinoma; Small cell lung cancer | 4 | 0 | 1 | 2 | 107 | 74 | 1 | |||||
Amin | Bipinkumar | UNMATCHED | 2008 | 2011 | Follicular lymphoma | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Amin | Himal | M | USA | 2014 | 2021 | Multiple myeloma | 4 | 0 | 2 | 2 | 92 | 61 | 1 | |||||
Amin | Mahul B. | M | Canada; USA | 1994 | 2020 | RTOG | Prostate cancer; Upper tract urothelial carcinoma | 3 | 0 | 2 | 0 | 61 | 57 | 1 | ||||
Aminossadati | Behnaz | F | 2001 | 2009 | Neuroendocrine tumor; Pancreatic NET | 1 | 0 | 1 | 0 | 13 | 13 | 1 | ||||||
Amiot | Martine | Not yet determined | France | 2012 | 2017 | Multiple myeloma | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Amista | P. | CBD | 2004 | 2004 | Glioblastoma | 1 | 0 | 0 | 0 | 6 | 6 | 1 | ||||||
Amler | Susanne | F | Germany | 2000 | 2018 | AML-CG | Acute myeloid leukemia; Autologous HSCT; Ewing sarcoma | 2 | 0 | 2 | 0 | 84 | 84 | 1 | ||||
Ammassari | Adriana | F | 2002 | 2002 | HIV-associated lymphoma | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Amonkar | Mayur | M | USA | 2006 | 2021 | Colorectal cancer; Head and neck cancer | 2 | 0 | 2 | 1 | 43 | 43 | 1 | |||||
Amorim | Gilberto | M | 2006 | 2019 | CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group) | Breast cancer | 1 | 0 | 1 | 0 | 37 | 37 | 1 | |||||
Amoroso | Domenico | M | Italy | 2007 | 2018 | GOIRC | Breast cancer; Colorectal cancer; Non-small cell lung cancer | 5 | 0 | 3 | 0 | 105 | 85 | 1 | ||||
Amoroso | Mariangela | F | 1990 | 2002 | Cervical cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Amoroso | Vito | M | Italy | 2014 | 2021 | Breast cancer | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Amos | Claire L. | F | United Kingdom | 2005 | 2019 | Prostate cancer | 3 | 0 | 1 | 0 | 141 | 83 | 1 | |||||
Amott | S. J. | Not yet determined | 1984 | 1996 | MRC | Rectal cancer | 1 | 1 | 1 | 0 | 2 | 2 | 1 | |||||
Amoura | Zahir | M | France | 2014 | 2014 | Erdheim-Chester disease | 1 | 1 | 0 | 0 | 20 | 20 | 1 | |||||
Amrein | Philip C. | M | 1990 | 2004 | CALGB | Acute myeloid leukemia | 2 | 0 | 1 | 0 | 16 | 16 | 1 | |||||
Amthauer | Holger | M | 2003 | 2012 | Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK | Hodgkin lymphoma | 1 | 0 | 1 | 0 | 30 | 30 | 1 | |||||
Amundsen | Tore | M | 2005 | 2012 | Non-small cell lung cancer | 2 | 0 | 2 | 0 | 21 | 15 | 1 | ||||||
Amunni | Gianni | M | 1990 | 2002 | Cervical cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Amutio | Elena | F | 1996 | 2003 | Programa de Estudio y Traitmiento de las Hemopatias Malignas | Acute promyelocytic leukemia | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Amylon | Michael D. | M | USA | 1987 | 1999 | POG | B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric; Graft versus host disease; T-cell acute lymphoblastic leukemia pediatric | 3 | 1 | 2 | 0 | 36 | 35 | 1 | ||||
Amzal | Billy | M | United Kingdom | 2011 | 2016 | Prostate cancer | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
An | Gang | Not yet determined | China | 2017 | 2021 | Multiple myeloma | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
An | J. Y. | Not yet determined | South Korea | 2013 | 2020 | Gastric cancer | 1 | 0 | 1 | 0 | 22 | 22 | 1 | |||||
An | Ruifang | Not yet determined | China | 2017 | 2022 | Ovarian cancer | 2 | 0 | 2 | 0 | 70 | 60 | 1 | |||||
An | Xin | Not yet determined | China | 2010 | 2022 | South China Breast Cancer Group (SCBCG) | Breast cancer | 2 | 0 | 2 | 0 | 58 | 40 | 1 | ||||
An | Xuebei | CBD | USA | 2016 | 2020 | Breast cancer; CNS carcinoma | 1 | 0 | 1 | 1 | 28 | 28 | 1 | |||||
Anagnostopoulos | Achilles | M | Greece | 2007 | 2022 | HORG | Acute myeloid leukemia; Chronic myelomonocytic leukemia; Colon cancer; Myelodysplastic syndrome | 5 | 0 | 4 | 1 | 104 | 80 | 1 | ||||
Anagnostopoulos | Athanasios | M | 1999 | 2007 | Multiple myeloma; Waldenstroem macroglobulinemia | 5 | 2 | 1 | 0 | 58 | 40 | 1 | ||||||
Anagnostopoulos | Ioannis | M | Germany | 1999 | 2016 | European PTLD Network; German PTLD Study Group. | Post-transplant lymphoproliferative disorder | 3 | 0 | 0 | 0 | 51 | 38 | 1 | ||||
Anagnostopoulos | Nikolaos | M | 1999 | 2007 | Multiple myeloma; Waldenstroem macroglobulinemia | 5 | 1 | 1 | 0 | 59 | 35 | 1 | ||||||
Anagnostopoulou | Ourania | F | 1999 | 2005 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | ||||||
Anaissie | Elias | M | USA | 1990 | 2010 | Multiple myeloma | 9 | 0 | 0 | 0 | 122 | 54 | 1 | |||||
Anak | Oezlem | F | Switzerland; USA | 1999 | 2021 | EORTC | Autologous HSCT; Colorectal cancer; Diffuse large B-cell lymphoma; Follicular lymphoma; Hepatocellular carcinoma; Renal cell carcinoma; Subependymal giant cell astrocytoma; Transformed lymphoma | 7 | 0 | 3 | 3 | 147 | 139 | 1 | ||||
Anand | Aseem | M | 2007 | 2010 | Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium | Prostate cancer | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Anand | Palka | UNMATCHED | USA | 2012 | 2016 | Multiple myeloma | 1 | 0 | 0 | 0 | 8 | 8 | 1 | |||||
Ananthakrishnan | Revathi | F | USA | 2016 | 2016 | Follicular lymphoma | 1 | 0 | 0 | 0 | 9 | 9 | 1 | |||||
Anasetti | Claudio | M | USA | 1985 | 2003 | Allogeneic HSCT; Chronic myeloid leukemia | 2 | 1 | 0 | 0 | 28 | 25 | 1 | |||||
Anastasi | John | M | 1998 | 2008 | CALGB | Acute myeloid leukemia | 2 | 0 | 1 | 0 | 23 | 16 | 1 | |||||
Anastasia | Antonella | F | Italy | 2008 | 2021 | FIL; Rete Ematologica Lombarda–CLL Workgroup | Chronic lymphocytic leukemia; Follicular lymphoma; Hairy cell leukemia; Hodgkin lymphoma | 5 | 0 | 1 | 0 | 136 | 121 | 1 | ||||
Anastasopoulou | Anastasia | F | 2001 | 2001 | EORTC | Cervical cancer | 1 | 0 | 0 | 0 | 12 | 12 | 1 | |||||
Ancell | Kristin | F | USA | 2010 | 2014 | Uveal melanoma | 1 | 0 | 0 | 0 | 27 | 27 | 1 | |||||
Anchisi | Sandro | Not yet determined | Switzerland | 2007 | 2016 | SAKK | Breast cancer; Colorectal cancer | 2 | 0 | 2 | 0 | 39 | 36 | 1 | ||||
Anciaux | Nicole | F | 1998 | 2006 | EORTC | Colorectal cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Ancliff | Philip | M | 2003 | 2010 | B-cell acute lymphoblastic leukemia pediatric; T-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||||
Ancona | Ermanno | M | Italy | 1992 | 2001 | Esophageal cancer | 1 | 1 | 1 | 0 | 8 | 8 | 1 | |||||
Ancukiewicz | Marek | M | 2006 | 2009 | Hepatocellular carcinoma | 1 | 0 | 0 | 0 | 20 | 20 | 1 | ||||||
Andel | Johannes | M | Austria | 2007 | 2016 | AGMT | Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma | 2 | 0 | 2 | 0 | 45 | 40 | 1 | ||||
Andergassen | Ulrich | M | Germany | 2005 | 2020 | Breast cancer | 1 | 0 | 1 | 0 | 24 | 24 | 1 | |||||
Anderl | Janet | F | USA | 2012 | 2016 | Multiple myeloma | 1 | 0 | 0 | 0 | 16 | 16 | 1 | |||||
Anderlini | Paolo | M | USA | 2009 | 2014 | Allogeneic HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma | 6 | 1 | 0 | 0 | 101 | 55 | 1 | |||||
Anders | Carey K. | F | USA | 2008 | 2022 | CALGB | Breast cancer; CNS carcinoma | 4 | 0 | 3 | 1 | 90 | 68 | 1 | ||||
Anders | Robert A. | M | USA | 2013 | 2017 | Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; MSI-H or dMMR | 2 | 0 | 0 | 1 | 79 | 57 | 1 | |||||
Andersen | Barbara L. | F | USA | 2015 | 2020 | Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Andersen | E. | CBD | 1983 | 1990 | Breast cancer | 1 | 0 | 1 | 0 | 6 | 6 | 1 | ||||||
Andersen | J. C. | Not yet determined | USA | 1994 | 1994 | Immune thrombocytopenia | 1 | 1 | 0 | 0 | 0 | 0 | 1 | |||||
Andersen | James S. | M | USA | 1992 | 1996 | Pancreatic cancer | 1 | 0 | 0 | 1 | 11 | 11 | 1 | |||||
Andersen | Janet W. | F | USA | 1977 | 2002 | ECOG | Acute promyelocytic leukemia; Breast cancer; Chronic lymphocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma | 6 | 0 | 5 | 0 | 56 | 43 | 1 | ||||
Andersen | Jay C. | M | USA | 2017 | 2022 | Breast cancer | 1 | 0 | 1 | 1 | 29 | 29 | 1 | |||||
Andersen | Joern Erik | M | Denmark | 1994 | 2000 | Ovarian cancer | 1 | 0 | 1 | 1 | 27 | 27 | 1 | |||||
Andersen | John | M | USA | 1992 | 1997 | Pancreatic cancer | 1 | 0 | 1 | 1 | 13 | 13 | 1 | |||||
Andersen | Jorn | M | Denmark | 1977 | 2013 | DBCG; Intergroup Exemestane Study; Scandinavian Breast Group | Breast cancer; Diffuse large B-cell lymphoma | 10 | 2 | 8 | 1 | 126 | 76 | 1 | ||||
Andersen | Knud West | M | 1977 | 1983 | DBCG | Breast cancer | 2 | 1 | 2 | 0 | 12 | 10 | 1 | |||||
Andersen | Niels Frost | M | Denmark | 2005 | 2020 | Multiple myeloma | 3 | 0 | 3 | 0 | 101 | 92 | 1 | |||||
Andersen | Niels S. | M | Denmark | 2000 | 2016 | Nordic Lymphoma Group | Autologous HSCT; Mantle cell lymphoma | 3 | 0 | 0 | 0 | 67 | 30 | 1 | ||||
Andersen | Willie A. | M | 1993 | 2004 | GOG | Cervical cancer; Endometrial cancer | 4 | 4 | 1 | 0 | 22 | 18 | 1 | |||||
Anderson | Abraham | M | USA | 2009 | 2021 | Esophageal adenocarcinoma; Non-small cell lung cancer | 2 | 0 | 0 | 1 | 40 | 40 | 1 | |||||
Anderson | Barrie | Not yet determined | 1990 | 1997 | GOG | Cervical cancer | 1 | 1 | 1 | 0 | 6 | 6 | 1 | |||||
Anderson | Barry | M | USA | 2001 | 2010 | CCG; COG | Ewing sarcoma; Neuroblastoma; Osteosarcoma | 2 | 0 | 1 | 1 | 26 | 26 | 1 | ||||
Anderson | Cathy | F | 1980 | 1987 | Autologous HSCT; Diffuse large B-cell lymphoma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Anderson | Charles K. | M | USA | 2016 | 2021 | Ovarian cancer | 2 | 0 | 2 | 0 | 47 | 47 | 1 | |||||
Anderson | Clay M. | M | USA | 1995 | 2022 | RTOG | Esophageal cancer; Melanoma | 2 | 0 | 2 | 0 | 41 | 41 | 1 | ||||
Anderson | Daniel M. | M | USA | 2011 | 2021 | ECOG | Breast cancer; Follicular lymphoma; Multiple myeloma | 3 | 0 | 2 | 0 | 74 | 74 | 1 | ||||
Anderson | David R. | M | Canada | 2003 | 2018 | Antiphospholipid antibody syndrome; Venous thromboembolism | 3 | 2 | 3 | 0 | 65 | 44 | 1 | |||||
Anderson | Harald | M | Sweden | 1978 | 2016 | Nordic Lymphoma Group; Scandinavian Breast Group | Autologous HSCT; Breast cancer; CNS lymphoma; Diffuse large B-cell lymphoma; Peripheral T-cell lymphoma | 7 | 0 | 5 | 0 | 92 | 76 | 1 | ||||
Anderson | Heather A. | F | 1995 | 2006 | BTOG | Esophageal cancer; Gastric cancer; Non-small cell lung cancer | 4 | 0 | 4 | 0 | 47 | 40 | 1 | |||||
Anderson | J. | Not yet determined | USA | 2008 | 2008 | Anaplastic glioma | 1 | 0 | 0 | 0 | 9 | 9 | 1 | |||||
Anderson | James R. | M | USA | 1972 | 2019 | CALGB; CCG; COG; ECOG | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Melanoma; Rhabdomyosarcoma; Soft tissue sarcoma | 14 | 2 | 11 | 1 | 164 | 124 | 1 | ||||
Anderson | Jeanne E. | F | USA | 1995 | 2002 | SWOG | Acute myeloid leukemia | 1 | 1 | 1 | 0 | 10 | 10 | 1 | ||||
Anderson | Jeffrey | M | USA | 2012 | 2020 | Hepatocellular carcinoma | 2 | 0 | 0 | 1 | 40 | 31 | 1 | |||||
Anderson | Jennifer J. | F | 1976 | 2004 | Autologous HSCT; Light-chain (AL) amyloidosis | 2 | 0 | 0 | 0 | 19 | 17 | 1 | ||||||
Anderson | John B. | M | United Kingdom | 1995 | 2012 | MRC; NCIC | Prostate cancer | 4 | 0 | 3 | 0 | 52 | 43 | 1 | ||||
Anderson | Karen S. | F | USA | 2013 | 2017 | Breast cancer | 1 | 0 | 0 | 0 | 33 | 33 | 1 | |||||
Anderson | Kenneth C. | M | USA | 1982 | 2022 | CALGB; FIRST Trial Team; IFM; SWOG; Waldenstroem's Macroglobulinemia Clinical Trials Group | Autologous HSCT; Diffuse large B-cell lymphoma; Multiple myeloma; Waldenstroem macroglobulinemia | 38 | 18 | 13 | 9 | 818 | 389 | 1 | ||||
Anderson | Larry D. | M | USA | 2010 | 2022 | Multiple myeloma | 4 | 1 | 2 | 2 | 167 | 151 | 1 | |||||
Anderson | Lisa | F | USA | 2017 | 2019 | Colorectal cancer | 1 | 0 | 1 | 1 | 34 | 34 | 1 | |||||
Anderson | Lxxx | Not yet determined | 1983 | 1994 | BNLI | Hodgkin lymphoma | 2 | 0 | 2 | 0 | 12 | 7 | 1 | |||||
Anderson | Mary Ann | F | Australia | 2011 | 2018 | Chronic lymphocytic leukemia; Mantle cell lymphoma | 2 | 0 | 0 | 1 | 34 | 32 | 1 | |||||
Anderson | Michael J. | M | Denmark; USA | 1979 | 2015 | BIG | Breast cancer; Cutaneous T-cell lymphoma | 2 | 0 | 2 | 0 | 29 | 29 | 1 | ||||
Anderson | Nancy | Not yet determined | USA | 2012 | 2020 | GOG | Gestational trophoblastic neoplasia | 1 | 0 | 1 | 0 | 12 | 12 | 1 | ||||
Anderson | Nicole D. | F | 2003 | 2003 | Autologous HSCT; CNS lymphoma; Stem cell mobilization | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Anderson | Patricia | F | USA | 1985 | 1992 | SWOG | Ovarian cancer | 1 | 0 | 1 | 1 | 9 | 9 | 1 | ||||
Anderson | Peter M. | M | USA | 2002 | 2002 | Osteosarcoma | 1 | 1 | 0 | 0 | 7 | 7 | 1 | |||||
Anderson | Richard T. | M | 1979 | 1991 | NCCTG | Non-small cell lung cancer; Small cell lung cancer | 2 | 2 | 2 | 0 | 24 | 19 | 1 | |||||
Anderson | Russell D. | M | 2009 | 2009 | Multiple myeloma | 1 | 0 | 0 | 0 | 15 | 15 | 1 | ||||||
Anderson | Sibyl | F | USA | 2003 | 2010 | Sorafenib TARGET Clinical Trial Group | Clear cell renal cell carcinoma; Renal cell carcinoma | 2 | 0 | 1 | 1 | 27 | 21 | 1 | ||||
Anderson | Stewart J. | M | USA | 1982 | 2018 | BOOG Dutch Breast Cancer Trialists' Group; Breast International Group; GEICAM Spanish Breast Cancer Group; International Breast Cancer Study Group; NRG Oncology; NSABP | Breast cancer | 11 | 0 | 11 | 2 | 153 | 81 | 1 | ||||
Anderson | Sxxx | Not yet determined | United Kingdom | 1996 | 2004 | Multiple myeloma | 1 | 0 | 1 | 0 | 7 | 7 | 1 | |||||
Anderson | Tara | F | 2009 | 2012 | Multiple myeloma | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Anderson | Thomas | M | USA | 1972 | 2008 | ECOG; Hoosier Oncology Group; US Oncology | Colorectal cancer; Non-small cell lung cancer; Ovarian cancer | 3 | 0 | 3 | 0 | 34 | 34 | 1 | ||||
Andersson | Borje S. | M | USA | 1990 | 2019 | Acute myeloid leukemia; Allogeneic HSCT; Breast cancer; Diffuse large B-cell lymphoma; Hodgkin lymphoma; Multiple myeloma | 8 | 3 | 2 | 0 | 125 | 99 | 1 | |||||
Andersson | Haakan | Not yet determined | 1995 | 2010 | EORTC | Endometrial cancer; Ovarian cancer | 3 | 0 | 3 | 0 | 29 | 23 | 1 | |||||
Andersson | Michael | M | Denmark | 1977 | 2021 | BIG; DBCG; EORTC; GBG; Herceptin Adjuvant (HERA) Trial Study Team; monarchE Committee Members | Breast cancer | 17 | 2 | 13 | 3 | 299 | 203 | 1 | ||||
Andersson | Per-Ola | Not yet determined | Sweden | 2011 | 2016 | Chronic lymphocytic leukemia | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Andersson | Ronny | M | 1998 | 1998 | Melanoma | 1 | 0 | 1 | 0 | 12 | 12 | 1 | ||||||
Andersson | Swen Olof | M | Sweden | 1989 | 2018 | SPCG | Prostate cancer | 6 | 0 | 1 | 0 | 78 | 22 | 1 | ||||
Ando | Jiro | M | 1994 | 2014 | JCOG | Breast cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | |||||
Ando | Kiyoshi | M | Japan | 2002 | 2021 | JCOG | Acute myeloid leukemia; Cutaneous T-cell lymphoma; Diffuse large B-cell lymphoma; Follicular lymphoma; Multiple myeloma; Peripheral T-cell lymphoma | 12 | 1 | 5 | 1 | 229 | 166 | 1 | ||||
Ando | Masahiko | M | Japan | 2000 | 2021 | JCOG; WJOG; WJTOG | Cholangiocarcinoma; Colorectal cancer; Non-small cell lung cancer; Non-small cell lung cancer squamous; Small cell lung cancer | 14 | 0 | 13 | 0 | 260 | 168 | 1 | ||||
Ando | Masahiro | M | Japan | 2006 | 2010 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 22 | 22 | 1 | |||||
Ando | Masashi | M | 2004 | 2009 | Breast cancer | 1 | 0 | 1 | 0 | 15 | 15 | 1 | ||||||
Ando | Nobutoshi | M | Japan | 1988 | 2011 | JCOG | Esophageal cancer | 3 | 3 | 3 | 0 | 43 | 32 | 1 | ||||
Ando | Yuichi | M | Japan | 2012 | 2018 | Colorectal cancer | 1 | 0 | 0 | 0 | 23 | 23 | 1 | |||||
Andoh | J. | CBD | 1999 | 2009 | JCOG | Breast cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | |||||
Andorsky | David | M | USA | 2011 | 2019 | Chronic myeloid leukemia; Diffuse large B-cell lymphoma | 2 | 0 | 2 | 0 | 35 | 35 | 1 | |||||
Andrade | Luciana | F | Brazil | 2017 | 2021 | Breast cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Andre | Fabrice | M | France | 2006 | 2022 | Breast cancer | 16 | 4 | 9 | 4 | 336 | 223 | 1 | |||||
Andre | Marc P. E. | M | Belgium | 1996 | 2021 | EORTC; European Mantle Cell Lymphoma Network; FIL; GELA; Lymphoma Study Association; LYSA; SFGM | Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Peripheral T-cell lymphoma; Transformed lymphoma | 14 | 1 | 14 | 1 | 340 | 212 | 1 | ||||
Andre | Niko | M | Switzerland | 2007 | 2013 | Colorectal cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | |||||
Andre | Thierry | M | France | 1996 | 2022 | AERO; FFCD; FNCLCC; GERCOR; GISCAD; Group Cooperateur Multidisciplinaire en Oncologie; HORG; PRODIGE investigators, GERCOR, Federation Francaise de Cancerologie Digestive, UNICANCER | Anal cancer; Colon cancer; Colorectal cancer; Desmoid tumor; Esophageal adenocarcinoma; Gastric cancer; MSI-H or dMMR; Pancreatic cancer; Rectal cancer | 35 | 16 | 20 | 5 | 612 | 348 | 1 | ||||
Andre | Valerie A. M. | F | USA | 2017 | 2021 | monarchE Committee Members | Breast cancer | 1 | 0 | 1 | 1 | 34 | 34 | 1 | ||||
Andreadis | Charalambos | M | USA | 1998 | 2021 | Autologous HSCT; Diffuse large B-cell lymphoma; Follicular lymphoma; Ovarian cancer; Primary mediastinal B-cell lymphoma; Transformed lymphoma | 5 | 0 | 2 | 3 | 124 | 101 | 1 | |||||
Andreas | Stefan | M | Germany | 2005 | 2016 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | |||||
Andreasson | Bjoern | M | 2007 | 2012 | Multiple myeloma | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||||
Andreeff | Michael | M | USA | 1984 | 2020 | Acute myeloid leukemia; Acute promyelocytic leukemia; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; CNS leukemia; Hypereosinophilic syndrome | 15 | 1 | 2 | 1 | 273 | 130 | 1 | |||||
Andreescu | Astrid C. | F | USA | 2010 | 2022 | Multiple myeloma | 1 | 0 | 1 | 0 | 55 | 55 | 1 | |||||
Andreesen | Reinhard | M | 1992 | 2012 | Arbeitsgemeinschaft Medikamentoese Tumortherapie; GHSG; SAKK | Breast cancer; Hodgkin lymphoma | 2 | 0 | 2 | 0 | 44 | 44 | 1 | |||||
Andreetta | Claudia | F | Italy | 2014 | 2021 | Breast cancer | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Andren | Ove | Not yet determined | Sweden | 1989 | 2018 | SPCG | Prostate cancer | 2 | 0 | 1 | 0 | 25 | 14 | 1 | ||||
Andreola | Giovanna | F | Switzerland | 2019 | 2021 | Diffuse large B-cell lymphoma; Waldenstroem macroglobulinemia | 2 | 0 | 1 | 0 | 53 | 53 | 1 | |||||
Andreoli | Laura | F | Italy | 2018 | 2018 | Antiphospholipid antibody syndrome | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
Andreopoulos | Demetrios | M | Cyprus | 2001 | 2021 | EORTC | Prostate cancer | 1 | 0 | 1 | 0 | 21 | 21 | 1 | ||||
Andreou | Cal | M | Canada | 2006 | 2008 | Prostate cancer | 1 | 0 | 1 | 1 | 8 | 8 | 1 | |||||
Andreou | Pantelis | Not yet determined | Canada | 2013 | 2018 | Venous thromboembolism | 2 | 0 | 2 | 0 | 47 | 28 | 1 | |||||
Andresen Daniil | Corina | F | USA | 2013 | 2018 | PLATO collaborators | Prostate cancer | 1 | 0 | 1 | 0 | 7 | 7 | 1 | ||||
Andreuccetti | Michele | M | 2001 | 2010 | GONO | Colorectal cancer | 2 | 0 | 1 | 0 | 34 | 30 | 1 | |||||
Andrews | Chris | M | United Kingdom | 2012 | 2015 | Myelofibrosis | 1 | 0 | 0 | 0 | 11 | 11 | 1 | |||||
Andrews | Glen I. | M | USA | 2010 | 2016 | Renal cell carcinoma | 1 | 0 | 1 | 0 | 8 | 8 | 1 | |||||
Andrews | Michael B. | M | 2000 | 2005 | Follicular lymphoma | 1 | 0 | 0 | 0 | 6 | 6 | 1 | ||||||
Andrews | Stephen | M | United Kingdom | 2007 | 2018 | Bladder cancer | 1 | 0 | 1 | 0 | 17 | 17 | 1 | |||||
Andrews | Vivienne E. | F | United Kingdom | 2008 | 2019 | National Cancer Research Institute Haemato-oncology Clinical Studies Group | Multiple myeloma | 1 | 0 | 2 | 0 | 21 | 21 | 1 | ||||
Andric | Zoran | M | Serbia | 2015 | 2021 | Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous | 2 | 0 | 1 | 1 | 39 | 25 | 1 | |||||
Andrien | J. M. | CBD | 1985 | 1993 | Breast cancer | 1 | 0 | 1 | 0 | 9 | 9 | 1 | ||||||
Andrieu | Jean Marie | M | 1990 | 2003 | Hodgkin lymphoma | 1 | 1 | 1 | 0 | 15 | 15 | 1 | ||||||
Andriole | Gerald L. | M | USA | 1994 | 2017 | Prostate cancer | 2 | 0 | 1 | 0 | 27 | 20 | 1 | |||||
Andritsos | Leslie A. | UNMATCHED | USA | 2011 | 2015 | Chronic lymphocytic leukemia | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Androulakis | Ioannis | M | 1993 | 2002 | HeCOG | Colorectal cancer | 1 | 0 | 1 | 0 | 13 | 13 | 1 | |||||
Androulakis | Nikolaos | M | Greece | 1999 | 2019 | HORG | Colon cancer; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Small cell lung cancer | 7 | 0 | 6 | 0 | 108 | 59 | 1 | ||||
Andrulis | Irene L. | F | Canada | 1989 | 2006 | NCIC-CTG | Breast cancer | 1 | 0 | 1 | 1 | 6 | 6 | 1 | ||||
Andtbacka | Robert H. I. | M | USA | 2009 | 2019 | Melanoma | 2 | 2 | 1 | 1 | 34 | 30 | 1 | |||||
Ang | Agnes | F | USA | 2012 | 2021 | Gastric cancer; Non-small cell lung cancer | 2 | 0 | 0 | 1 | 45 | 45 | 1 | |||||
Ang | Kie Kian | M | USA | 1994 | 2015 | EORTC; RTOG | Head and neck cancer | 9 | 5 | 5 | 1 | 120 | 73 | 0 | ||||
Ang | Mei Kim | F | Singapore | 2004 | 2015 | Nasopharyngeal carcinoma | 1 | 0 | 0 | 0 | 13 | 13 | 1 | |||||
Ang | Peng Tiam | M | 1990 | 1994 | Nasopharyngeal carcinoma | 1 | 1 | 0 | 0 | 1 | 1 | 1 | ||||||
Angchaisuksiri | Pantep | Not yet determined | Thailand | 2016 | 2016 | Venous thromboembolism | 1 | 0 | 1 | 0 | 13 | 13 | 1 | |||||
Angele | Martin | M | Germany | 1997 | 2018 | EORTC; European Society for Hyperthermic Oncology | Soft tissue sarcoma | 1 | 0 | 1 | 0 | 21 | 21 | 1 | ||||
Angeli | Alberto | M | 1993 | 2005 | Italian Group for the Study of Adrenal Cancer | Adrenocortical carcinoma | 2 | 0 | 0 | 0 | 16 | 12 | 1 | |||||
Angelopoulou | Maria K. | F | 2010 | 2010 | Mantle cell lymphoma | 1 | 1 | 0 | 0 | 16 | 16 | 1 | ||||||
Angelot Delettre | Fanny | F | France | 2013 | 2014 | Blastic plasmacytoid dendritic cell neoplasm | 1 | 0 | 0 | 0 | 14 | 14 | 1 | |||||
Angelsen | Anders | M | Norway | 1995 | 2018 | Scandinavian Prostate Cancer Group; SPCG; Swedish Association for Urological Oncology | Prostate cancer | 3 | 0 | 3 | 0 | 25 | 24 | 1 | ||||
Angelucci | Emanuele | M | Italy | 1995 | 2022 | CYTO-PV Collaborative Group; FIL; GIMEMA; Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation | Aplastic anemia; Chronic lymphocytic leukemia; Chronic myelomonocytic leukemia; Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Polycythemia vera | 9 | 0 | 6 | 0 | 221 | 188 | 1 | ||||
Angermund | Ralf | M | Germany | 2006 | 2013 | Multiple myeloma | 2 | 0 | 0 | 1 | 20 | 17 | 1 | |||||
Anghel | Rodica | F | Romania | 2008 | 2016 | Breast cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | |||||
Angiolillo | Anne L. | F | USA | 2000 | 2021 | CCG; COG | B-cell acute lymphoblastic leukemia pediatric; Ewing sarcoma; Osteosarcoma | 4 | 2 | 3 | 1 | 63 | 43 | 1 | ||||
Anglaret | Bruno | M | 1995 | 2012 | GELA; IFM | Diffuse large B-cell lymphoma; Multiple myeloma | 3 | 0 | 3 | 0 | 78 | 61 | 1 | |||||
Anglin | Peter | M | Canada | 2003 | 2015 | NCIC-CTG | Multiple myeloma; Transformed lymphoma | 2 | 0 | 1 | 0 | 26 | 26 | 1 | ||||
Angra | Natasha | F | USA | 2015 | 2020 | Bladder cancer | 1 | 0 | 1 | 0 | 28 | 28 | 1 | |||||
Angrilli | Francesco | M | Italy | 2000 | 2017 | FIL; IELSG | CNS lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma | 6 | 0 | 2 | 0 | 132 | 92 | 1 | ||||
Angyalfi | Steve J. | M | Canada | 1999 | 2022 | NCIC-CTG | Prostate cancer | 2 | 0 | 2 | 0 | 41 | 41 | 1 | ||||
Anichini | Andrea | Not yet determined | Italy | 2017 | 2018 | Bladder cancer | 1 | 0 | 0 | 0 | 22 | 22 | 1 | |||||
Anker | Christopher J. | M | USA | 2008 | 2017 | RTOG | Esophageal cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||
Anker | Gun | F | 1994 | 2000 | Scandinavian Breast Group | Breast cancer | 1 | 0 | 1 | 0 | 17 | 17 | 1 | |||||
Annamalai | Lakshmanan | M | USA | 2015 | 2016 | Merkel cell carcinoma | 1 | 0 | 0 | 1 | 30 | 30 | 1 | |||||
Anne | P. Rani | F | 1999 | 2006 | RTOG | Esophageal adenocarcinoma | 1 | 0 | 0 | 0 | 10 | 10 | 1 | |||||
Annechini | Giorgia | F | Italy | 2016 | 2016 | Hodgkin lymphoma | 1 | 0 | 0 | 0 | 17 | 17 | 1 | |||||
Annecke | K. | CBD | Germany | 2001 | 2016 | Breast cancer | 1 | 0 | 1 | 0 | 11 | 11 | 1 | |||||
Annett | Robert D. | M | USA | 2014 | 2022 | COG | T-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 1 | 0 | 35 | 35 | 1 | ||||
Annibali | Ombretta | F | Italy | 2007 | 2019 | Acute promyelocytic leukemia | 1 | 0 | 2 | 1 | 45 | 45 | 1 | |||||
Annino | Luciana | F | Italy | 1988 | 2016 | EORTC; GIMEMA | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia; Multiple myeloma | 3 | 1 | 3 | 1 | 67 | 66 | 1 | ||||
Annunziata | Annalisa | F | 2003 | 2006 | MITO | Ovarian cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Annunziata | Mario | M | Italy | 2017 | 2021 | Chronic myeloid leukemia; Thrombotic thrombocytopenic purpura | 2 | 0 | 1 | 1 | 32 | 32 | 1 | |||||
Anota | Amelie | F | France | 2014 | 2018 | Anal cancer | 1 | 0 | 0 | 0 | 26 | 26 | 1 | |||||
Ansari | Hassan | M | 1983 | 1994 | Chronic myeloid leukemia | 1 | 1 | 1 | 0 | 43 | 42 | 1 | ||||||
Ansari | Marc | M | Switzerland | 2007 | 2020 | EBMT Paediatric Diseases Working Party; I-BFM SCT Study Group; IBFM Study Group; IntReALL Study Group; SIOPEL | Allogeneic HSCT; Hepatoblastoma | 2 | 0 | 2 | 0 | 53 | 53 | 1 | ||||
Ansari | Rafat H. | M | USA | 1984 | 2013 | Alpha Oncology Research Network; CALGB; Fox Chase Network; Hoosier Oncology Group; NCIC-CTG; US Oncology | Breast cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer | 16 | 0 | 15 | 1 | 186 | 151 | 1 | ||||
Ansell | Peter J. | M | USA | 2012 | 2021 | Non-small cell lung cancer; Non-small cell lung cancer squamous; Ovarian cancer | 3 | 0 | 2 | 0 | 70 | 67 | 1 | |||||
Ansell | Stephen M. | M | USA | 2002 | 2022 | NCCTG | Diffuse large B-cell lymphoma; Follicular lymphoma; Hodgkin lymphoma; Mantle cell lymphoma; Transformed lymphoma; Waldenstroem macroglobulinemia | 26 | 7 | 1 | 4 | 410 | 217 | 1 | ||||
Anselmo | Anna Paola | F | 1988 | 2004 | FIL; GHSG | Diffuse large B-cell lymphoma; Hodgkin lymphoma | 4 | 0 | 1 | 0 | 57 | 50 | 1 | |||||
Ansfield | Fred J. | M | 1961 | 1985 | Cooperative Breast Cancer Group | Breast cancer; Head and neck cancer | 4 | 0 | 3 | 0 | 23 | 17 | 1 | |||||
Ansstas | George | M | USA | 2016 | 2022 | Glioblastoma | 1 | 0 | 1 | 0 | 23 | 23 | 1 | |||||
Antal | Joyce | F | USA | 2014 | 2017 | Bladder cancer | 1 | 0 | 0 | 1 | 18 | 18 | 1 | |||||
Anter | A. H. | CBD | 2006 | 2013 | Breast cancer | 1 | 0 | 1 | 0 | 3 | 3 | 1 | ||||||
Anthes | M. | Not yet determined | 1996 | 2004 | Glioblastoma | 1 | 0 | 0 | 0 | 17 | 17 | 1 | ||||||
Anthoney | Alan | M | United Kingdom | 2000 | 2021 | Advanced Biliary Cancer Working Group; European Study Group for Pancreatic Cancer | Cholangiocarcinoma; Gallbladder cancer; Pancreatic cancer; Periampullary adenocarcinoma | 5 | 0 | 5 | 0 | 119 | 84 | 1 | ||||
Anthony | Alan | M | United Kingdom | 2006 | 2022 | Cholangiocarcinoma; Gallbladder cancer | 2 | 0 | 1 | 0 | 52 | 29 | 1 | |||||
Anthony | Stephen P. | M | 1997 | 2006 | Breast cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | ||||||
Antimi | Mauro | M | 1991 | 2003 | Italian Co-operative Group on Bladder Cancer | Bladder cancer; Breast cancer | 2 | 0 | 1 | 0 | 27 | 27 | 1 | |||||
Antin | Joseph H. | M | USA | 2003 | 2016 | BMT CTN | Allogeneic HSCT; Chronic myeloid leukemia; Graft versus host disease; Multiple myeloma | 4 | 1 | 3 | 0 | 79 | 76 | 1 | ||||
Antinori | Andrea | UNMATCHED | 2002 | 2002 | HIV-associated lymphoma | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Antman | Karen | F | USA | 1987 | 1993 | Autologous HSCT; Breast cancer; Soft tissue sarcoma | 2 | 2 | 1 | 0 | 26 | 25 | 1 | |||||
Antolin Novoa | Silvia | F | Spain | 2008 | 2021 | GEICAM | Breast cancer | 2 | 0 | 2 | 0 | 63 | 61 | 1 | ||||
Anton Torres | A. | CBD | 1994 | 1998 | TTD | Colorectal cancer | 1 | 0 | 1 | 0 | 12 | 12 | 1 | |||||
Anton | Antonio | M | Spain | 1990 | 2020 | CIBOMA; GEICAM; LACOG (Latin American Cooperative Oncology Group); Spanish Lung Cancer Group; TTD | Breast cancer; Colorectal cancer; Esophageal adenocarcinoma; Head and neck cancer; Non-small cell lung cancer; Small cell lung cancer | 17 | 0 | 17 | 2 | 380 | 273 | 1 | ||||
Antonarakis | Emmanuel S. | M | USA | 2011 | 2021 | Prostate cancer | 2 | 1 | 0 | 0 | 39 | 38 | 1 | |||||
Antonelli | G. | CBD | 1998 | 2002 | Bladder cancer | 1 | 0 | 0 | 0 | 9 | 9 | 1 | ||||||
Antonescu | Cristina R. | F | USA | 2002 | 2011 | ACOSOG | Gastrointestinal stromal tumor; Melanoma | 2 | 0 | 1 | 1 | 31 | 31 | 1 | ||||
Antonia | Scott J. | M | USA | 2007 | 2022 | Malignant pleural mesothelioma; Non-small cell lung cancer; Non-small cell lung cancer nonsquamous; Non-small cell lung cancer squamous; Small cell lung cancer | 17 | 6 | 7 | 5 | 408 | 222 | 1 | |||||
Antonini | Ninja F. | F | Netherlands | 2003 | 2009 | Dutch Colorectal Cancer Group | Colorectal cancer | 2 | 0 | 2 | 0 | 36 | 28 | 1 | ||||
Antonioli | Elisabetta | F | Italy | 2014 | 2021 | Multiple myeloma; Paroxysmal nocturnal hemoglobinuria | 2 | 0 | 1 | 1 | 37 | 37 | 1 | |||||
Antoniotti | Carlotta | F | Italy | 2008 | 2022 | Colorectal cancer | 3 | 0 | 2 | 0 | 70 | 54 | 1 | |||||
Antoniou | Dimosthenis | M | Greece | 2000 | 2010 | Non-small cell lung cancer | 2 | 0 | 2 | 0 | 33 | 27 | 1 | |||||
Antoniou | Nicos | M | Greece | 2000 | 2013 | SEUG | Prostate cancer | 1 | 0 | 1 | 0 | 10 | 9 | 1 | ||||
Antonuzzo | Lorenzo | M | Italy | 2008 | 2022 | Colorectal cancer | 2 | 0 | 2 | 0 | 45 | 42 | 1 | |||||
Antonyan | Igor | Not yet determined | Ukraine | 2017 | 2022 | Renal cell carcinoma | 1 | 0 | 1 | 0 | 20 | 20 | 1 | |||||
Anttila | Pekka | M | Finland | 2012 | 2016 | Multiple myeloma | 1 | 0 | 0 | 0 | 30 | 30 | 1 | |||||
Antunes | Luis | M | Brazil | 2017 | 2021 | Esophageal cancer | 1 | 0 | 1 | 1 | 24 | 24 | 1 | |||||
Antunovic | Petar | M | 2004 | 2010 | Acute myeloid leukemia; Chronic myelomonocytic leukemia; Myelodysplastic syndrome | 1 | 0 | 0 | 0 | 19 | 19 | 1 | ||||||
Anz | Bertrand | M | USA | 2014 | 2018 | Chronic lymphocytic leukemia | 1 | 0 | 1 | 1 | 19 | 19 | 1 | |||||
Aogi | Kenjiro | M | Japan | 1994 | 2021 | JCOG; NSAS | Breast cancer | 9 | 0 | 8 | 1 | 140 | 103 | 1 | ||||
Aokage | Keiju | Not yet determined | Japan | 2013 | 2020 | JCOG | Small cell lung cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | ||||
Aoki | Daisuke | M | Japan | 2003 | 2021 | JGOG | Cervical cancer; Endometrial cancer; Ovarian cancer | 6 | 1 | 5 | 0 | 121 | 89 | 1 | ||||
Aoki | Hiroshi | M | 2005 | 2013 | Bladder cancer; Upper tract urothelial carcinoma | 1 | 0 | 0 | 0 | 22 | 22 | 1 | ||||||
Aoki | Takuya | Not yet determined | Japan | 2001 | 2021 | WJTOG | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 20 | 20 | 1 | ||||
Aoki | Yoichi | M | Japan | 2008 | 2021 | Cervical cancer; Ovarian cancer | 2 | 1 | 2 | 0 | 60 | 57 | 1 | |||||
Aondio | Gian Marco | M | 2004 | 2009 | IELSG | CNS lymphoma | 1 | 0 | 0 | 0 | 31 | 31 | 1 | |||||
Aotani | Eriko | F | Japan | 2006 | 2016 | JGOG | Ovarian cancer | 1 | 0 | 1 | 0 | 23 | 23 | 1 | ||||
Aoudjhane | A. | CBD | France | 2003 | 2014 | Lymphoma Study Association | Hodgkin lymphoma | 1 | 0 | 1 | 0 | 17 | 17 | 1 | ||||
Aoudjhane | Malek | M | France | 1989 | 2003 | EORTC | Hodgkin lymphoma | 1 | 0 | 2 | 0 | 28 | 28 | 1 | ||||
Aoyama | H. | CBD | 1993 | 1996 | Breast cancer | 1 | 0 | 0 | 0 | 6 | 6 | 1 | ||||||
Aoyama | Norio | M | 1992 | 2011 | JCOG | Esophageal cancer | 2 | 0 | 2 | 0 | 32 | 29 | 1 | |||||
Aoyama | Toru | Not yet determined | Japan; USA | 2011 | 2017 | Gastric cancer; Rectal cancer | 2 | 1 | 2 | 0 | 30 | 30 | 1 | |||||
Aozasa | Katsuyuki | Not yet determined | 2005 | 2005 | Castleman disease | 1 | 0 | 0 | 0 | 20 | 20 | 1 | ||||||
Apanovitch | Anne Marie | F | USA | 2005 | 2007 | B-cell acute lymphoblastic leukemia | 1 | 0 | 0 | 1 | 11 | 11 | 1 | |||||
Aparicio | Jorge | M | Spain | 1994 | 2011 | Spanish Germ Cell Cancer Cooperative Group; TTD | Colorectal cancer; Hodgkin lymphoma; Testicular cancer | 6 | 3 | 2 | 0 | 81 | 68 | 1 | ||||
Aparicio | Samuel | M | Canada | 2008 | 2015 | NCIC-CTG | Breast cancer | 1 | 0 | 1 | 0 | 26 | 26 | 1 | ||||
Aparicio | Thomas | M | France | 2000 | 2018 | FFCD; SFRO; UNICANCER | Colorectal cancer; Esophageal adenocarcinoma; Gastric cancer; Hepatocellular carcinoma; Pancreatic cancer | 5 | 2 | 5 | 0 | 89 | 71 | 1 | ||||
Apfelbeck | Ute | F | Austria | 1994 | 2003 | Chronic myeloid leukemia | 1 | 0 | 1 | 0 | 25 | 25 | 1 | |||||
Apffelstaedt | Justus | M | South Africa | 1996 | 2003 | Breast cancer | 3 | 0 | 2 | 1 | 51 | 32 | 1 | |||||
Aplenc | Richard | M | USA | 2011 | 2014 | COG | Acute myeloid leukemia pediatric; B-cell acute lymphoblastic leukemia; B-cell acute lymphoblastic leukemia pediatric | 3 | 1 | 0 | 0 | 44 | 36 | 1 | ||||
Apolo | Andrea B. | M | USA | 2014 | 2022 | Bladder cancer; Renal cell carcinoma | 4 | 2 | 1 | 2 | 81 | 59 | 1 | |||||
Apolone | Giovanni | M | 1987 | 1998 | EORTC; Gruppo Interdisciplinare Valutazione Interventi in Oncologia; Japanese Foundation for Cancer Research | Colon cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Aponte | John | M | 1996 | 2002 | Barcelona Liver Cancer Group | Hepatocellular carcinoma | 1 | 0 | 1 | 0 | 11 | 11 | 1 | |||||
Apostolou | Theofanis | M | 2008 | 2012 | Light-chain (AL) amyloidosis | 1 | 0 | 0 | 0 | 12 | 12 | 1 | ||||||
Appel | Tabea | F | 2006 | 2006 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 10 | 10 | 1 | ||||||
Appel | Wiebke | F | United Kingdom | 2008 | 2017 | CONVERT Study Team | Small cell lung cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | ||||
Appelbaum | Frederick R. | M | USA | 1971 | 2021 | CALGB; ECOG; SWOG | Acute myeloid leukemia; Acute promyelocytic leukemia; Allogeneic HSCT; B-cell acute lymphoblastic leukemia; Chronic lymphocytic leukemia; Chronic myeloid leukemia; Chronic myelomonocytic leukemia; Follicular lymphoma; Graft versus host disease; Hairy cell leukemia; Myelodysplastic syndrome; T-cell acute lymphoblastic leukemia | 36 | 11 | 16 | 4 | 477 | 273 | 1 | ||||
Appenzeller | Christina | Not yet determined | Switzerland | 2017 | 2021 | Small cell lung cancer | 1 | 0 | 1 | 0 | 21 | 21 | 1 | |||||
Apperley | Jane F. | F | United Kingdom | 1981 | 2021 | B-cell acute lymphoblastic leukemia; Chronic myeloid leukemia; Hypereosinophilic syndrome | 12 | 1 | 1 | 4 | 227 | 140 | 1 | |||||
Appiani | Carlos | M | USA | 2008 | 2018 | Mantle cell lymphoma | 1 | 0 | 1 | 1 | 15 | 15 | 1 | |||||
Appleman | Leonard J. | M | USA | 2008 | 2014 | Bladder cancer | 1 | 0 | 0 | 0 | 18 | 18 | 1 | |||||
Aprea | Pasquale | M | 2002 | 2013 | SICOG | Melanoma | 1 | 0 | 1 | 0 | 17 | 17 | 1 | |||||
Aprile | Giuseppe | M | Italy | 2005 | 2022 | Colorectal cancer; Esophageal adenocarcinoma; Esophageal cancer; Gastric cancer | 4 | 0 | 3 | 2 | 89 | 81 | 1 | |||||
Apte | Ron N. | M | Israel | 2014 | 2017 | Colorectal cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | |||||
Aqui | Nicole A. | F | USA | 2008 | 2015 | Follicular lymphoma; Mantle cell lymphoma | 2 | 0 | 0 | 0 | 14 | 8 | 1 | |||||
Aquino | Sara | Not yet determined | Italy | 2011 | 2021 | Multiple myeloma | 3 | 0 | 1 | 0 | 123 | 78 | 1 | |||||
Arachchillage | Deepa R. J. | Not yet determined | United Kingdom | 2016 | 2016 | Antiphospholipid antibody syndrome | 1 | 0 | 0 | 0 | 13 | 13 | 1 | |||||
Aracil | Miguel | Not yet determined | Spain | 2015 | 2021 | Ovarian cancer | 1 | 0 | 1 | 0 | 19 | 19 | 1 | |||||
Aragon Ching | Jeanny B. | F | USA | 2011 | 2020 | Bladder cancer | 3 | 0 | 2 | 1 | 91 | 82 | 1 | |||||
Arahmani | Amal | F | Belgium | 2011 | 2021 | Breast cancer | 2 | 0 | 2 | 2 | 55 | 51 | 1 | |||||
Arai | Gaku | Not yet determined | Japan | 2001 | 2020 | Prostate cancer | 2 | 0 | 2 | 0 | 48 | 45 | 1 | |||||
Arai | Kuniyoshi | M | Japan | 1993 | 2011 | ACTS-GC Group; JCOG | Gastric cancer | 2 | 2 | 2 | 0 | 21 | 16 | 1 | ||||
Arai | Makoto | Not yet determined | Japan | 2019 | 2019 | Carcinoma of unknown primary | 1 | 0 | 0 | 0 | 20 | 20 | 1 | |||||
Arai | Masahide | Not yet determined | Japan | 2006 | 2019 | JGOG | Endometrial cancer | 1 | 0 | 1 | 0 | 16 | 16 | 1 | ||||
Arai | Sally | F | USA | 2006 | 2016 | Allogeneic HSCT | 2 | 0 | 1 | 0 | 45 | 45 | 1 | |||||
Arai | Yasuaki | M | Japan | 2010 | 2018 | Hepatocellular carcinoma | 2 | 2 | 2 | 0 | 34 | 32 | 1 | |||||
Arai | Yoichi | M | 2000 | 2013 | Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer | Bladder cancer; Prostate cancer; Upper tract urothelial carcinoma | 3 | 1 | 1 | 0 | 38 | 34 | 1 | |||||
Arakelyan | Nina | F | 1994 | 2013 | GOELAMS | Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma | 3 | 0 | 1 | 0 | 57 | 46 | 1 | |||||
Araki | K. | CBD | 1994 | 2001 | JCOG | Adult T-cell leukemia-lymphoma | 1 | 0 | 0 | 0 | 15 | 15 | 1 | |||||
Araki | Nobuhito | M | Japan | 2008 | 2016 | Soft tissue sarcoma | 3 | 0 | 1 | 1 | 45 | 40 | 1 | |||||
Arana Yi | C. | CBD | USA | 2007 | 2014 | Acute myeloid leukemia | 1 | 0 | 0 | 0 | 17 | 17 | 1 | |||||
Arance | Ana M. | F | Spain | 2009 | 2022 | CheckMate 238 Collaborators | CNS melanoma; Melanoma | 24 | 1 | 11 | 8 | 562 | 205 | 1 | ||||
Aranda | Enrique | M | Spain | 1994 | 2020 | GEICAM; TTD | Breast cancer; Colon cancer; Colorectal cancer; Esophageal adenocarcinoma | 9 | 7 | 7 | 0 | 179 | 127 | 1 | ||||
Aranda | Ignacio | M | Spain | 1999 | 2010 | GEICAM | Breast cancer | 1 | 0 | 1 | 0 | 30 | 30 | 1 | ||||
Aranda | J. | CBD | Spain | 1987 | 2003 | GEICAM | Breast cancer | 1 | 0 | 1 | 0 | 14 | 14 | 1 | ||||
Arango Hisijara | Israel | M | USA | 2013 | 2021 | Marginal zone lymphoma; Waldenstroem macroglobulinemia | 2 | 0 | 1 | 2 | 37 | 36 | 1 | |||||
Arango Ossa | Juan E. | Not yet determined | USA | 2011 | 2022 | Polycythemia vera | 1 | 0 | 1 | 0 | 42 | 42 | 1 | |||||
Arasteh | Keikawus | M | 1993 | 1998 | Kaposi sarcoma | 1 | 0 | 1 | 0 | 8 | 8 | 1 | ||||||
Araujo | Carla | F | France | 2008 | 2022 | IFM | Autologous HSCT; Multiple myeloma | 6 | 0 | 4 | 1 | 217 | 121 | 1 | ||||
Araujo | John C. | M | USA | 2008 | 2013 | Prostate cancer | 1 | 1 | 1 | 0 | 24 | 24 | 1 | |||||
Aravantinos | Gerasimos | M | Greece | 1989 | 2012 | HCOG; HeCOG | Bladder cancer; Breast cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Testicular cancer | 13 | 2 | 11 | 0 | 212 | 101 | 1 | ||||
Arazy | Melina | F | USA | 2017 | 2020 | Multiple myeloma | 1 | 0 | 1 | 1 | 57 | 57 | 1 | |||||
Arbogast | Daria | F | 2010 | 2010 | Thyroid cancer medullary | 1 | 0 | 0 | 0 | 18 | 18 | 1 | ||||||
Arbuck | Susan G. | F | 1992 | 2003 | Cervical cancer; Ovarian cancer | 2 | 1 | 1 | 0 | 22 | 21 | 1 | ||||||
Arbushites | Michael C. | M | USA | 2004 | 2020 | Breast cancer; Graft versus host disease | 2 | 0 | 1 | 1 | 25 | 25 | 1 | |||||
Arcaini | Luca | M | Italy | 2006 | 2021 | FIL; SPRINT trial investigators and in collaboration with the European Mantle Cell Lymphoma Network | Follicular lymphoma; Mantle cell lymphoma | 7 | 1 | 3 | 0 | 164 | 132 | 1 | ||||
Arcamone | Manuela | F | 2012 | 2012 | Follicular lymphoma | 1 | 0 | 0 | 0 | 14 | 14 | 1 | ||||||
Arcangeli | Annarosa | F | 1995 | 2008 | Italian Oncology Group for Cancer Research | Gastric cancer | 1 | 0 | 1 | 0 | 15 | 15 | 1 | |||||
Arcangeli | Giuseppina | F | 1995 | 1995 | Hepatocellular carcinoma | 1 | 1 | 0 | 0 | 3 | 3 | 1 | ||||||
Arcangeli | Valentina | F | Italy | 2010 | 2015 | MITO | Ovarian cancer | 1 | 0 | 0 | 0 | 22 | 22 | 1 | ||||
Arcari | Annalisa | F | Italy | 2003 | 2021 | ANZ BCTG; FIL | Diffuse large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma | 4 | 0 | 2 | 0 | 93 | 78 | 1 | ||||
Arcasoy | Murat O. | M | USA | 2009 | 2022 | Myelofibrosis; Polycythemia vera | 6 | 0 | 2 | 1 | 161 | 74 | 1 | |||||
Arce Lara | Carlos | M | USA | 2015 | 2019 | Multiple myeloma | 1 | 0 | 0 | 0 | 10 | 10 | 1 | |||||
Arce Salinas | Claudia H. | F | Mexico | 2011 | 2021 | Breast cancer | 2 | 0 | 2 | 1 | 61 | 60 | 1 | |||||
Arceci | Robert J. | M | USA | 1979 | 2011 | CCG; COG | Acute myeloid leukemia; B-cell acute lymphoblastic leukemia pediatric; Chronic myeloid leukemia pediatric; Langerhans cell histiocytosis | 5 | 2 | 4 | 2 | 60 | 53 | 1 | ||||
Arcenas | Anthony | M | 2000 | 2000 | Non-small cell lung cancer | 1 | 0 | 1 | 0 | 18 | 18 | 1 | ||||||
Arcese | William | M | Italy | 1988 | 2015 | Acute myeloid leukemia; Allogeneic HSCT | 2 | 0 | 1 | 0 | 40 | 40 | 1 | |||||
Archambaud | Baptiste | Not yet determined | France | 2017 | 2022 | French Sarcoma Group | Leiomyosarcoma | 1 | 0 | 1 | 0 | 19 | 19 | 1 | ||||
Archambault | Robert | M | Canada | 2000 | 2020 | Prostate cancer | 2 | 0 | 2 | 0 | 23 | 17 | 1 | |||||
Archer | Caroline | F | United Kingdom | 2007 | 2014 | Pancreatic cancer | 1 | 0 | 1 | 0 | 32 | 32 | 1 | |||||
Archer | J. Hunter | Not yet determined | USA | 2014 | 2022 | COG | T-cell acute lymphoblastic leukemia pediatric | 1 | 0 | 1 | 0 | 35 | 35 | 1 | ||||
Archer | Laura | F | 2003 | 2010 | CALGB | Renal cell carcinoma | 2 | 0 | 1 | 0 | 21 | 11 | 1 | |||||
Archer | Venice | F | United Kingdom | 2005 | 2019 | Non-small cell lung cancer; Non-small cell lung cancer nonsquamous | 4 | 0 | 3 | 2 | 49 | 38 | 1 | |||||
Archimbaud | Eric | M | 1980 | 2004 | ALFA; EAPLG; EORTC; European APL Group; GELA; HOVON | Acute myeloid leukemia; Acute promyelocytic leukemia; Diffuse large B-cell lymphoma | 6 | 0 | 5 | 0 | 110 | 83 | 1 | |||||
Arcila | Maria E. | F | USA | 2012 | 2021 | ERBB2 (HER2); Erdheim-Chester disease; Multiple myeloma | 3 | 1 | 0 | 1 | 88 | 85 | 1 | |||||
Arcusa | Angels | F | Spain | 1988 | 2010 | GEICAM | Breast cancer; Gastric cancer | 3 | 0 | 3 | 0 | 59 | 52 | 1 |